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Abstract
Vaccines against some of the most pervasive pathogens, including HIV, TB, and malaria, are desperately
needed. Available evidence suggests that both central memory and effector CD8+ T cells play a role in
mediating protective immunity against many pathogens. Recombinant adenoviruses currently under
development as vaccine carriers induce potent and sustained transgene product-specific CD8+ T cell
responses. The transgene product-specific CD8+ T cell response remains activated and is delayed in
transitioning to central memory. Here we investigate how this response is maintained.
Adenoviral vectors persist and remain transcriptionally active in vivo. We investigated the role that
continuous transgene expression plays in maintaining the effector memory-biased transgene productspecific CD8+ T cell response. Dual expression vectors based on AdC7 expressing transgenes that could
be regulated temporally were generated. Vectors were unexpectedly unstable in vivo. Alternatively we
inhibited the mTOR pathway, which is downstream of the T cell receptor and has recently been implicated
in memory development, using a low dose of rapamycin. Rapamycin failed to enhance the quality of the
transgene-product specific CD8+ T cells.
Persisting transgene product could maintain the transgene product-specific CD8+ T cell response by
continual recruitment of naÃ¯ve CD8+ T cells, similar to some other persistent viruses. However, in an
adoptive transfer model, we demonstrate that the response is primarily maintained by antigenexperienced cells that do not lose function over time.
Pre-existing anti-adenovirus immunity is common, particularly for the human adenoviruses currently in
development as vaccine carriers. Here we demonstrate that pre-existing anti-adenovirus neutralizing
antibodies accelerate and enhance transgene product-specific CD8+ T cell differentiation into central
memory. These cells were highly functional and responded robustly to booster immunization. Importantly,
this may be due in part to a reduction the vector's reservoir in T cells.
These data suggest that further study of transgene product expression and its functional impact on
immune responses is necessary. Further understanding this impact will allow manipulation of immune
responses induced by the adenovirus vaccine platform such that they can be tailored to specific
pathogens.
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ABSTRACT
+

INVESTIGATION OF THE MAINTENANCE OF CD8 T CELL RESPONSES INDUCED BY
PERSISTENT ADENOVIRUS VECTORS

Juliana Small
Dr. Hildegund C.J. Ertl
Vaccines against some of the most pervasive pathogens, including HIV, TB, and malaria,
are desperately needed. Available evidence suggests that both central memory and effector
+

CD8 T cells play a role in mediating protective immunity against many pathogens. Recombinant
adenoviruses currently under development as vaccine carriers induce potent and sustained
+

+

transgene product-specific CD8 T cell responses. The transgene product-specific CD8 T cell
response remains activated and is delayed in transitioning to central memory. Here we
investigate how this response is maintained.
Adenoviral vectors persist and remain transcriptionally active in vivo. We investigated the
role that continuous transgene expression plays in maintaining the effector memory-biased
+

transgene product-specific CD8 T cell response. Dual expression vectors based on AdC7
expressing transgenes that could be regulated temporally were generated. Vectors were
unexpectedly unstable in vivo. Alternatively we inhibited the mTOR pathway, which is
downstream of the T cell receptor and has recently been implicated in memory development,
using a low dose of rapamycin. Rapamycin failed to enhance the quality of the transgene-product
+

specific CD8 T cells.
+

Persisting transgene product could maintain the transgene product-specific CD8 T cell
+

response by continual recruitment of naïve CD8 T cells, similar to some other persistent viruses.
However, in an adoptive transfer model, we demonstrate that the response is primarily
maintained by antigen-experienced cells that do not lose function over time.
Pre-existing

anti-adenovirus

immunity

is

common,

particularly

for

the

human

adenoviruses currently in development as vaccine carriers. Here we demonstrate that preexisting anti-adenovirus neutralizing antibodies accelerate and enhance transgene productv

+

specific CD8 T cell differentiation into central memory. These cells were highly functional and
responded robustly to booster immunization. Importantly, this may be due in part to a reduction
the vector’s reservoir in T cells.
These data suggest that further study of transgene product expression and its functional
impact on immune responses is necessary. Further understanding this impact will allow
manipulation of immune responses induced by the adenovirus vaccine platform such that they
can be tailored to specific pathogens.
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CHAPTER 1
INTRODUCTION

1

ADENOVIRUS PHYLOGENY
In 1953, culture of human adenoid tissues led to the isolation and identification of a
distinct virus that was subsequently named after the tissue from which it was isolated: adenovirus
(Ad)

1,2

. After more than half a century since they were first identified, adenoviruses have been

divided into four genera containing species isolated from many classes of the animal kingdom,
including fish, amphibians, reptiles, birds, and other mammals. Human adenoviruses belong to
the genus Mastadenovirus, which contains all other mammalian adenoviruses, and are further
grouped into seven subgroups: A-G. Individual human adenoviruses are identified and assigned a
species typically on the basis of neutralization by homologous sera. This has led to the
identification of 57 distinct human serotypes.
Historically, hemagglutination properties and neutralization criteria were used to classify
the various human adenoviruses. However, advances in genomics and bioinformatics have given
us great insight into adenovirus phylogeny. The evolutionary relationships previously designated
on the basis of immunological criteria have been confirmed owing to the availability of sequenced
Ad genome reference strains. These data have also enabled the investigation of the source of
adenovirus genome diversity. Adenoviruses exhibit potential for recombination in experimental
co-infection models

3,4

. Recently, whole genome analysis of the completed Ad genome

sequences has confirmed that naturally occurring homologous recombination, particularly in the
5

capsid proteins’ hypervariable regions , is a source of the wide diversity of adenoviruses

6-8

.

Additionally, such advances have allowed us to investigate the possibility of interspecies
transmission as an additional source of adenoviral genetic diversity. High-resolution X-ray crystal
structures and amino acid alignment of hexon suggested that a member of subgroup E, HAdV-4,
9

is closely related to chimpanzee adenovirus 68 . The close phylogenetic relationship of human
and simian adenoviruses has lead to the simian adenoviruses’ classification within the human
subgroups B, C, and E

6,10,11

.

2

ADENOVIRUS STRUCTURE AND GENOME
Adenoviruses have a ~30-36 kilobase (kb) double-stranded DNA (dsDNA) genome
surrounded by a non-enveloped icosahedral protein capsid

12

. Each of the twenty faces of the

adenovirus capsid contains twelve hexon trimers; thereby making hexon the most abundant
9

capsid structural protein. Hexon is highly conserved between serotypes . However, the outer
surface, which is subject to more intense selective pressures, is comprised of amino acid loops
9

with a high degree of sequence diversity, termed hypervariable loops . Most serotype specific
neutralizing antibodies are directed against these loops within hexon

13

. Two other major proteins

comprise the capsid: penton and fiber. At each vertex where three hexon facets meet, fiber
trimers form a spike that protrudes from the penton complex. Fiber has three domains: the highly
conserved N-terminus that binds to the penton base, a flexible shaft whose length varies between
serotypes and influences virus internalization
cellular receptors

16,17

14,15

, and a globular head responsible for binding to

. Five minor capsid proteins function to stabilize the capsid.

The adenoviral genome is organized based on the temporal expression of viral
transcription units. There are four early transcription units (E1, E2, E3, and E4) each of which
have multiple open reading frames or are alternatively spliced into several mRNAs throughout the
course of infection

12

. The four early transcription units encode non-structural proteins. E1A

proteins are the first to be transcribed as soon as the viral DNA enters the nucleus. These
proteins have the critical job of serving as transcription factors to stimulate transcription of the
other viral transcription units

18-20

and promoting cell cycle progression such that the cellular

replication machinery can be hijacked to replicate the virus

21-23

. E1B proteins largely function to

prevent apoptosis of infected cells. The E2 transcription unit encodes proteins necessary for viral
DNA replication, including the viral DNA polymerase. Proteins encoded in the E3 transcription
unit are responsible for subversion of the host immune response and promoting longevity of the
infected cell through prevention of apoptosis. E4 proteins have a wide variety of regulatory
functions, including modulation of DNA repair and cell signaling, and promoting synthesis of the
late viral proteins. There are five late transcription units (L1-L5) that encode the virus’ structural
3

proteins.

ENTRY AND LIFECYCLE
Early studies of adenovirus revealed that the virus is capable of attaching to HeLa cells
16,24

, an immortalized epithelial cell line derived from the cervix. Armed with the knowledge that

Coxsackie B virus competes with adenovirus for binding to these cells

25

, Bergelson et al. isolated

the common receptor used by both viruses for attachment to target cells
adenovirus receptor (CAR) is a 365 amino acid transmembrane protein
adhesion

27

26,27

26

. Coxsackie and

that functions in cell

. It has since been confirmed that CAR is the receptor for virtually all adenoviruses,

with the notable exception of subgroup B viruses

28

.

Additionally, CAR is also thought to facilitate dissemination of adenovirus in vivo. The
studies that identified CAR as the receptor were performed in vitro on non-polarized cells.
However, in vivo, CAR expression is limited to the basolateral side of polarized epithelial cells
27,29

below the tight junctions binding them to one another, ultimately restricting the virion’s

access. Late in the viral life cycle fiber is produced in excess and has been demonstrated to open
tight junctions by disrupting CAR-CAR interactions

30

, thus promoting the spread of infection.

The studies demonstrating that fiber mediated attachment to the then unidentified
receptor did so using the common subgroup C viruses, HAdV-2 and HAdV-5, on cell lines that
were permissive to adenovirus infection

16

. Attempts to determine if subgroup B viruses interacted

similarly with target cells permissive to subgroup C viruses revealed that subgroup B viruses did
not share a common receptor with subgroup C viruses

28,31

. It has since been revealed that

CD46, a ubiquitously expressed regulator of complement, serves as a receptor for subgroup B
viruses

32

. Notably, HAdV-3, HAdV-7, and HAdV-14 do not use CD46

32,33

as their primary

receptor but instead use desmoglein 2, a calcium-binding transmembrane glycoprotein involved
in cell adhesion of epithelial cells.
As adenoviruses can bind independently of CAR and CD46 to a wide variety of cells, a
number of alternative receptors have been proposed. CD80 and CD86 have been proposed as
4

alternate receptors for some subgroup B viruses

34

. Subgroup C viruses have been proposed to

utilize a number of alternative receptors, including glycosaminoglycans in the extracellular matrix
35

but this was not confirmed

37

.

Finally, subgroup D viruses are proposed to bind sialic acid at the very tip of the fiber knob

38

.

and major histocompatibility complex (MHC) class I α2 subunit

36

The extent to which these are used as receptors in vivo has yet to be confirmed.
High affinity binding of fiber with the receptor allows the virion to be held close enough to
the cell surface to facilitate entry into the cell. However, entry is not mediated solely through
attachment to CAR but requires binding to the integrins αvβ3 or αvβ5

39,40

. Adenoviruses bind to

these integrins using a conserved Arg-Gly-Asp (RGD) motif located on the penton base
interaction triggers internalization of the virion into clathrin-coated pits

42,43

40,41

. This

. Once internalized,

adenoviruses rapidly escape the endosome in a pH-dependent manner. As the pH drops during
endosomal trafficking inward, the capsid undergoes a conformational change that triggers lysis of
the endosome, thereby allowing the virus to escape

44,45

microtubules by binding the molecular motor, dynein

46

. The virion then traffics to the nucleus via

. The capsid forms a stable interaction with

the nuclear pore and the genome is then transported into the nucleus

47

, where it can begin

transcription of the gene products described earlier.

CLINICAL FEATURES
Adenoviruses are a significant cause of global morbidity in humans and typically cause
48

.

48,49

.

mild infections of the respiratory and gastrointestinal tracts during the first few years of life
Indeed most children will have evidence of prior exposure by the time they are five years old

Although infection is often asymptomatic, adenoviruses are responsible for approximately 5% of
symptomatic upper respiratory tract and 10-15% of lower respiratory infections in children
about 17% of gastroenteritis disease in infants

51

50

and

. While not all human adenoviruses are

associated with disease, certain species are responsible for the vast majority of adenovirus
morbidity. Subgroup C viruses are most associated with respiratory tract infections; while viruses
belonging to subgroups B and D more commonly cause enteral infections.
5

Healthy adults are normally not at risk of infection with adenovirus. However, certain
populations are at risk for serious adenoviral infection. Military recruits are disproportionately
infected with HAdV-4 and HAdV-7, which are responsible for between 60-80% of acute
respiratory illness in this population

52

. Ad infection is an even greater issue for those that are

immunosuppressed either for transplants or due to HIV. Indeed, disseminated infection occurs in
40% of hematopoietic stem cell transplant patients

53

and is common among HIV patients

54-56

. In

these cases, disease is most often severe and life threatening.

ADENOVIRUS AS A PERSISTENT INFECTION
Early clinical evidence suggests that adenovirus establishes a persistent infection.
Longitudinal analysis of adenoviral infection in families demonstrated that even after resolution of
primary infection when adenovirus could no longer be detected in the upper respiratory tract,
virus could be intermittently shed in stool
49

48,50

. As adenoviruses often cause subclinical infections

, it was unclear that this shedding represented a new infection or reactivation of a persistent

infection. Using serologic evidence, these longitudinal analyses demonstrated that shedding
could be due to either scenario: in some patients reinfection was clearly the cause, but in others
shedding was due to reactivation

50

. What distinguished the two scenarios though was the

duration of shedding. Short-term shedding was observed in individuals who were re-infected,
whereas shedding was detected for months to years in individuals who were shedding persistent
virus. These results were later confirmed using restriction analysis of viral isolates from infants
persistently shedding adenovirus for over a year. The analysis revealed that viruses isolated
throughout the study period were always identical to each other

57

.

Experimental evidence suggested that this persistent virus was establishing a latent
infection as opposed to a chronic infection. The first evidence of this came with the initial
identification of adenovirus. When tonsils and adenoids isolated in the absence of adenovirus
infection were cultured long-term small amounts of infectious adenovirus could be isolated

2,58

.

However, culture did not always result in production of infectious virus, and yet adenoviral DNA
6

could be isolated from the tissue

59

. Together this suggested that while the virus was there, it was

not replicating. In support of this, the addition of phytohaemagglutinin (PHA), a mitogen
commonly used to stimulate lymphocytes

60

, to cultures that failed to produce replication

competent virus resulted in the successful production of infectious virus

61

. These data suggested

that adenovirus establishes a persistent but latent infection in these tissues. Since these early
studies, adenoviruses have been isolated in the absence of productive infection from an array of
tissues, including the gastrointestinal tract, urinary tract, circulating peripheral blood mononuclear
cells, the central nervous system, and the conjunctiva of the eye.
Decades of study have been devoted to the determination of the cell type that harbors
persistently infecting adenovirus. Initial attempts suggested that fibroblasts within the tonsils and
adenoids were responsible

62,63

. In a study to model persistent adenoviral infection of the tonsils

and adenoids using suspensions of such tissues, Strohl and Schlesinger estimated the frequency
7

of infected cells in these tissues to be 1 in 10 cells. This frequency was then correlated to the
frequency of fibroblasts in uninfected tissue, which led to the conclusion that these cells were the
primary source of persistent virus

63

. However, evidence began to accumulate that implicated

lymphocytes instead. First, it was demonstrated using fluorescent antibodies that lymphocytes
isolated from oral ulcers carried adenoviral antigens

64

. Additionally, infectious adenovirus could

be cultured from a small fraction of lymphocytes purified from tonsil and adenoid explants, most
notably when PHA was added during culture to stimulate lymphocytes

61

. Finally, even when

infectious virus could not be isolated, lymphocytes were commonly found to harbor adenoviral
DNA

59

.
A study to quantify the amount of adenoviral DNA in purified lymphocytes residing in

tonsils and adenoids provided definitive evidence that adenovirus persists in lymphocytes

65

.

Garnett et al. additionally demonstrated that adenovirus DNA was enriched in a particular subset
of lymphocytes, T cells. Subgroup C viruses are exclusively isolated from lymphocytes residing in
tonsils and adenoids

49,65

, but adenoviruses belonging to additional subgroups have since been

isolated from lymphocytes in the gut mucosa

56,66

.

7

It is of particular interest that T cells are the source of latent adenovirus as it remains
unclear exactly how adenovirus infects them. T cells poorly express CAR, and αvβ3 and αvβ5 are
only upregulated during T cell activation

67

. As such, T cells should be refractory to adenovirus

infection. Indeed, experimental infection of T cells with adenovirus is difficult, often requiring
ectopic CAR expression
fiber-modified virus

70

39,68

, immortalized lymphocyte lines with high CAR expression

69

, or

. This may suggest that CAR isn’t the primary receptor on T cells in vivo.

MECHANISMS OF PERSISTENCE OF NATURALLY ACQUIRED ADENOVIRUS
In order for adenovirus to establish a latent infection in lymphocytes the genome would
have to be stably maintained in these cells. Common strategies to accomplish this include
integration into the host genome and formation of stable DNA structures that are maintained
extrachromasomally, such as episomes. Early work suggested that the former strategy is
employed. HAdV-12 infection of neonate hamsters leads to integration of at least the E1A and
E1B domains, ultimately resulting in tumorigenesis
evidence of adenoviral DNA within the tumor

72-74

71

. Studies of human tumors occasionally find

. However, there is a dearth of evidence that

suggests that the virus’ presence in the tumor is due to integration

73,74

, suggesting that

adenovirus likely does not integrate into the human genome as a means of persistence.
Integration machinery is not encoded in the adenoviral genome; therefore, the frequency of
integration would be expected to be low and would have to occur randomly through
recombination of the viral genome with the host genome. In vitro studies suggest that this occurs
-3

-4

with a relatively high frequency, ranging from approximately 5x10 – 1 x10 integrations per cell
75

. In contrast, a recent study examining the integration frequency in the liver following gene

transfer instead suggested that the frequency of integration was significantly less, ranging from
-6

-7

about 10 to 10 integrations per cell. Alternatively, experimental infection of human T cell lines
provided evidence that the adenovirus genome instead persists extrachromosomally as an
episome. Southern blot analysis revealed that following restriction digest the resulting DNA
fragments were the correct size, as predicted from virus alone

69

.
8

In addition to stable maintenance of the genome, the virus would also have to subvert the
host’s immune responses in order to persist in vivo. Indeed, a number of proteins are encoded in
the genome that specifically function to this end. Evasion of the host innate response begins as
early as expression of the E1 transcription unit. Proteins encoded in this unit prevent interferonmediated gene expression

76

. The majority of adenoviruses’ immune evasion proteins are

encoded in the E3 domain, which has long been implicated in adenovirus’s persistence. The E3
transcription unit’s expression is induced in response to inflammation. Indeed, the E3 promoter
contains NF-κB binding sites, which when mutated prevent expression of the E3 unit in response
to tumor necrosis factor α (TNF-α)

77

. The E3 transcription unit is alternatively spliced into a

number of proteins that prevent CTL-mediated killing of infected cells. One such protein, E3-19K,
is responsible for preventing MHC class I transport to the cell surface by sequestering the
78,79

complex in the endoplasmic reticulum

, thus preventing CTL-mediated lysis. While the

function of E3-19K is conserved within adenovirus subgroups
between subgroups

5,81

80

, there is genetic variation

. This is thought to influence the avidity with which E3-19K from the

different species binds HLA alleles

81

. It has been suggested this could indicate that an

individual’s haplotype may determine if they are more susceptible or resistant to persistent
adenoviral infection

82

. Other E3 proteins function to prevent cell-mediated killing by blocking the

infected cell’s apoptosis cascade. The RID complex, E3-14.7K, and E3-19K all function to this
end, interfering with Fas and TRAIL-R1

83

, thus preventing FasL- and TRAIL-mediated apoptosis.

VECTORED ADENOVIRUS
Adenoviruses have long been explored as vectors for gene delivery, at first in order to
correct inherited genetic disorders but more recently for vaccination. Such intense exploration has
largely been fueled by their tropism for numerous tissues, ability to transduce both dividing and
non-dividing cells, and their relatively low pathogenicity. Further, adenoviruses have proven easy
to manipulate genetically and to grow in culture

84

.

9

The first generation of Ad vectors was deleted in the E1 domain, a modification that not
only allowed for the inclusion of a transgene-expression cassette but also rendered the vector
replication defective. As such, the E1 domain must be provided in trans in order for the vector to
be grown in culture. These first generation vectors could also be deleted in the E3 domain in
order to increase their packaging capacity. Gene products from the E3 domain are not necessary
for replication and as such do not need to be provided in trans.
These first generation vectors could achieve stable transgene expression in
immunodeficient mice

85

. However, transgene expression was transient in immune competent

animals due to the robust anti-adenovirus immune response. Indeed, these responses were in
part directed against viral gene products that continued to be expressed at low levels even
though the vector genome was deleted in the E1 domain

86

. This precipitated the development of

vectors with fewer encoded viral genes in an effort to reduce the anti-vector response. Later
generations of vectors are sometimes deleted in E2, E4, or are completely gutted but for the
LTRs and packaging sequence. While these deletions reduce the number of viral antigens and
weaken the anti-adenovirus immune response, the vectors are still capable of eliciting transgene
product-specific responses

87

. It is this characteristic induction of potent immune responses to

encoded transgenes that has prompted the development of adenoviruses as vaccine carriers.

ADENOVIRUS AS A VACCINE CARRIER
Extensive development of vaccines based on adenovirus is under way. This platform is
currently being tested for numerous and diverse targets, including viruses, bacteria, parasites,
and cancers. Pre-clinically, these vectors induce potent and sustained immune responses
directed against the transgene product that can be protective in an appropriate challenge model.
Several of these vaccine candidates, including those against malaria

88

, Ebola

89

, and HCV

90

,

have performed so well in preclinical models that they are now in various stages of clinical
testing.

10

The most widely studied Ad vector is based on HAdV-5. However, pre-existing immunity
to this virus is common globally. Pre-existing immunity poses a serious issue because it limits
91,92

transduction of target cells
vector’s immunogenicity

93

, thereby reducing transgene expression and ultimately the

. To overcome this problem, alternative serotypes have also been

developed as vectors. These include human serotypes that circulate less frequently in
populations, including HAdV-26 and HAdV-35
as those that circulate in chimpanzees

11,96,97

94,95

, and novel non-human primate serotypes such

. These alternative species also induce potent B and
+

T cell responses against both the encoded transgene product and the Ad capsid. The CD8 T cell
response is particularly robust.
While the gold standard for vaccine-mediated protection is considered to be induction of
neutralizing antibodies directed against a pathogen

98

+

, CD8 T cells are also important in vaccine-

+

induced immunity. The CD8 T cell response induced by a vaccine or in response to a natural
infection has the potential to be broad as it is not limited to antigens on the surface of a pathogen
but can also be directed against both internal epitopes and highly conserved elements.
+

During a primary immune response, naïve CD8 T cells are activated in lymphatic tissues
following engagement with an antigen presenting cell (APC) displaying the T cell’s cognate
antigen in the context of MHC class I. The APC provides additional signals in the form of
+

costimulation and cytokines to fully activate these cells. Once activated, CD8 T cells undergo a
period of vast proliferation, during which time effector functions are acquired, including the ability
to produce antiviral cytokines such as interferon-γ (IFNγ) and the cytotoxic granules perforin and
+

granzyme needed to eliminate target cells. Fully activated effector CD8 T cells exit the lymph
nodes and traffic to inflamed tissues in the periphery to carry out their effector function and kill
infected cells. Once the pathogen is cleared, the overwhelming majority of effector cells, up to 90+

95%, will undergo apoptosis. The remaining cells differentiate into memory CD8 T cells that can
endure for life

99

. T cell vaccines specifically seek to take advantage of this natural process in

order to generate high numbers of memory cells, which is correlated to protection
The CD8

+

100-102

.

T cell memory population is highly heterogeneous and can be broadly

classified based on the expression of L-selectin (CD62L), a cell adhesion molecule required to
11

gain entry into the lymph nodes through the high endothelial venules, and CCR7, a chemokine
receptor that promotes migration to the T cell areas of the lymph nodes. Central memory T cells
(TCM) express both CD62L and CCR7, which allow them to enter and reside in lymphoid tissues
103

. In contrast, effector memory T cells (TEM) express neither CD62L nor CCR7

promotes their circulation through the periphery

104

103

. This

. These two subsets are also functionally

distinct. TCM are less differentiated and metabolically quiescent

105

reacquire effector abilities following secondary antigen stimulation

. As such, they are slower to

106

. However, they will robustly

proliferate, and secrete IL-2, in response to stimulation. On the other hand, TEM are more
activated and differentiated, which poises them to rapidly execute effector functions following
reencounter with their cognate antigen. Additionally, they are armed with a large amount of
106

cytotoxic molecules, including perforin
107

and can secrete IFN-γ and TNF-α upon restimulation

. However, while they will rapidly kill target cells, they have a reduced proliferative capacity

compared to TCM cells. The number of effector memory cells declines over time while central
memory cells are maintained at very stable frequencies through homeostatic proliferation
primarily driven by IL-7 and IL-15

99,108

.
+

A single cell is capable of giving rise to the diverse subsets of memory CD8 T cells

109

.

There exist two models to explain how memory T cell populations arise. The first model, the linear
differentiation model, suggests that an effector T cell will either die during the contraction phase
or progressively transition and dedifferentiate from effector to effector memory to central memory
over time

110-112

. Alternatively, the second model, the decreasing potential model, suggests that
+

the fate of a CD8 T cell is determined early in the response by the summation of the signals it
receives during priming

113,114

. The fate decisions that give rise to these populations are thus

influenced by several factors, including the number of naïve precursors

115,116

, strength and

duration of the signal from the T cell receptor upon engagement with the peptide-MHC complex
117

+

, the type of costimulation the CD8 T cell receives

priming

114

118,119

, and the degree of inflammation at

+

. As such, the fate of a CD8 T cell may, potentially be determined as soon as the first

cell division after TCR engagement

120

.

12

+

At the peak of the expansion phase, CD8 T cells can already be divided into the subset
of cells that will eventually die off, i.e. short-lived effector cells (SLEC), and those that will survive
contraction and differentiate into memory cells, i.e. memory precursor effector cells (MPEC)
114,121

. The heterogeneity of the memory response is also established at this time; the MPEC

population can be further divided into those cells that will become TCM and those that will become
TEM

122

.

PERSISTING VACCINES
Immunization with a recombinant Ad-based vaccine induces a transgene product-specific
+

CD8 T cell response that is robust and fails to contract following its peak. Moreover, the
population of cells that fails to contract is primarily composed of cells with effector and TEM
phenotypes. TCM differentiation is delayed, often taking months to years to accumulate in the
+

lymph nodes because the CD8 T cells are slow to regain CD62L expression

123

.

Reacquisition of CD62L expression on memory cells is slower with subsequent antigen
encounters

124,125

. As such, bias toward induction of a memory population primarily composed of

more activated, effector memory cells with low CD62L expression is a function of repeated
antigen exposure and viral persistence

125-127

and not the transgene itself

vectors persist in vivo following administration

123

126

. Indeed, adenoviral

, despite deletion of the gene products

responsible for immune evasion. As expected from the study of wild type virus, the genome is
also enriched in T cells, where it can be detected for years following immunization of mice and
non-human primates

123

. Strong, constitutively active promoters, e.g. cytomegalovirus (CMV)

promoter, are often used to drive expression of the encoded transgene. As such, the encoded
transgene is continuously transcribed, presumably intermittently at low levels

123

.
+

A persistent vaccine vector that maintains an effector memory pathogen-specific CD8 T
cell response may be highly advantageous, particularly in the development of vaccines against
other persisting pathogens. These pathogens are not only quick to spread but also to put in place
immune evasion mechanisms thereby preventing their clearance and allowing them to live in a
13

balance with the host

128

. Many vaccine strategies that aim to mimic natural infection employ non-

persistent vectors that primarily induce central memory. However, because TCM need time in
order to respond to re-infection, they may not be able to catch up to the pathogen once its
immune evasion strategies are in place. Therefore, a front line of defense made up of activated
Tem could be advantageous against both persisting and non-persisting pathogens. Indeed, many
+

infection models have supported this concept. For example, intravenous transfer of CD8 OT-1specific T cells, which recognize the immunodominant epitope of ovalbumin, with a more
activated, effector memory phenotype conferred more rapid protection against challenge with
virulent Listeria moncytogenes expressing ovalbumin than their central memory counterpart

125

.

+

Persistent and protective CD8 TEM responses have also been described for other infections
including, Plasmodium berghei

129,130

, influenza virus

131

, and Salmonella enterica

132

.

Other persistent vectors are also being explored as HIV vaccine platforms and have
supplied encouraging results. It is generally believed that a T cell vaccine against HIV will not
completely protect from or eliminate HIV infection but would instead lower the viral load and delay
progression to AIDS

133

. However, recent studies of vaccines based on CMV have suggested that

a strong T cell response biased toward effector memory may be able to control infection before
HIV can disseminate and avoid control by the immune system

134,135

. A series of rhesus macaque

CMV vectors were engineered to express SIV proteins and used to immunize rhesus macaques.
The vaccine induced very robust, persistent effector memory responses that localized to the
periphery. More than year after their final immunization, the monkeys were repeatedly challenged
intrarectally with a lose dose of SIVmac239, a highly pathogenic, neutralization-resistant clone of
a rhesus macaque SIV isolate

136

. Not only did the vaccine delay the onset of progressive

infection, it also prevented disseminated infection in 4 of 12 animals

134

+

. CD8 T cell depletion of
+

the 4 animals did not result in SIV viremia. The presence of de novo CD8 T cell responses to
SIV antigens not encoded in the vaccine suggested that these animals were able to control early
replication. A follow up study directly compared the CMV platform to others

135

. Monkeys were

immunized with the CMV vector platform alone, the CMV vectors followed by an AdHu5 boost, or
a DNA prime followed by AdHu5 boost. Over a year after the final immunization, the monkeys
14

were challenged as described above. The results were largely consistent with the previous study.
13 of 24 animals that received the CMV vaccines were able to rapidly control SIV infection, while
the DNA prime/Ad5 boost platform only lowered the viral load setpoint. Control in both studies
+

was mediated by effector memory CD8 T cells; whereas, the DNA prime/Ad5 boost induced a
more central memory-biased response. This may suggest that there is a window of opportunity in
which TEM can mediate control. These results are encouraging for the design of vaccines that
induce effector memory T cell responses.

CONCERNS WITH A PERSISTING VACCINE
The persistence of adenoviral vectors may have important consequences on the function
+

of the induced CD8 T cell memory response. Studies of other persistent infections, including
LCMV clone 13, have revealed that chronic antigen exposure can dramatically impair the induced
+

+

CD8 T cell response and, in the most severe scenarios, cause deletion of the induced CD8 T
cells

137-139

. This can be measured by hierarchal loss of the ability to secrete IL-2, followed by
+

tumor necrosis factor-α (TNF-α), and IFN-γ. Additionally, the CD8 T cells lose their cytotoxic
+

capabilities. Some groups have reported that the CD8 T cell population induced following
immunization with recombinant adenovirus primarily consists of effector memory cells that bear a
partially exhausted phenotype and fail to produce IL-2 upon restimulation

140

. However, it is

important to note that these “partially exhausted” cells were protective when immunized animals
were challenged

140

. Indeed, this phenotype is more consistent with highly activated effector cells

than exhausted cells that cannot mediate protection upon challenge. The progressive loss of
function as cells become exhausted as described above is directly related to the amount of
persisting antigen

137

+

. High amounts of antigen are sufficient to drive responding CD8 T cells to

exhaustion. However, adenoviral vectors persist latently and presumably only produce transgene
product intermittently

123

. Therefore, levels of persisting antigen are not high enough to drive the
+

transgene product-specific CD8 T cell response to exhaustion.

15

Even though adenoviral vectors are unlikely to drive a CD8

+

T cell response to

exhaustion, it is worth considering that TEM cells are more terminally differentiated than TCM. They
have shorter teleomeres

141

and express less telomerase than TCM

142

. While this is in agreement

with their limited proliferative potential, this may also suggest the extent to which they can divide
is limited. In support of this, TEM also express higher levels of killer cell lectin-like receptor G1
(KLRG1)

143

, a marker of replicative senescence

family, thereby preventing IL-2 production

145

144

. KLRG1 binds members of the cadherin

and proliferation following TCR stimulation

146

.

KLRG1 accumulates on these cells with successive rounds of antigen stimulation and is
considered a reliable marker of antigen experience

124,147

. Additionally, repetitive antigen

stimulation drives permanent changes to the cell’s transcriptome, including increasing expression
of genes associated with senescence

148

. As such, the first line of defense generated in the

context of a persisting vaccine could potentially be pushed to a point after which it may no longer
mediate protection.

THE ROLE OF CENTRAL MEMORY T CELLS
+

CD8 central memory T cells play a role in maintaining the TEM population. Repetitive
antigen stimulation skews the memory response in favor of increased numbers of TEM

124

.

However, in situations in which antigen does not persist, the TEM population gradually declines
over time

132

, as residual antigen is cleared from depots located in the draining lymph nodes of

peripheral tissues

149

. Once the depot is cleared, the numbers of TEM stabilize

replenished through homeostatic proliferation of TCM

132,149,151

150

and are

. It may be beneficial in vaccine

design to induce a population of TCM that can maintain a first line of defense.
However, there exists controversy on the role that central memory cells play in controlling
+

infection. Studies in which equal numbers of effector memory or central memory CD8 T cells are
adoptively transferred into mice prior to infection generally support the concept that effector
memory cells confer more rapid control. However, in these models the use of mouse lymphocytic
choriomeningitis virus clone 13 (LCMV), which rapidly establishes a chronic infection,
16

demonstrated that central memory cells were better able to control disseminated infection. This
was largely attributed to their increased proliferative capacity that resulted in large numbers of
effector cells during the anamnestic response that likely compensated for an overwhelmed TEM
response at the periphery

107,152

. Other lines of evidence also support a role for TCM. In the context

of the HIV vaccine model described earlier, a DNA prime following by an Ad5 boost generates a
more central memory T cell population

135,153

. While this response does not protect against

infection, it serves to ameliorate the course of disease by reducing the SIV viral load

135,153

.

Interestingly, while the CMV-based SIV vaccine described above protected more than 50% of the
animals from SIV challenge, those that were unable to control the initial infection also had high
+

viral load setpoints. This was attributed to the lack of expansion in the memory CD8 T cell
response after challenge. These studies highlight the importance of TCM as a second line of
defense.

GOALS OF THE STUDY
Available evidence thus suggests that both subsets of memory CD8

+

T cells play

important roles in control of infection. The contribution of each subset into control of infection will
likely depend on several factors, including the pathogen’s route of entry, how quickly it can
replicate and disseminate, and where the pathogen may localize in the host. In designing vaccine
platforms it will be important to assess these factors in order to optimize the vaccine. The studies
+

presented in this thesis were designed to investigate strategies to balance the CD8 T cell
response induced following immunization with adenoviral-based vaccines. More specifically, as
+

vectors based on adenovirus induce robust CD8 T cell responses that are biased toward effector
+

memory, we explored methods to create a CD8 T cell memory response with a better balance
between central and effector memory cells.

17

AIM 1
Adenoviral vectors persist and remain transcriptionally active in activated T cells in vivo.
+

This correlates with two features of the transgene product-specific CD8 T cell response induced
by immunization with adenoviral vectors. First, the transgene product-specific CD8

+

T cell

response fails to contract following immunization. Second, there is a marked delay of more than a
+

year in the accumulation of transgene product-specific CD8 T cells with a central memory
phenotype. As levels of persistent antigen are known to influence anti-viral CD8

+

T cell

responses, we hypothesized that continued production of transgene product from the adenoviral
+

vector genome prevents the contraction of the transgene product-specific CD8 T cell pool,
thereby maintaining them in an activated effector and effector memory state. In chapters 2 and 3
of this dissertation we address this hypothesis in two ways. In the first approach, we aimed to
generate vectors with transgenes whose expression could be temporally regulated. We
hypothesized that discontinuing transgene expression would allow the transgene product-specific
+

CD8 T cell response to contract and differentiate into the central memory compartment. In a
second approach, we aimed to manipulate the mTOR pathway that is downstream of T cell
receptor signaling and recently has been implicated in memory development

154

. We

hypothesized that inhibition of mTOR activity following adenoviral immunization would accelerate
+

the formation of a pool of central memory transgene product-specific CD8 T cells. To this end,
we inhibited mTOR activity in a mouse model using a low dose of rapamycin at different phases
+

of the CD8 T cell response following immunization with an adenoviral vector. Mice were assayed
+

for CD8 T cell numbers and memory phenotypes in several tissues.

AIM 2
+

The CD8 T cell pool that fails to contract following induction with an adenoviral vaccine
+

bears some resemblance to those induced by other persistent viruses. The CD8 T cell pool is
phenotypically heterogeneous, composed primarily of effector and effector memory cells, but is
18

highly functional and protective. A common strategy for maintaining such activated and functional
responses necessary for combating ongoing, low-level viral replication is to continuously prime de
novo CD8+ T cells. However, adenoviral vectors are replication-defective, although transgene
product continues to be expressed at low levels during persistence, which may give responding
+

transgene product-specific CD8 T cells an opportunity to rest from antigenic stimulation and
transition to central memory. Therefore we hypothesized that the transgene product-specific
CD8

+

T cell pool is maintained by recall of antigen-experienced CD8

+

T cells instead of

+

asynchronously primed CD8 T cells. The hypothesis was explored in chapter 4 by adoptively
+

transferring naïve or antigen-experienced CD8 T cells into adenovirus-immunized mice and
following the transferred cells’ responses over time.

19

CHAPTER 2
	
  
OPTIMIZATION OF ADENOVIRAL VECTORS TO INVESTIGATE
THE INFLUENCE OF PERSISTENT TRANSGENE EXPRESSION
ON CD8+ T CELL RESPONSES INDUCED FOLLOWING
IMMUNIZATION

20

ABSTRACT
Adenoviral vectors persist and remain transcriptionally active in vivo. This persistent
+

transgene expression is correlated to the failure of the transgene product-specific CD8 T cell
response to contract and transition to central memory following immunization. In order to directly
investigate these correlations, we utilized a well-characterized recombination system that would
allow us to temporally regulate expression of the encoded transgene. This required the
construction of adenoviral vectors capable of expressing two transgenes at once. In the first part
of this chapter, we describe the optimization of a series of replication-defective adenovirus
vectors designed to express transgene products from two expression cassettes placed into the
deleted E1 and E3 domains. Vectors with fewer shared elements in E1 and E3 expression
cassettes optimally expressed transgenes and induced B and T cell responses to encoded
transgenes. In the second the part of this chapter, we constructed vectors based on the optimal
design from part 1 to generate vectors encoding a transgene that could be temporally regulated.
However, these vectors were unexpectedly unstable. Alternative approaches to regulating
transgene expression from an adenoviral vector will have to be utilized.

First part adapted from:
Construction and Characterization of E1- and E3-Deleted Adenovirus Vectors Expressing
Two Antigens from Two Separate Expression Cassettes. Small JC*, Kurupati RK*, Zhou X*,
Bian A, Chi E, Li Y, Xiang Z, and Ertl HCJ. Human Gene Therapy. 25, 328-338 (2013).
*These authors contributed equally
21

INTRODUCTION
Ad vectors persist in a transcriptionally active state at low levels in mice and non-human
primates

123

and naturally acquired adenoviruses persist in human lymphatic tissues, particularly

in tonsils and adenoids

65

. Additionally, Ad vectors induce a robust population of activated

transgene product-specific CD8

+

T cells that fails to contract over time and is delayed in

differentiating into the central memory compartment. Studies of other pathogens suggest that
persisting antigen is sufficient to maintain this type of response. Therefore, we aimed to
investigate the influence of persistent transgene expression on the differentiation of transgene
+

product-specific CD8 T cell responses following immunization with adenoviral vectors. This
necessitated the development of Ad vectors carrying transgenes whose expression could be
regulated in vivo. The first part of this chapter concerns the optimization of vectors encoding
multiple transgenes, the results of which were applied in the second part in the construction of
vectors generated to explore the question described above.
Ad vectors are deleted in the E1 to limit their replication in vivo. Deletion of the E1
domain allows exogenous DNA sequences up to 4.7 kilobases (kb) to be inserted into the vector
genome

155

. Insertion of foreign DNA enables us to direct an immune response to an antigen from

a particular pathogen. However, protection against many pathogens may require vaccines that
express multiple antigens. Historically, several approaches to achieve this goal have been
explored. One approach is to mix vectors expressing different target antigens

156

; however, this

approach requires generation of multiple vectors, which is both cumbersome and costly,
especially for large-scale, clinical applications. Alternatively, multiple transgenes, either in the
form of a single fusion gene or separated by an internal ribosomal entry site (IRES), whose
expression is driven by a single promoter, can be inserted into the E1 domain. This approach is
not without limitations, as insertion of long coding sequences into the E1 domain results in
diminished transgene expression that ultimately reduces induction of transgene product-specific
immune responses

157

. A third approach that has been explored is to insert independent

expression cassettes with identical promoters into the deleted E1 domain

158

, but this often results
22

in homologous recombination between the promoters and, consequently, the removal of one
expression cassette from the Ad genome.
To avoid these complications, a different approach is necessary. Secondary generations
of Ad vectors are deleted in multiple domains, including the E3 domain, which encodes genes
that are unnecessary for viral replication. Deletion of the E3 domain increases the packaging
capacity of Ad vectors to 7.5 kb

159

. This was taken advantage of in the study presented here. A

series of vectors based on chimpanzee Ad serotype 7 (AdC7), also called SAdV-24, were
generated that carried one expression cassette in the deleted E1 domain and a second different
expression cassette in the deleted E3 domain. Each expression cassette carried a different
promoter to drive their respective transgene’s expression. Additionally, combinations of various
regulatory elements, including introns and enhancers, and expression cassette orientation were
tested for their impact on transgene expression and subsequent induction of immune responses.
The results indicate that the orientation of the E3 expression cassette dramatically affects
vector fitness and transgene expression. Vectors with E3 expression cassettes inserted parallel
to E3 transcription (5’ to 3’, or forward oriented) could commonly not be rescued whereas
insertion in the opposite orientation resulted in fitter vectors, although this was influenced by the
choice of the promoter in the E3 cassette. Additionally, the presence of shared sequences, such
as introns and enhancers, between the E1 and E3 expression cassettes impacted transcription of
each transgene and thereby induction of transgene product-specific immune responses.
In the second part of this chapter, the above results were applied to generate AdC7
vectors encoding a transgene whose expression could be temporally controlled. Vectors were
designed such that the E1 expression cassette contained a transgene flanked by loxP sites
(floxed) and the E3 expression cassette contained CreERT2, a fusion protein of Cre
recombinase, which recombines loxP sites, and a mutated version of the ligand-binding domain
of the human estrogen receptor (ER). The mutation makes CreERT2 activity inducible as only the
synthetic ligand and estrogen antagonist, 4-hydroxytamoxifen (4-OHT), can bind to the ER

160

.

Administration of 4-OHT would therefore provide conditional and temporal control over
expression of the floxed transgene and thus enable studies into its role in maintaining the
23

elevated and prolonged transgene product-specific effector/effector memory CD8

+

T cell

response. Floxed dual expression vectors were constructed and results indicated that transgene
expression could be regulated in vitro. However, upon further inspection it was discovered that
the vectors recombined at the loxP sites during viral expansion.

RESULTS A.	
  OPTIMAL DESIGN OF ADENOVIRAL VECTORS EXPRESSING DUAL
TRANSGENES
Vector construction and quality control
In order to optimize vectors expressing transgenes from both the E1 and E3 loci, a series
of shuttle vectors was designed to insert expression cassettes encoding transgenes and various
regulatory elements into the E1- and E3-deleted AdC7 vector genome. Expression cassettes
designed for insertion into the deleted E1 domain used the cytomegalovirus (CMV) promoter to
drive expression of the inserted transgene and the bovine growth hormone (BGH) poly(A) tail.
The expression cassette was further modified by deletion of the CMV enhancer, intron, or both.
Shuttle vectors designed to insert expression cassettes into the deleted E3 domain contained
expression cassettes whose transgene’s expression was driven either by the Rous Sarcoma
Virus (RSV) promoter or by the chicken β-actin (CB) promoter. All expression cassettes encoded
the rabbit globin poly(A) tail. E3 expression cassettes were further modified by deletion of the
CMV enhancer sequence, the intron, or both. Additionally, E3 shuttle vectors were designed to
insert the E3 expression cassette in the same direction as E3 transcription, 5’ to 3’ (forward), or
the opposite orientation, 3’ to 5’ (reverse). Once constructed, the E1 and E3 shuttle vectors were
used to construct pAdC7 molecular clones. Completed pAdC7 clones were linearized and
transfected into HEK 293 cells in order to rescue AdC7 virus. Rescued viruses were further
expanded on 293 cells. A list of the different vectors generated and their qualities is shown in
Figure 2.1.
If three attempts failed to rescue virus that could be further expanded, the virus was
considered unfit. Most recombinant AdC7 molecular clones bearing an E3 cassette with the RSV
24

promoter were unfit. When this cassette was forward-oriented, all viruses failed to rescue,
regardless of whether or not an E1 expression cassette was included. One viral clone with only a
reverse-oriented E3 expression cassette was also unable to be rescued. However, when an E1
expression cassette was included in that construction, the virus was successfully rescued. Use of
the CB promoter in the E3 cassette yielded more promising vectors. Two of four molecular clones
yielded infectious viral particles when this cassette was in the forward-orientation; all viruses
containing this cassette in the reverse-orientation were rescued.
All rescued viruses were quality controlled following expansion by assessing genetic
integrity, viral particle yields, and infectivity. Genetic integrity was confirmed by restriction digest
of isolated viral DNA from expanded virus; enzymes were chosen to specifically identify the
unique expression cassettes. All viruses showed expected banding patterns for their expression
cassettes. Viral particle yield was determined following expansion on 10

9

HEK 293 cells.

Expansion of traditional AdC7 vectors encoding a single transgene in E1 typically yield between
0.1 to 2x10

14

viral particles (vp) (Figure 2.2A). All viruses capable of being rescued, regardless of

E3 promoter and orientation, yielded similar numbers of virus particles and were comparable to
the traditional vector. However, removal of sequences (intron, enhancer, or both) shared between
the E1 and E3 cassettes tended to result in superior yields. Infectivity, or the number of viral
particles needed to productively infect a single cell, is determined by the ratio between the
number of viral particles isolated and the multiplicity of infection (MOI), which is assessed by
titrating vector on HEK 293 cells. Traditional AdC7 vectors typically have an infectivity ratio of
<1:500 (Figure 2.2B). All rescued dual expression vectors had infectivity ratios that were
comparable to that of the single expression AdC7 vector. The pattern of variation observed
between groups followed that observed in the differences in viral particle yields. The infectivity
ratio was highly variable within each construct family but this appeared to be dependent on the
type of transgene encoded in each expression cassette.
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FIGURE 2.1. Diagrams of dual expression vectors’ expression cassettes and their
qualities

For each vector discussed in Figures 5.2 - 5.7, a schematic of the expression cassettes inserted into the E1
and E3 domains are shown with the vector number and the long form list of E1 and E3 characteristics is
included. The first four vectors described are the control vectors, the following six are the experimental
vectors presented in all figures, and the final two vectors are the two that carried the RSV promoter and are
discussed only in Figure 2. The a key for list of characteristics provided in the E1 makeup/E3 makeup
column is included: Domain into which the cassette was inserted: promoter (cytomegalovirus (CMV),
chicken β-actin (CB), or rous sarcoma virus (RSV)), cassette orientation (forward (f) or reverse (r)),
enhancer (e), intron (i), transgene (influenza nucleoprotein (NP) or gag of simian immunodeficiency virus
(SIV gag)). If the list does not contain an “e” or “i”, then the cassette does not contain them. If there is no
expression cassette in one domain that domain is listed as “empty”.
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FIGURE 2.2. Dual expression vectors’ growth characteristics and infectivity
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[A] Shows the virus particle yield per 109 HEK 293 cells as medians + interquartile range (IQR). Each bar
represents the growth characteristics for pooled lots of viruses with the same basic vector design described
on the X-axis. Vectors that conform to the appropriate design are listed in parentheses. Their characteristics
are described in Figure 5.1.
[B] Graph shows the vp to MOI ratios as a representation of infectivity for the same types of vectors shown
in [A] as median + IQR.
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Transgene product expression
We specifically focused on vectors that carried gag of Simian Immunodeficiency Virus
(SIV) and nucleoprotein (NP) of influenza A/PR8 as transgenes in either E1 or E3. These vectors
drove expression from the E1 domain using the CMV promoter and used the CB promoter in E3.
Controls for the remaining experiments included AdC7 vectors that encoded gag or NP in either
E1 or E3. Transgene expression from each cassette was measured using reverse transcription
real-time PCR (qRT-PCR). HEK 293 cells were infected with 1000 vp per cell and total RNA was
isolated and reverse transcribed 24 hours later. Real time PCR analysis showed that transcription
of each transgene varied between vector types. This variation was only partially explained by
differences in vector infectivity (vp to MOI ratio shown in Figure 2.2).
As expected, NP was not expressed in cells infected with vectors that did not encode NP
(E1175, E1043, Ad-GFP) (Figure 2.3A). Single expression control vectors encoded with NP in E1
(E1288) or in E3 (E1219) demonstrate that moving the position of the NP expression cassette
from E1 to E3 reduces its transcription. This phenomenon was largely recapitulated in the dual
expression vectors. Those vectors that carried NP in the E3 domain (E1492, E1324) expressed
NP at levels comparable to E1219. However, the reduced NP expression in cells infected with
E1492 was likely due to its high vp to MOI ratio, implying that there were fewer infectious viral
particles available to infect the 293 cells. Dual expression vectors with NP encoded in the E1
domain tended to express higher levels of NP. The highest NP expression level was observed
when the NP expression cassette was accompanied by the forward-oriented E3 expression
cassette (E1310). Reversing the orientation of the E3 expression cassette dampened NP
expression (E1174). Further modification of the two expression cassettes gave mixed results. As
expected, removal of the regulatory elements from the E1 NP expression cassette (E1301)
resulted in decreased in NP expression. Interestingly, removal of regulatory elements from the E3
cassette (E1303, E1302) enhanced NP transcription.
Different patterns of gag expression were observed. While moving NP to E3 expression
cassettes resulted in lowered expression, encoding gag in E3 resulted in overall higher gag
expression (Figure 2.3B). This phenomenon was observed for both the control vectors (E1175,
28

E1043) and for the dual expression vectors. Orientation of the E3 cassette affected gag
transcription in the opposite manner it affected expression of NP in the E1 cassette – gag
expression was lowest when the E3 cassette was in the forward orientation (E1310). Reversal of
the E3 expression cassette resulted in higher levels of gag transcription. Removal of the
regulatory elements from the E1 domain had little effect on gag transcription from the E3 domain.
We expected that removal of the regulatory elements from the E3 gag expression cassette would
reduce gag expression, similar to what was observed for NP expression (E1301, Figure 2.3A).
Instead, gag expression was the highest in cells infected with the vectors from which the
enhancer element was removed (E1303) or both the enhancer and intron were removed from the
E3 expression cassette (E1302).
Protein expression was measured by western blot on protein lysates harvested 24 hours
after infection with the dual expression vectors. NP protein expression was measured in 293 cells
infected with either 1000 or 10,000 vp per cell of the dual expression vectors that carried NP in
E1 (E1174, E1303, E1302, E1301) and the two control vectors encoding only NP in E1 or in E3
(E1219, E1228). As shown in Figure 2.4A, NP expression was comparable between all vectors
at each dose. More vectors were included (E1175, E1310, E1324, E1492) and tested for Gag
expression by infecting cells with 10,000 vp per cell (Figure 2.4B). Gag expression was more
variable than that of NP protein but the results largely mirrored those seen for gag RNA
transcripts. As expected, if gag was not encoded in the vector, Gag protein was not detected. The
lowest amount of Gag was detected in lysates from cells infected with E1310, the vector carrying
NP in E1 and gag in the forward-oriented E3 expression cassette. Gag was most highly
expressed in cells infected with the vector that encoded NP in the standard E1 expression
cassette and encoded gag in E3 in the reverse-orientated expression cassette that lacked the
enhancer element (E1302). Both of these results were consistent with those observed for RNA
transcription (Figure 2.3).

29

FIGURE 2.3. Levels of NP and gag transcript expression
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Graphs show quantitative reverse transcriptase PCR results indicating levels of transcript expression
6
10
achieved within 24 hours by 10 HEK 293 cells infected with 10 vp of the indicated vector. Experiments
were conducted twice for most vectors and bars show median levels + IQR range. [A] shows results for NP
transcripts, [B] shows results for gag transcripts as median + range. Numbers above the bar show the vp to
MOI ratio of the indicated vector. H2O and an Ad vector expressing green fluorescent protein (GFP) were
used as negative controls.
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FIGURE 2.4. NP and Gag protein expression

6

Graphs show Western Blots for NP [A] and Gag [B]. To determine expression levels of NP, 10 HEK 293
9
10
6
cells were infected with 10 or 10 vp of indicated vector. Gag expression was tested in 10 HEK 293 cells
10
infected with 10 vp of indicated vector. Cell lysates were collected 24 hours after infection for both [A] and
[B]. Blots were probed for β-actin as a loading control.
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Vector Immunogenicity
As the vectors were demonstrated to express well in vitro, their immunogenicity was next
measured. Outbred ICR mice were immunized intramuscularly (IM) with 10

10

vp of the more

promising vectors that express NP and Gag. As controls, groups of mice were immunized with
vectors expressing NP or Gag from E1 or E3. Mice were bled six weeks after immunization and
serum was tested for NP- and Gag-specific antibodies by ELISA. Each dual expression vector
induced detectable antibody responses to both the NP and Gag antigens (Figure 2.5). E1303,
which lacked both the intron and enhancer elements in the E3 expression cassette, induced a
NP-specific antibody titer of approximately 200 µg/mL, the highest of all the dual expression
vectors (Figure 2.5A). The lowest anti-NP antibody titer (less than 100 µg/mL) was induced by
E1302, which did not carry an enhancer in the E3 expression cassette, despite a similar
expression pattern in vitro to that of E1303. Two other dual expression vectors were tested for
induction of NP-specific antibody responses: E1301, which lacked the intron and enhancer in the
E1 expression cassette, and E1174, which contained both the enhancer and intron in both the E1
and E3 expression cassettes. Both vectors induced NP antibody titers comparable to those
induced by the two NP-only control vectors, approximately 125-150 µg/mL (E1288, E1219).
Immunization with the dual expression vectors induced higher titers of Gag-specific antibodies
than NP-specific antibodies (Figure 2.5B). The E1303 vector induced a Gag-specific antibody
titer of ~800 µg/mL, which was the highest titer induced. The other vectors tested induced titers of
approximately 500 µg/mL, which was comparable to titers induced by the control vectors, E1043
and E1175.
+

Induction of CD8 T cell responses specific to each transgene was also measured as a
test of vector immunogenicity. Groups of C57Bl/6 mice were immunized IM with 10

10

vp of the

indicated vectors; a group of naïve mice was included as a control. Two and six weeks following
+

immunization, peripheral blood mononuclear cells (PBMCs) were isolated and tested for CD8 T
cell responses specific to NP and Gag by intracellular cytokine staining (ICS) for IFN-γ, TNF-α,
and IL-2 following in vitro stimulation with corresponding peptides. Boolean gating was used to
determine the sum of all possible cytokine responses and background was subtracted. All vectors
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+

with the exception of E1174 and E1301 induced NP-specific CD8 T cell responses (Figure
2.6A). The control vector only carrying NP in E1 (E1288) induced, as expected, a robust NP+

specific CD8 T cell frequency of about 6% at two weeks after immunization that contracted to 1%
at six weeks post-immunization. The vector in which the E3 cassette was in the forward
+

orientation, E1310, induced an equally potent NP-specific CD8 T cell response that contracted
less than that of the control vector at six weeks. This corresponded well with its expression data,
which demonstrated that NP was most highly expressed from this vector (Figure 2.3). Complete
removal of the regulatory elements that were shared between E1 and E3 resulted in a vector that
+

induced a more modest NP-specific CD8 T cell frequency of 2% at two weeks following
immunization. However, the response contracted less than that of the other dual expression
vectors. The similar vector, E1302, which has the intron in the E3 cassette, induced a response at
+

two weeks comparable to that induced by the control vector and E1310. The NP-specific CD8 T
cell response contracted and was maintained at a frequency similar to that of E1302. Gag+

+

specific CD8 T cell responses were overall lower and more delayed than the NP-specific CD8 T
+

cell response (Figure 2.6B). E1310 induced a very robust NP-specific CD8 T cell response but
failed to induce a Gag-specific response at either timepoint; whereas, E1174 failed to induce an
+

NP-specific response but did induce a very modest Gag-specific CD8 T cell response of less
than 1% that was sustained throughout the experiment. E1301, which also did not induce a
detectable NP-specific CD8

+

T cell response, induced a modest Gag-specific CD8

+

T cell

response at 2 weeks that did not peak until 6 weeks after immunization. E1302 and E1303 both
+

induced robust Gag-specific CD8 T cell responses. While E1302’s peak response was more
delayed than that of E1303, it was maintained at a higher level.

33

FIGURE 2.5. NP- and Gag-specific antibody responses
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Pooled sera from mice immunized with the indicated vectors were tested for antibodies to NP [A] or Gag [B]
by ELISA four weeks after vaccination. The graphs show area under the curve for two replicates of serially
diluted sera. Lines indicate significant differences between the samples determined for by one-way ANOVA
with Tukey correction.
* indicates level of significance as follows: * p >0.05-0.01, ** p < 0.01 – 0.001, *** p < 0.001-0.0001, **** p <
0.0001.
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FIGURE 2.6. Kinetics of NP- and Gag-specific CD8+ T cell responses
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PBMCs from individual mice were tested 2 and 6 weeks after immunization for NP- [A] and Gag- [B] specific
+
+
+
CD8 T cell responses by ICS. Graphs show the % of CD8 T cells over total CD8 T cells that produced
cytokines after stimulation with the specific peptides after subtraction of background data obtained with
cultures stimulated with an irrelevant peptide. Differences from results obtained with PBMCs from naïve
mice were assessed with one-way ANOVA and uncorrected Fischer’s LSD.

* indicated level of significance as follows: * p >0.05-0.01, ** p < 0.01 – 0.001, *** p < 0.001-0.0001, **** p <
0.0001.
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RESULTS B. DEVELOPMENT OF NOVEL ADENOVIRAL VECTORS WITH
CONDITIONAL TRANSGENE PRODUCT EXPRESSION
Test of concept with single expression vectors
A primary goal of this thesis was to directly investigate the role of persistent transgene
expression from the Ad vector genome on the maintenance of the transgene product-specific
CD8

+

T cell response. This necessitated the generation of Ad vectors whose transgene

expression could be temporally regulated. One system often used to this end is the Cre/lox
system that conditionally induces site-specific recombination

160

. As a test of concept, Ad vectors

based on chimpanzee serotype 7 were generated that carried green fluorescent protein (GFP)
flanked by loxP sites (5’-ATA ACT TCG TAT AGC ATA CAT TAT ACG AAG TTA T-3’) in an
expression cassette inserted into the E1 domain (AdC7-GFP

loxP

) (Figure 2.7A). In order to

determine if the expression of the transgene could be regulated using this method, HEK 293 cells
were engineered to stably express CreERT2 (293-CreERT2. 10
7

8

infected with 10 or 10 vp AdC7-GFP

loxP

6

293-CreERT2 cells were

. At the time of infection, cells were treated with either

0.2 µM, 2 µM 4-OHT, or the equivalent volume of vehicle. Flow cytometry was used to measure
GFP expression 24 hours after infection. Results indicated that even a low dose of 4-OHT was
capable of inducing Cre activity in the cell line and thereby excision of the floxed GFP from the Ad
genome (Figure 2.7B). This experiment suggested that transgene expression from the Ad
genome could be regulated using the Cre/lox site-specific recombination system.
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FIGURE 2.7. Test of concept – Ad vectors can have inducible transgene
expression.
A.

B.
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schematic of the E1 cassette carried by AdC7-GFP , which was used to infect cells for [B]. The E1
cassette used the cytomegalovirus (CMV) promoter to control expression of GFP. Additionally, the CMV
enhancer and an intron were used to enhance expression. The Bovine Growth Hormone (BGH)
polyadenylation signal was inserted 3’ to the GFP coding sequence. LoxP sites (5’-ATA-ACT-TCG-TATAGC-ATA-CAT-TAT-ACG-AAG-TTA-T-3’) were inserted 5’ to the CMV enhancer and 3’ to the poly(A) tail in
parallel orientation, so that the flanked sequence is excised from the genome upon Cre-mediated
recombination. LoxP sites and directionality are indicated by black triangles. This expression cassette was
inserted 5’ to 3’ (forward orientation) into the genome of an E1- and E3-deleted AdC7 molecuar clone.
8

7

loxP

[B] 10 and 10 viral particles (vp) of AdC7-GFP
were used to infect HEK 293 cells stably expressing
inducible Cre recombinase (293-CreERT2 cells). 1 hour prior to infection, 293-CreERT2 cells were treated
with 9.5 µL 2 µM or 0.2 µM 4-hydroxytamoxifen (4-OHT) to activate Cre-ERT2 activity. To demonstrate that
Cre activity is inducible, cells were treated with the equivalent volume of vehicle (95% EtOH). As a negative
control for expression, groups of uninfected cells were treated with both doses of tamoxifen and vehicle. 24
hours after infection, cells were assayed for GFP expression by flow cytometry. Graph shows percentage of
GFP positive 293-CreERT2 cells over all cells.
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Dual expression vector construction
Use of Ad vectors carrying only a floxed transgene would limit the use of these vectors to
a transgenic mouse model that ubiquitously expressed CreERT2, vectors were engineered to
carry CreERT2 as a transgene in the deleted E3 domain. The previous set of experiments
demonstrated that vectors containing fewer shared sequences between the E1 and E3
expression cassettes had more optimal, balanced expression of both transgenes. As such new
series of dual expression vectors was constructed following the design of the best performing
vector (E1302) described above. Their design is shown in Figure 2.8A. The E1 expression
cassette was constructed such that the CMV promoter controlled expression of the inserted
transgene, which, in the following studies, was either gag of HIV-1 or GFP. Removal of the CMV
enhancer and the intron from the E1 expression cassette was shown to dampen expression of
the E1 transgene without having much effect on expression from E3; therefore, we included both
elements in the cassette. Finally, the expression cassette was floxed. The E3 expression cassette
encoded CreERT2 under the control of the CB promoter. It was demonstrated earlier that the
orientation of the E3 expression cassette dramatically influences the expression of both encoded
transgenes. Although placing the E3 cassette in the forward (5’ to 3’) orientation lead to very
robust E1 transgene expression, expression from the E3 cassette was not optimal. Optimal
expression of CreERT2 needed to be achieved to ensure excision of all floxed sequences;
therefore, as vectors carrying the E3 cassette in the reverse orientation tended to have better
expression of the E3 transgene, the CreERT2 expression cassette was inserted into E3 in the
reverse orientation. Additionally, only an intron was included in the E3 expression cassette
because inclusion of both the intron and enhancer, which were shared between both expression
cassettes, reduced expression of the E3 transgene.

In vitro transgene expression and regulation
In order to confirm that both the floxed transgene, in this case HIV gag, and CreERT2
were expressed and that CreERT2-mediated recombination of loxP sites could be induced, 10

6

Chinese hamster ovary (CHO) cells expressing the coxsackie and adenovirus receptor (CAR)
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9

were infected with 10 vp of AdC7-HIVgag

loxP

-CreERT2 and treated with either 4-OHT or the

equivalent volume of vehicle. As a positive control for gag expression, a group of cells was
9

infected with 10 vp of AdC7-HIVgag

loxP

. One week later, total RNA and protein lysates were

collected. Reverse transcription of total RNA revealed that gag was expressed in the absence of
CreERT2 activity but following treatment with 4-OHT gag RNA was no longer detected (Figure
2.8B). Of note, gag expression from AdC7-HIVgag

loxP

-CreERT2 was reduced compared to the

positive control vector.
Gag and CreERT2 expression were also confirmed by Western blot of infected cells
8

(Figure 2.8C). Doses ranging from 10 vp to 10
vp of AdC7-HIVgag

loxP

10

6

vp were used to infect 10 CHO-CAR cells. 10

9

was used as a positive control. Groups of cells were again treated either

with 4-OHT or vehicle. Protein lysates were collected one week later. In the absence of 4-OHT,
the highest expression of Gag was achieved with the 10

10

vp dose of AdC7-HIVgag

loxP

-CreERT2,

which was slightly greater than that of the positive control. As expected, Gag expression
decreased as the vector dose was decreased. The same expression pattern was observed for
CreERT2. These results demonstrate that while CreERT2 is expressed, it is not active in the
absence of tamoxifen treatment. However, CreERT2 activity was induced following tamoxifen
treatment as evidenced by only faint detection of Gag one week after infection. Taken together,
these results indicate that both transgenes are expressed in vitro and, importantly, CreERT2
activity,

and

thereby

Gag

expression,

can

be

regulated

with

tamoxifen.
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In vivo transgene expression
As the transgenes were demonstrated to express well in vitro, transgene expression was
next determined in vivo. BALB/c mice were injected IM with 10

11

vp of AdC7-GFP

loxP

-CreERT2 or

the equivalent dose of AdHu5-GFP as a positive control for GFP expression. Two days later, the
injected muscle was visualized for GFP expression as shown in Figure 2.9A. Very robust GFP
expression was observed in the legs of mice injected with the positive control vector.
Unexpectedly, GFP was unable to be detected in mice injected with AdC7-GFP

loxP

The lack of expression in vivo could perhaps be explained if AdC7-GFP

-CreERT2.

loxP

-CreERT2 had

a very high infectivity ratio (vp to MOI), although this would impact in vitro expression as well.
However, the ratio was 182:1, which is considered average. Another possible explanation for the
lack of expression could be that the integrity of the vector’s genome was compromised. To this
end, viral DNA was purified from all dual expression vectors carrying a floxed transgene in E1
and CreERT2 in E3. Both the viral DNAs and the corresponding molecular clones used for viral
rescue were subjected restriction digest with an enzyme chosen specifically to screen the floxed
transgene (Figure 2.9B). Some banding pattern differences between the plasmid and viral DNA
were expected, because the viral DNA lacks some sequences present in the molecular clone.
However, a 2.2 kb band was missing from the isolated viral DNA. This band corresponded to the
restriction sites that flanked the E1 cassette that the floxed transgene. Lack of this band indicated
that the cassette was no longer present in the genome. The viral DNAs were sequenced to
confirm loss of the E1 expression cassette. Sequencing data was in agreement with the
restriction digests (schematic in Figure 2.9C). Only a single loxP site was detected in each
genome and no expression cassette sequences were detected. This indicated that the viral
genome recombined at the loxP sites during viral expansion, which most likely gave the mutant a
growth advantage over the original recombinant vector. Interestingly, restriction digestion of the
vectors that carried a floxed transgene in the E1 domain but did not carry CreERT2 revealed that
the genome of these vectors remained intact during rescue and expansion.
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FIGURE 2.8. Construction and expression of AdC7 vectors dually expressing a
floxed transgene and CreERT2.

[A] Shows a schematic of the E1 and E3 expression cassettes. The E1 cassette was identical to that
described in Figure 2.7. A. The transgenes used for the following experiments were gag of HIV-1 (shown in
[B] and [C]) and GFP (shown in Figure 2.9A and B). The E3 expression cassette was modeled after that
loxP
carried in E1302 (described in Figure 2.1). The vectors will be referred to as AdC7-HIVgag -CreERT2 or
loxP
AdC7-GFP -CreERT2.
6

[B] Expression of HIV gag (p24) as measured by reverse transcriptase PCR. 10 CHO-CAR cells were
9
loxP
infected 10 vp AdC7-HIVgag -CreERT2. 1 hour prior to infection cells were treated with either 2 µM 49
loxP
OHT or the same volume of vehicle. Cells were infected with 10 vp AdC7-HIVgag
as a positive control
9
for gag expression. As a negative control cells were infected with 10 vp AdC7 expressing rabies virus
glycoprotein. Total RNA was isolated 1 week following infection and 2 µg was reverse transcribed. Gag was
then amplified in a regular PCR from 1 µL of cDNA template. The resulting PCR fragments were visualized
on a 1% TAE agarose gel stained with EtBr.
6

[C] Protein expression of HIV gag (p24) and CreERT2 as measured by Western Blot. . 1x10 CHO-CAR
10
9
8
loxP
cells were infected 10 ,10 , or 10 vp AdC7-HIVgag -CreERT2. 1 hour prior to infection cells were treated
9
loxP
with either 2 µM 4-OHT or the same volume of vehicle. Cells were infected with 10 vp AdC7-HIVgag
as a
positive control for gag expression. They were also treated either with vehicle (V) or 2 µM 4-OHT (T).
Uninfected cells were used as a negative control.
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FIGURE 2.9. Dual expression vectors carrying floxed transgene and inducible Cre
recombinase fail to express in vivo.

[A] Shows GFP expression in hind limbs following immunization with GFP-expressing Ad vectors. BALB/c
11
loxP
mice were immunized with 10 vp AdC7-GFP -CreERT2 or, as a positive control from GFP expression,
11
10 vp AdHu5-GFP. 48 hours later, mice were sacrificed and legs were removed and visualized for GFP
expression using Illumatool Lighting System. A Kodak DCS14N digital SLR camera with a 60-mm Micro
Nikkor lens at f3.5 using 1:2.2 magnification was used to take photographs.

FIGURE LEGEND CONTINUED ON PAGE 43
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[B] The molecular clone (plasmid) DNA of all dual expression vectors carrying floxed transgenes and the
corresponding viral DNA isolated from expanded viruses were subjected to restriction digestion with BglII
loxP
enzyme for 1 hour at 37°C. Additionally, AdC7-GFP
viral DNA was subjected to restriction digest with
SphI for 1 hour at 37°C Digests were visualized on a 1% TAE agarose gel stained with EtBr. “M” indicates
the 1 kb plus ladder. For the dual expression vector digests: the grey arrow indicates an expected band
because the plasmid DNA is circular while the viral DNA is linear. The black arrow indicates an unexpected
missing band at 2.2 kb corresponding to the floxed E1 expression cassette. For the sing expression vector:
the white arrow indicates the expected 2.7 kb band corresponding to the floxed E1 expression cassette.
loxP
Shown here are digestions for AdC7-GFP -CreERT2 plasmid and viral DNA. Identical results were
obtained for all other vectors tested.
[C] Shows a schematic of results. The missing band corresponded to a 2281 kb fragment that encompassed
the floxed expression cassette in the E1 domain. The viral DNA was additionally sequenced (not shown) and
the sequencing data corresponded with the restriction digestion. It revealed that the two BglII sites now
encompassed a fragment that no longer contained the E1 expression cassette but contained only a single
loxP site and the remaining base pairs between each BglII and loxP site.
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DISCUSSION
Ad vectors elicit potent immune responses not only to their viral antigens but also to the
products of encoded transgenes. Their consistently potent induction of transgene product-specific
+

B and CD8 T cell responses has made them ideal vaccine platform candidates. As such, Ad
vectors derived from a variety of serotypes have been extensively developed as vaccine carriers
and are currently being tested in clinical trials.
For some pathogens it may be necessary to direct a broader immune response that is not
limited to a single antigen. To this end, multiple Ad vectors, each expressing a different antigen of
interest, could be used for immunization. This approach has been used with success

156

but it is

both cumbersome and costly. Therefore, several strategies have been employed to express
multiple transgenes from a single Ad vector. Two of the most commonly used strategies are to
encode a long fusion protein of the genes of interest or to separate two transgenes by an internal
ribosomal entry site (IRES). The former strategy may interfere with folding of the resultant fusion
protein, which may alter protein functionality and immunogenicity. Dual expression Ad vectors
have been designed using the latter method

161,162

. While both transgenes separated by an IRES

are expressed, very often the downstream transgene is expressed at lower levels than the
upstream transgene. This would be problematic if stoichiometric amounts of each transgene are
required. It is worth noting that long transgenes inserted into the Ad genome are not expressed
as well as shorter transgenes, leading to dampened immune responses

157

. Therefore, this would

be problematic for all the strategies described above.
Insertion of tandem expression cassettes into the deleted E1 domain has also been used
to design dual expression Ad vectors. The earliest vectors encoded two identical expression
cassettes that only differed in the transgene each cassette carried

158

. However, serial passaging

of vectors carrying identical expression cassettes often reveals that vectors with large regions of
homology, e.g. identical promoters or other shared sequences, are genetically unstable and often
recombine, resulting in excision of one expression cassette

163

. Others have designed vectors

44

using different promoters alone
as the polyA tail

163

164,165

or in combination with different regulatory elements, such

, to drive expression of the transgenes inserted into the E1 domain.

Ad vectors are often deleted in multiple gene domains or are fully gutted. These deletions
not only reduce immune responses to viral antigens but also increase the carrying capacity of the
vector

155

. One group used this approach to design vectors that expressed three transgenes by

encoding one in the E1 domain under the CMV promoter and using a bidirectional promoter to
drive expression of two other transgenes inserted into the region between the E4 domain and
fiber

166

.
In the study presented here, we designed a series of AdC7 vectors encoding transgenes

in the deleted E1 and E3 domains and systematically tested how the components of each
cassette impact transgene expression. As use of identical expression cassettes has been shown
to promote homologous recombination in Ad5- and Ad35-based vectors

163,167

and use of

heterologous expression cassettes inserted into E1 and E3 have been shown to express well in
Ad5-based dual expression vectors

168,169

, we chose to control expression of each transgene with

heterologous promoters. The CMV promoter is widely used to drive ubiquitous and high levels of
gene expression, although it is sensitive to silencing

170,171

. Despite this, we constructed our dual

expression vectors such that the CMV promoter always drove E1 transgene expression. Two
other widely used promoters, the RSV and chicken beta-actin (CB) promoters, were used to drive
expression of the E3 transgene, in most cases gag of SIV. Others have used the RSV promoter
in dual expression Ad vectors in the E3 domain

172

. However, our attempts to generate Ad vectors

with this promoter often yielded unstable vectors that could not be rescued. Vectors’ growth
characteristics were improved by using the CB promoter in the E3 cassette.
Expression cassette orientation is an important consideration in the construction of
adenoviral vectors. Others have demonstrated that orienting transgenes in the same direction as
E1 transcription (5’ to 3’) leads to better growth characteristics

173

and transgene expression

174

.

While E1 orientation was not tested in these studies, the findings concerning E3 cassette
orientation are in contrast with this, even though E3 transcription also occurs 5’ to 3’. When the
E3 cassette was inserted in that direction (forward orientation), vectors were often unable to be
45

rescued. Use of the RSV promoter in this orientation did not yield viable vectors, whereas, some
vectors encoding the CB promoter in the forward orientation were able to be rescued and
propagated. Interestingly, the vectors that could be rescued (E1310) had the highest level of
transcription from the E1 cassette but lower levels of expression from the E3 cassette. Switching
the orientation to the opposite of E3 transcription (3’ to 5’) improved growth characteristics of
these vectors and led to more balanced expression of the E1 and E3 transgenes.
The presence of shared introns and enhancer sequences in both E1 and E3 directly
affected expression of the E1 transgene. Removal of one or both regulatory elements from the E3
domain tended to increase expression from E1 without having much impact on expression from
the E3 domain. This may suggest that the shared elements are competing for limited factors.
In vitro expression data for each transgene suggested that the position of each transgene
within the Ad genome influenced expression. NP was more highly expressed from the E1 domain
than the E3 domain, while gag was more highly expressed from the E3 domain. Therefore, it was
important to consider if the position of the transgene within the Ad genome also impacted
corresponding B and T cell responses, which could be affected by expression in vivo, processing
of each transgene, and presentation. In vitro expression data did not predict transgene productspecific antibody responses from control vectors. Those expressing NP alone in either the E1
(E1288) or E3 (E1219) domain induced comparable NP-specific antibody titers, despite unequal
expression in vitro. Whereas, Gag expression was higher from the vector carrying gag in the E3
domain (E1175) but induced a slightly lower Gag-specific antibody response than the vector
carrying gag in the E1 domain (E1043). Taken together these results may indicate that the impact
of position on induced immune responses may be dependent on the transgene itself and not on
processing and presentation of the transgene.
Immune responses to the transgenes in some dual expression vectors were predicted by
their respective expression in vitro. E1310, the vector in which NP was encoded in E1 and gag in
the forward-oriented E3 cassette, had high levels of NP expression but low levels of Gag
+

expression in vitro and accordingly had the highest NP-specific CD8 T cell responses but failed

46

+

to induce Gag-specific CD8 T cells. Other vectors followed this pattern as well, including E1301
and E1174.
In some cases, immune responses to the dual expression vectors were not predicted by
in vitro expression patterns. The E1302 and E1303 vectors, which differ only in that E1303 lacked
both the enhancer and intron in E3 while E1302 only lacked the enhancer, showed similar levels
of NP and Gag expression in vitro. However, T cell responses to the two vectors were opposite –
+

E1302 induced a robust NP-specific CD8 T cell response, while E1303 induced a modest NP+

+

specific CD8 T cell response. Responses followed the opposite pattern for Gag-specific CD8 T
cell responses – E1302 initially induced a modest response that became more robust later, while
E1303 induced a very robust and sustained response. It is possible that E1302 and E1303
expressed NP and Gag differently in vivo. While this may be part of the explanation, it is also
+

possible that the immunodominance of each transgene product influenced the resulting CD8 T
cell responses. In a similar study of an AdHu35-based dual expression vector encoding HIV Env
+

gp-160 and malaria antigens, the CD8 T cell responses to the malaria antigen encoded in the E3
domain were very low, while the Env-specific response was robust

167

. This observation was

attributed to Env’s immunodominance over the malaria antigen and was overcome by increasing
the vector dose. The dual expression vectors designed this study would be expected to express
NP and Gag in the same cells. It is therefore possible that NP is more immunodominant than
+

Gag. As such, the E1302 vector appears to induce NP- and Gag-specific CD8 T cell responses
+

that suggest this – the NP-specific CD8 T cell response is rapid and robust and the Gag-specific
+

CD8 T cell response is initially very modest but peaks following contraction of the NP-response.
Perhaps removal of all regulatory elements from the E3 domain resulted in increased Gag
expression that could overcome the immunodominance of the NP antigens to induce a more
+

robust Gag-specific CD8 T cell response sooner after immunization.
An additional goal of this study was to generate a dual expression vector encoding a
transgene whose expression could be regulated temporally. This vector was designed to give
insight into how continued transgene expression from the adenoviral genome during its
+

persistence alters the corresponding CD8 T cell responses against the transgene. To this end,
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we chose the Cre/lox system of recombination to regulate transgene expression from AdC7derived vectors. In a preliminary study, we demonstrated that inducible CreERT2 recombinase
stably expressed in HEK 293 cells could be used to recombine loxP sites in the adenoviral
genome. In order to make the system more translatable to animal models, floxed transgenes and
CreERT2 were cloned into an AdC7 dual expression vector modeled after the E1302 vector
described above. The E1302 vector was chosen as the model for the floxed dual expression
vectors because it was shown to express both transgenes well in vitro and it induced a robust
+

CD8 T cell response against the transgene product from the E1 domain. Therefore, a cassette
carrying a floxed transgene was inserted into the E1 domain and a cassette carrying CreERT2
was inserted into the E3 domain. While expression of both the floxed transgene and CreERT2
could be detected in vitro, expression could not be measured in vivo. Analysis of genome stability
revealed that the floxed transgene had unexpectedly been deleted from the genome during viral
rescue. One potential explanation for this is that adenoviruses are known to recombine
homologous sequences between two genomes during replication

175

. However, if this were the

case, we would expect to see similar deletion of transgenes in vectors that carry the floxed
expression cassette only. However, we only observed this deletion in the dual expression vectors
carrying both the floxed expression cassette and CreERT2, suggesting that the observed deletion
is Cre-mediated recombination. It is important to note that CreERT2 is constitutively expressed in
infected cells but is sequestered in the cytoplasm by Hsp90

160

. Only when tamoxifen is

introduced can the recombinase translocate into the nucleus to recombine loxP sites.
Alternatively, the size of the vector genome can directly influence the genome’s stability. Larger
genomes generated by inserting overly long transgenes into a deleted E3 domain tend to be
slightly less stable than if no transgene was inserted

159

. The E3 deletion provides space for an

expression cassette 3.5 kb in length. While the CreERT2 expression cassette was shorter than
this (3.3 kb), it is possible that its inclusion in the dual expression vector made the vector less
stable than the matched single expression vectors, which ultimately promoted rearrangement of
the genome at the homologous loxP sites.
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In order to continue to investigate the question the floxed dual expression vectors were
designed to answer, alternative approaches must be used. Future studies could be undertaken in
CreERT2 transgenic mice that are available to us using the AdC7 vectors encoding only the
floxed transgene. Alternatively, vectors could be designed using inducible promoters to
temporally control transgene expression. This may be a more ideal approach, as it would avoid
the homologous recombination that potentially could occur between the loxP sites.
In conclusion, the studies presented here demonstrate that genetically stable dual
expression vectors based on AdC7 can be generated. These vectors express both transgenes
well and induce potent B and T cell responses. These studies also highlight that factors other
than the strength of the promoters used in each expression cassette influence gene expression
and the corresponding immune responses raised against each transgene. Careful consideration
of the choice of transgenes and elements to enhance expression must be made. These studies
will aid in the development of future Ad-based vaccines.
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MATERIALS AND METHODS A.
OPTIMAL DESIGN OF ADENOVIRAL VECTORS EXPRESSING DUAL TRANSGENES
Adenovirus vector construction
Ad vectors were deleted in the E1 and E3 domains. Shuttle plasmids were used to subclone transgenes together with regulatory elements into these deleted domains. Shuttle plasmids
designed to insert transgenes into the deleted E1 domain contained an expression cassette
composed of the transgene of interest and regulatory elements to control the transgene’s
expression, including the cytomegalovirus promoter and enhancer, an intron, and a poly(A) tail. In
some cases, a second transgene was inserted into the deleted E3 domain. The shuttle plasmids
facilitating this contained an expression cassette comprised of the transgene and its regulatory
elements, including the chicken beta-actin promoter or the RSV promoter and the rabbit betaglobin poly(A) tail. Transgenes were inserted into the Ad molecular clone using rare-cutting
restriction enzymes. Insertion into the E1 domain was facilitated by digestion with I-CeuI and PISceI followed by ligation. The resulting expression cassette was oriented 5’ to 3’. Insertion into
the E3 domain was achieved by digestion with SceI followed by ligation. The resulting expression
cassette was oriented 3’ to 5’ or 5’ to 3’.
Viruses were rescued following successful cloning, as follows. 5 µg of the molecular
clone were linearized by digestion with PacI for 1 hour at 37°C in a final volume of 50 µL.
Linearized DNA was then transfected into HEK 293 cells (at 50% confluency) using CaCl2
transfection kit (Invitrogen, Grand Island, NY). The protocol was modified slightly from the
manufacturer’s protocol. The digested DNA was added to 37 µL of 2M CaCl2 and the final volume
was brought to 300 µL with sterile H2O. The DNA-CaCl2 solution was then slowly dripped into 300
µL of HEPES-buffered saline solution while gently vortexing. After 30 minutes of incubation at
room temperature, the precipitate was added to the cells. Transfected cells were then returned to
a 37°C incubator and monitored for 7-10 days for cytopathic effect (CPE), which would be
indicative of replicating virus. When CPE was extensive, the cells and media were collected.
Three consecutive rounds of rapid freezing and thawing were performed to release virus
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contained in cells. Rescued virus was then expanded by serially passaging on HEK 293 cells.
The final product was purified on a CsCl2 gradient and concentration of virus particles (vp) was
measured by spectrophotometry.

RT-PCR Analysis
Total RNA from HEK 293 cells transduced with AdC7 vectors 24 hours earlier was
isolated using RNeasy Mini prep kit (Qiagen, Valencia, CA). The quantity of RNA was determined
by spectrometry. RNA samples were stored at -80 °C till use. For each sample, 2 µg of RNA were
reversed transcribed using the High Capacity cDNA Reverse Transcription kit (Life Technologies,
Carlsbad, CA) following the manufacturer’s protocol. The real-time PCR reaction was
subsequently carried out using Fast SYBR Green Master Mix (Applied Biosystems; Carlsbad, CA)
at a final volume of 25 µl. For amplification of NP, the following primers were used at 5 pmol/µl:
forward: 5’-AGC-AGG-TAC-TGG-GCC-ATA-AGG-3’ and reverse: 5’-ACT-GAG-AAC-GTA-GGTTGT-ATG-CTG-3’. For amplification of SIV gag, the following primers were used at 5 pmol/µl:
forward: 5’-AAG-CCC-ATC-AAG-TGC-TGG-AAC-3’ and reverse: 5’-TCT-TGC-CGC-ACT-TCCAC-3’. The housekeeping gene GAPDH was used as an internal control and was amplified
using 5 pmol/µl of the following primers: forward: 5’-TGC-CCC-CAT-GTT-GTG-ATG-G-3’ and
reverse: 5’-AAT-GCC-AAA-GTT-GTC-ATG-GAT-GAC-C-3’. 1 µL of cDNA was used as template.
Quantitative RT-PCR amplification of each gene was performed as follows: initial amplification of
primers was performed at 95°C for 20 seconds, followed by 40 cycles of denaturation at 95°C for
3 seconds and amplification at 60°C for 30 seconds. All real-time PCR reactions were carried out
on ABI Prism 7500 Fast Sequence Detection System. Reactions were run in triplicate in two
separate experiments. Standard curves used to calculate amounts of NP and SIV gag RNA in
each sample were determined by serially diluting plasmids encoding NP and SIV gag from 5
ng/well to 0.31625 ng/well. Expression data for NP and SIV gag were normalized to GAPDH to
control for variability in samples.

Western Blots
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HEK 293 cells plated on 6-well plates were infected with two different doses of viral vectors (10

3

4

and 10 vp/ cell). 24 hours post infection cells were harvested and treated with RIPA buffer
containing HALT protease inhibitors (Thermo Fisher Scientific, Pittsburgh, PA). Protein samples
were prepared by diluting in a reducing sample buffer and electrophoresed on 4-15% SDS-PAGE
gels (Bio-Rad, Hercules, CA) with Tris running buffer (Bio-Rad), transferred to PVDF membrane,
and probed with either primary monoclonal antibody anti-NP (Southern Biotech, Birmingham, AL)
or primary monoclonal anti-SIV Gag p27 (NIH AIDS Research and Reference Reagent Program,
Germantown, MD) at 4 °C overnight. Horseradish peroxidase-conjugated goat anti-mouse
secondary antibody (KPL, Gaithersburg, MD) was added and protein expression was detected by
autoradiography using ECL substrate kit (Thermo Fisher Scientific). β-actin was used as protein
loading control and probed with an anti-mouse β-actin primary antibody (Sigma-Aldrich, St. Louis,
MD).

Mice
+

Thy1.1 C57BL/6 mice were purchased from Jackson Laboratories (Bar Harbor, ME). ICR mice
were purchased from ACE Animals (Boyertown, PA). Mice were housed in the vivarium at the
Wistar Institute (Philadelphia, PA). All experiments and procedures were performed in
accordance with approved animal protocols.

ELISA
Sera of individual mice were pooled and tested for Gag- or NP-specific antibodies by ELISA.
Briefly, 96-well plates were coated overnight at 4°C with Gag protein at 10 µg/ml or A/PR8 virus
at 32 HAU/ml. Wells were washed with PBS/0.05% Tween-20, followed by overnight blocking at
4°C with PBS/3% BSA/0.05% Tween-20. Wells were then washed and incubated with serialdiluted samples (in duplicates) for 2 hours at room temperature. Wells were subsequently
washed, and bound IgG was detected with a goat anti-mouse IgG alkaline phosphatase
conjugate (Sigma-Aldrich). Bound enzyme was detected with DEA substrate (KPL) and read on a
microplate reader at 405 nm.
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Tetramer and ICS
ICS to detect Gag- and NP-specific CD8

+

T cell responses was performed as follows.
b

Lymphocytes were stimulated either with a peptide (2 µg/ml) carrying the immunodominant H2k restricted class I epitope of NP (ASNENMETM) or with a peptide pool (3 µg/ml) of 15-mers
overlapping by 11 amino acids covering the entire SIVmac239 Gag sequence. A rabies virus
b

glycoprotein peptide or a peptide of the H2k -restricted class I epitope of ovalbumin, SIINFEKL,
were used as a negative stimulation controls; both negative peptides were used at the same
concentration ad the positive peptides. After stimulation, lymphocytes were stained with anti-CD8,
and anti-CD44 antibodies and with a stain identifying dead cells. Cells were stained for 30
minutes at 4°C then washed twice with PBS. Following permeablization, samples were stained for
30 minutes at 4°C with APC-labeled anti-IFNγ, Alexa700-labeled anti-IL-2, and PE-Cy7-labeled
anti-TNFα. All antibodies (Biolegend, San Diego, CA) were diluted at 1:100 in 1X Perm/Wash.
After washing, cells were fixed with Fixative Buffer (BD Biosciences, Franklin Lakes, NJ). Cells
were run on an LSRII (BD Biosciences) and data were analyzed with FlowJo (TreeStar, Ashland,
OR).

Statistical analysis
Experiments were conducted repeatedly using 3-4 mice per group. Results show the median ±
IQR. Significances between groups were analyzed by one-way ANOVA.

MATERIALS AND METHODS B.
DEVELOPMENT OF NOVEL ADENOVIRAL VECTORS WITH CONDITIONAL TRANSGENE
PRODUCT EXPRESSION
Construction of loxP single and dual expression vectors
Shuttle vectors were constructed to insert transgenes flanked by loxP sequences (floxed)
into the deleted E1 domain. LoxP sites (5’- ATA ACT TCG TAT AGC ATA CAT TAT ACG AAG
TTA T-3’) were cloned into the empty shuttle vector such that they flanked the regulatory
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elements of the empty expression cassette. Both loxP sites were oriented in the same direction
(5’ – 3’). This was achieved by generating forward and reverse primers, each with loxP sites, to
amplify the region of the empty expression cassette in the shuttle plasmid. Additionally, each
primer contained a restriction site to facilitate cloning the amplified fragment into the shuttle
vector. The amplified PCR product was then sub-cloned into the in shuttle plasmid by restriction
enzyme digestion and ligation. Successful cloning was confirmed by sequencing over regions
containing loxP sites. The transgene, either gag of HIV-1 or GFP, was inserted into the empty
loxP shuttle plasmid using the multiple cloning site (MSC) downstream from the intron and
upstream of the poly(A) tail. The resulting shuttles were used to sub-clone the floxed expression
cassette into the deleted E1 of the AdC7 molecular clone, as described above.
Additionally, dual expression vectors were generated that encoded floxed transgenes in
E1 (as described above) and CreERT2 in the deleted E3 domain. CreERT2 is a fusion protein of
Cre recombinase and mutated version of the human estrogen receptor that can only bind the
synthetic estrogen ligand 4-hydroxytamoxifen. CreERT2 was cloned into the MCS of a shuttle
vector used to insert transgenes into the E3 domain. The chicken beta-actin promoter (CB) was
used to drive CreERT2 expression. Additionally, the CreERT2 expression cassette lacked an
intron and contained the rabbit beta-globin poly(A) tail sequence. CreERT2 was then cloned into
the E3 domain as described above. All vectors were rescued and quality controlled as described
above.

Cre-293 cell line
For in vitro studies of Ad vectors containing a single floxed transgene, generation of a cell
line stably expressing the inducible recombinase CreERT2, which identifies and recombines loxP
sites, was necessary. 5 µg of a plasmid that expressed CreERT2 under the control of the CMV
promoter and encoded the neomycin resistance gene was linearized and transfected into HEK
293 cells with CaCl2 in the method described above. The following day, the antibiotic geneticin
(G418) (Sigma-Aldrich) was added to the culture media at a concentration of 0.5 mg/mL to select
for cells that were stably transfected with the plasmid that carried a G418-resistance gene. Fresh
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media and G418 were added to cultures every 3 days. When individual colonies could be
observed, they were harvested and transferred to individual wells of a 24-well plate to continue to
be cultured under selective conditions. Ten days later colonies were transferred to T-75 flasks
and expanded. When these cultures were confluent, cells were trypsinized and plated on a 6-well
plate. 24 hours later, both reverse transcriptase PCR and Western Blot were used to confirm
CreERT2 expression.

LoxP Site Functionality
6

1x10 293-CreERT2 cells were infected with doses ranging from 1000 vp/cell to 10
vp/cell of AdC7 encoding floxed GFP (AdC7-GFP

loxP

). 2 µM or 0.2 µM 4-hydroxytamoxifen (4-

OHT or tamoxifen) (Sigma-Aldrich) was added at time of infection. As a negative control, cells
were treated with equal volume of vehicle (95% EtOH). Importantly, the volume of vehicle and
tamoxifen was less than 10 µL per well, which contained 3 mL of culture media. Cells remained
viable through the experiment as they remained attached to the plate. GFP expression was
analyzed 48 hours later by flow cytometry.
6

LoxP site functionality was tested in dual expression vectors by infecting 1x10 chinese
hamster ovary (CHO) cells stably transfected with the coxsackie-adenovirus receptor (CHO-CAR)
with AdC7 vectors dually expressing floxed Gag from E1 and CreERT2 from E3 (AdC7-gag
CBr-CreERT2). Doses ranged from 10

10

loxP

-

8

vp to 10 vp. 2 µM 4-OHT and vehicle treatment was

started 1 hour prior to infection. 3 and 7 days after infection, Gag and CreERT2 expression were
confirmed by Western blot and reverse transcriptase PCR. As a control, groups of cells were
9

infected 10 vp of AdC7-HIVgag

loxP

and treated with either vehicle or 2 µM 4-OHT.

For Western blot, cells were washed 3 times with ice cold PBS without Ca

2+

or Mg

2+

then

lysed for 1 hour on ice in RIPA Buffer containing Complete protease inhibitors (Roche;
Indianapolis, IN). Protein samples were then diluted in loading buffer containing NuPAGE
reducing reagent (Life Technologies) and electrophoresed on NuPAGE 4-10% SDS-PAGE gels
(Life Technologies) with Tris running buffer. Samples were then transferred to PVDF membrane
and probed overnight at 4°C with mouse monoclonal anti-HIV gag p24 or rabbit polyclonal
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antibody anti-Cre recombinase (Abcam, Cambridge, MA). After washing with 0.1% PBS-T, HRPconjugated secondary antibodies (anti-mouse for Gag, anti-rabbit for CreERT2) were diluted in
5% blotto and incubated for 1 hour at room temperature. PBS-T was used to wash the
membranes a final time and protein expression was detected on membranes using ECL substrate
kit (Thermo Fischer Scientific).
Total RNA was isolated for reverse transcriptase PCR using TRI reagent (Sigma-Aldrich)
according to the manufacturer’s protocol. RNA was reverse transcribed using SuperScript II
Reverse Transcriptase (Life Technologies) according to the manufacturer’s protocol. HIV gag and
CreERT2 were amplified by regular PCR using Platinum Taq polymerase (Life Technologies),
resulting in a 250 bp fragment and a 200 bp fragment, respectively. 5’ and 3’ primers used for
amplification of gag were: 5’-ACC-ACA-TCT-ACC-CTG-CAG-GAA-CAG-3’ and 5’-AGG-GTCTCT-GTC-ATC-CAA-TTC-TTC-3’. The PCR consisted of 30 cycles of 94°C for 30 seconds, 57°C
for 30 seconds, and 72°C for 1 minute. The 5’ and 3’ primers used for amplification of CreERT2
were:

5’-ACG-GCG-CTA-AGG-ATG-ACT-CTG-G-3’

and

5’-ATC-CGC-CGC-ATA-ACC-AGT-

GAA-AC-3’, respectively. The PCR consisted of 30 cycles of 94°C for 30 seconds, 57°C for 30
seconds, and 72°C for 1 minute. Amplicons (5 µL) were visualized on a 1% TAE agarose gel.

Muscle imaging
BALB/c mice were immunized IM in the lower leg with 10

11

vp of AdC7-GFP

loxP

-CBr-

CreERT2. Legs were removed 48 hours later and GFP expression was visualized using
Illumatool Lighting System (Lightools Research, Encinitas, CA). A Kodak DCS14N digital SLR
camera (Kodak, Rochester, NY) with a 60-mm Micro Nikkor lens of f3.5 using a 1:2.2
magnification (Nikon, Tokyo, Japan) was used to take photographs. Raw images were converted
to TIFF files.

Quality control of isolated viral DNA
Isolated viral DNA from vectors encoding floxed GFP or gag and matched plasmid
molecular clones used to rescue the vectors were subjected to restriction digest to determine if
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the transgene had been excised from Ad genome during viral rescue and expansion. DNAs were
digested with BglII and SphI (both from New England BioLabs, Ipswich, MA) for 1 hour at 37°C.
Digestion products were run on a 1% TAE agarose gel.
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CHAPTER 3
	
  
INHIBITION OF THE MAMMALIAN TARGET OF RAPAMYCIN
FAILS TO AUGMENT FORMATION OF CENTRAL MEMORY CD8+
T CELLS IN THE PRESENCE OF PERSISTING ANTIGEN
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ABSTRACT
Inhibition of the mammalian target of rapamycin (mTOR) pathway enhances
+

differentiation of anti-viral central memory CD8 T cells induced during acute viral infections.
Recombinant adenovirus (Ad) vectors persist at low levels and remain in a transcriptionally active
form. A consequence of this persistence is that Ad vector vaccination induces potent and
+

sustained transgene product-specific CD8 T cell responses that fail to transition into central
memory. Here we tested in mice if treatment with rapamycin, which blocks mTOR activity, could
promote formation of central memory transgene product-specific CD8

+

T cells following

vaccination with Ad vectors. Our results demonstrate that rapamycin given early after Ad vector
+

vaccination transiently increases the magnitude of the transgene product-specific CD8 T cell
response while a delayed treatment has no such effect. Neither regimen improves formation of
+

central memory CD8 T cells. These results show that transient inhibition of the mTOR pathway
does not override the effect of persisting antigen on continuous CD8

+

T cell activation.

59

INTRODUCTION
+

In recent years, CD8 T cell metabolism has been extensively studied and it has been
+

revealed that along their path of differentiation, CD8 T cells undergo two major switches in their
metabolism

105

+

. Mature, naïve CD8 T cells are actively maintained in a quiescent state. As such,

these cells are locked in G0 and rely on catabolic metabolism for their energy needs. This is
mediated by mitochondrial oxidative phosphorylation of glucose, amino acids, and lipids.
+

However, full activation of CD8 T cells results in vast clonal expansion and upregulation of
+

effector molecules. As such, CD8 T cells shift to an anabolic metabolism in order to keep up with
+

increased energy demands. Glucose uptake is dramatically increased and effector CD8 T cells
switch from oxidative phosphorylation to primarily aerobic glycolysis, which is unusual as
glycolysis is less efficient but enables synthesis of the cells’ building materials. Following
pathogen clearance the vast majority of effector cells will undergo apoptosis, but those that
remain and differentiate into memory will again switch their metabolism and revert back to a
catabolic, quiescent state.
Mammalian target of rapamycin (mTOR) is a key regulator of cellular metabolism that
tightly controls cellular growth and proliferation. mTOR is a serine/threonine kinase that exists in
two distinct complexes: mTORC1 and mTORC2

176

. A key difference in these two complexes is

that mTORC1 is sensitive to inhibition by rapamycin, an immunosuppressant often administered
to prevent rejection of organ transplants, while mTORC2 is not. mTORC1 is directly inhibited by
the TSC1/TSC2 complex, whose activity is controlled by the PI3K-AKT and AMPK pathways.
Given this, mTOR integrates environmental signals to regulate protein synthesis predominantly
via S6K1 and 4E-BP1 and to promote glycolysis and lipid biosynthesis.
Emerging evidence has demonstrated that mTOR is intimately involved in shaping CD8

+

T cell metabolism and differentiation. In order for naïve T cells to maintain quiescence, mTOR
activity must be held in check. T cells that are deficient in the TSC complex, and thus unable to
inhibit mTOR, are activated, proliferate, and are prone to apoptosis

177

+

. In activating naïve CD8 T

cells, TCR engagement and co-stimulation activates a signaling cascade that results in optimal
60

mTOR activation, the level of which is directly dependent on amount and duration of antigen
stimulation

105

. This causes dramatic upregulation of the glucose transporter

105

thus allowing the

cell to switch metabolic programs and acquire effector functions. Simultaneously, mTOR activity
178

promotes downregulation of CD62L and CCR7

, thereby allowing the activated effector cells to

traffic to sites of inflammation. When antigen is cleared and the TCR is no longer engaged, the
glucose transporter is downregulated and effector cells are effectively starved. Those cells that
survive contraction transition into memory and metabolically switch back to autophagy for energy
demands. Sensing glucose deprivation, AMPK blocks mTORC1 activity
autophagy in the form of fatty acid oxidation

180

179

and promotes

, allowing effector cells to transition to memory. As

such, drugs that activate AMPK or block mTOR activity, like rapamycin, promote transition into
memory

154,180

. Additionally, mTOR alters transcriptional programs crucial for T cell fate decisions.

It has been demonstrated that inhibition of mTOR activity blocks the transcription factor T-bet
while promoting Eomesodermin
respectively

182

181

, which control differentiation of effector and memory cells,

.

Manipulation of the mTOR pathway was shown to enhance formation of central memory
+

CD8 T cells, suggesting the potential of mTOR inhibitors as vaccine adjuvants. Araki et al.
demonstrated in mice that treatment with a low dose of rapamycin during the T cell expansion
+

phase following LCMV infection enhanced the quantity of memory CD8 T cells, while treatment
during contraction enhanced the quality of these cells

154

. Similar results were observed in rhesus

macaques treated with rapamycin during vaccinia virus infection

183

. These studies suggest that

rapamycin could potentially be used as a vaccine adjuvant.
Replication-defective adenoviral (Ad) vectors have garnered much attention as vaccine
platforms. An attractive feature of Ad vectors is that they are known to induce very potent and
+

sustained transgene product-specific CD8 T cell responses following immunization

184

. The

+

failure of this CD8 T cell response to contract is due to persistent transgene product expression
from Ad vectors maintained in activated T cells

123

+

. Transgene product-specific CD8 T cells that

remain following primary immune responses bear an effector or effector memory phenotype and
their differentiation to central memory is markedly delayed

123

. While a large pool of armed
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+

effector-like CD8 T cells standing guard at a pathogen’s port of entry may be beneficial in
preventing acquisition of viruses

134,185

+

, a larger pool of long-lived central memory CD8 T cells,

with their vast potential for expansion following antigenic reencounter, could be beneficial to
protect against systemic dissemination of reinvading pathogens

185

.

Here we tested if inhibition of mTOR through rapamycin could override the continuous
+

stimulation of CD8 T cells by low levels of transgene product produced by persisting Ad vaccine
vectors. To this end mice were treated with a low dose of rapamycin either early during the CD8

+

T cell expansion phase following immunization or later after responses had peaked. We
demonstrate that early rapamycin treatment transiently increases the magnitude of the transgene
+

product-specific CD8 T cell responses in blood and, less so, in spleen, but fails to alter
+

frequencies of CD8 T cells that migrated to lymph nodes. Beginning treatment with rapamycin
+

several days following immunization fails to enhance the magnitude of the CD8 T cell responses.
+

Neither regimen increases formation of central memory CD8 T cells. While rapamycin treatment
+

enhances the formation of central memory CD8 T cells to non-persisting pathogens, our data
+

show that it is not effective in overriding the effect of persisting antigen on continuous CD8 T cell
activation.

RESULTS
+

The effect of early rapamycin treatment of CD8 T cell responses to the transgene product
of an Ad vector
+

Low dose rapamycin treatment given to limit mTOR activity during the CD8 T cell
+

expansion phase was demonstrated to increase the number of CD8 memory precursors and
thus increase the resulting number of memory cells following infection with lymphocytic
choriomeningitis virus (LCMV)
specific CD8

+

154

. To test if rapamycin affected the quantity of transgene product-

T cell responses induced following immunization with an Ad-based vaccine,

BALB/c mice were intramuscularly (IM) vaccinated with 10

10

vp of an E1-deleted adenovirus

based on human serotype 5 expressing Gag of HIV-1 (AdHu5-gag). Groups of mice were treated
daily for 10 days starting on the day of immunization either with 75 µg/kg of rapamycin or with 10
62

µL/g of sham as a control. Mice were bled or euthanized periodically and numbers of Gag+

specific CD8 T cells were measured by staining isolated lymphocytes with a tetramer specific to
d

the immunodominant, H-2 -restricted immunodominant epitope of Gag (AMQMLKETI). As shown
+

in Figure 3.1A, Gag-specific CD8 T cells from both rapamycin-treated and sham-treated groups
expanded in all compartments until day 21 post-immunization, after which point modest
+

contraction was observed in the blood and spleen. Gag-specific CD8 T cells remained fairly
+

stable in the lymph nodes. The most robust expansion of Gag-specific CD8 T cells was observed
in blood. Here, rapamycin treatment significantly increased the absolute number of Gag-specific
+

CD8 T cells at the peak response as compared to those from mice that had only received sham
treatment. Although numbers remained elevated for the duration of the experiment, the difference
was only significant at the peak of the response.
+

Analysis of the CD8 T cells at the peak of their response has revealed that they are a
heterogeneous population consisting of terminally differentiated short-lived effector cells (SLEC)
and memory precursor effector cells (MPEC) fated to become memory cells with high proliferative
capacity, and cells with more intermediate phenotypes

186

. MPEC and SLEC can be defined by

differential expression of the interleukin-7 receptor α chain (CD127), which is required for
formation of memory cells

187

, and killer cell lectin-like receptor subfamily member G1 (KLRG1),
+

which is a marker of terminally differentiated antigen-experienced CD8 T cells

143

. As such,

MPEC are defined by high CD127 expression and low KLRG1 expression; whereas, the opposite
expression pattern is observed on SLEC

186

+

. Inhibition of mTOR during the CD8 T cell expansion

phase increased the overall magnitude of the response by enhancing the number of memory
+

precursors formed following LCMV infection but did not alter the quality of the induced CD8 T
cells

154

. In order to determine if rapamycin treatment increased memory precursor numbers and
+

altered the memory phenotype of the transgene product-specific CD8 T cells following Ad
vaccination, KLRG1, CD127, and CD62L, which can be used to distinguish between effector
memory and central memory T cells based on low or high expression, respectively, were
+

measured over time on Gag-specific CD8 T cells isolated from blood, spleen, and lymph nodes
+

(Figure 3.1B). In both groups, the frequency of Gag-specific CD8 T cells that had converted to a
63

hi

CD62L phenotype were modest in all tissues tested, with the highest conversion occurring in
hi

lymph nodes. Rapamycin treatment did not significantly alter frequencies of CD62L Gag-specific
+

CD8 T cells except 10 days after cessation of treatment (day 21) in blood, however this increase
hi

+

was modest and transient. Percentages of CD127 Gag-specific CD8 T cells were also similar
between the two cohorts at most time points in all tissues. Significant differences were measured
in blood on day 10 and 49 and in both lymph nodes and the spleen on day 21. Additionally,
rapamycin treatment had no effect on the numbers of cells expressing decreased levels of
KLRG1. Therefore, rapamycin treatment did not increase the MPEC frequency.
One measure of T cell quality is their capacity to produce multiple cytokines in response
to re-stimulation. It is generally considered that an antigen-specific CD8+ T cell population that is
capable of producing multiple cytokines, or is more polyfunctional, is more effective. To test if
rapamycin treatment affected polyfunctionality of Gag-specific CD8

+

T cells, we measured

production of the cytokines interferon−γ (IFN-γ), tumor necrosis factor-α (TNF-α) and interleukin-2
(IL-2) in blood and spleen. Additionally, the chemotactic cytokine macrophage inflammatory
protein-1α (MIP-1 α) was measured in T cells from spleen. As shown in Figure 3.2A, rapamycin
+

treatment increased the magnitude of cytokine producing Gag-specific CD8 T cells in blood and
spleen, although this reached significance only in cells isolated from the blood. Cytokine profiles
+

were measured following in vitro re-stimulation of Gag-specific CD8 T cells isolated from blood
+

and spleen at 12 weeks following immunization (Figure 3.2B). Gag-specific CD8 T cell cytokine
profiles were largely similar between the two cohorts of mice and consisted of cells producing
mainly

IFN-γ alone

or

in

combination

with

TNF-α; in the spleen,

these

combinations

included MIP−1α. Again, although the profiles were largely the same between the two groups,
rapamycin treatment preferentially expanded the number of cells producing these combinations of
effector cytokines. In some cases, rapamycin treatment also lead to a small increase in
polyfunctional cells, although this was not significant.
+

As an additional measure of the functional quality of the induced Gag-specific CD8 T cell
response, both the rapamycin- and sham-treated groups were boosted 12 weeks after
64

immunization with 10

10

vp of a heterologous Ad vector based on chimpanzee serotype 7 carrying

the HIV-1 Gag transgene (AdC7-HIVgag). A group of mice primed with this virus alone was
+

included as a control. In all compartments, Gag-specific CD8 T cells from both groups robustly
expanded following booster immunization regardless of treatment (Figure 3.3). Rapamycin+

treated mice developed higher numbers of Gag-specific CD8 T cells than sham treated mice.
Nevertheless the fold of expansion as assessed by the ratio of the numbers of Gag-specific CD8

+

T cells before and after the boost was very similar between the rapamycin- and sham-treated
groups in the blood, 10.5 and 9, respectively, (Figure 3.3A) and lymph nodes, each boosted 1.7fold (Figure 3.3C). In spleen (Figure 3.3B), the sham-treated group actually showed a more
+

pronounced expansion of Gag-specific CD8 T cells compared to rapamycin-treated mice, 2.8fold compared to 4.2-fold, respectively. Taken together, these results demonstrate that rapamycin
+

treatment did not enhance the ability of the Gag-specific CD8 T cells to expand following
secondary exposure to their cognate antigen and therefore did not enhance the quality of the
+

induced Gag-specific CD8 T cell response.
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FIGURE 3.1. Early rapamycin treatment transiently increases Gag-specific CD8+ T
cells without altering memory phenotype.

10

Groups of 5 BALB/c mice were immunized intramuscularly with 10 vp AdHu5-HIVgag. At the time of
immunization and continuing until day 10 post-immunization, one group was treated intraperitoneally (IP)
with 75 µg/kg/day of rapamycin. As a control, the other group was IP injected with sham (0.1% DMSO in
PBS) treatment given at 10 µL/g. Rapamycin-treated group is indicated by black boxes while sham-treated
group is indicated by white boxes. The grey area indicates the treatment phase. Significance was
determined using multiple t-tests with Holm-Sidak correction for multiple comparisons.
[A] All mice were bled for PBMCs or euthanized for splenocytes and lymphocytes at the indicated time
+
6
points. Graphs show the mean number of Gag-specific CD8 T cells over 10 live cells ± standard deviations
(SD). The following p-values were obtained: Blood: Day 35: p=0.0011; Lymph nodes: Day 49: p=0.0019.
+

[B] Shows the longitudinal phenotyping of Gag-specific CD8 T cells from indicated time points and tissues.
+
+
Graphs show the mean frequency of Gag-specific CD8 T cells with the indicated phenotype (CD127 ,
+
lo
+
CD62L , or KLRG1 ) over the total Gag-specific CD8 T cell response ± SD. The following p-values were
obtained: Blood: CD127: Day 10: p=0.0057, Day 49: p<0.0001; Spleen: CD127: Day 10: p=0.0089.
Significant differences are indicated by * for p-values ≤ 0.05-0.01, ** p-values < 0.01-0.001, *** p-values ≤
0.001-0.0001, **** p-values < 0.0001. Lines show the comparison groups.
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FIGURE 3.2. Early rapamycin treatment transiently increases cytokine production.

Shows the kinetics of total cytokine-producing cells [A] and the cytokine profile 12 weeks following
immunization [B]. IFN-γ (G), TNF-α (T), and IL-2 (2) production was measured for PBMCs. IFN-γ, TNF-α, IL2, and MIP-1α (M) production was measured for splenocytes. For determination of the kinetics, mice were
bled or euthanized at the indicated time points and PBMCs or splenocytes were isolated, respectively. The
lymphocytes were stimulated with either the Gag peptide AMQMLKETI or the equivalent amount of an
irrelevant peptide to measure background stimulation. Line graphs show the mean number of cytokine
producing cells following the subtraction of background stimulation and summation of Boolean gates used to
determine the cytokine profile ± SD. Significance between rapamycin- and sham–treated groups was
determined for each time point using multiple t-tests with Holm-Sidak correction for multiple comparisons.
The following p-values were obtained: [A] Blood: Day 21: p=0.002, Day: 35: p=0.006, Day 84: p=0.0038.
Significant differences are indicated by * for p-values ≤ 0.05-0.01, ** p-values < 0.01-0.001, *** p-values ≤
0.001-0.0001, **** p-values < 0.0001. Lines show the comparison groups.
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FIGURE 3.3. Early rapamycin treatment causes a more robust peak recall
response.

10

BALB/c mice treated with either rapamycin or sham were boosted with 10 vp AdC7-HIVgag 12 weeks after
first vaccination. A group of naïve mice was primed with this vaccine in order to serve as a control. Gag+
specific CD8 T cell responses in blood [A] were measured 2 days prior to the boost and again at 15 and 56
days after the boost. In the spleen [B] and lymph nodes [C], Gag-specific CD8+ T cell responses were
measured 2 days prior to the boost and 56 days after the boost. Graphs show mean number of Gag-specific
+
6
CD8 T cells identified by staining with the tetramer over 10 live lymphocytes ± SD. In the blood [A], the
rapamycin-treated group is indicated by the black bar, the sham-treated group is indicated by the grey bar,
and the prime only group is indicated by the white bar. In spleen [B] and lymph nodes [C], the white bar
indicates the prebleed 2 days prior to boosting and the black bar indicates the day 56 post-boost time point.
Statistical significance was determined by 2-way ANOVA with Holm-Sidak correction for multiple
comparisons. The following p-values were obtained: [A] Day 15: rapamycin vs. prime only: p<0.0001, sham
vs. prime only: p=0.0058, rapamycin vs. sham: p=0.0021; Day 56: rapamycin vs. prime only: p=0.0446;
Rapamycin: prebleed vs. day 15: p=0.001, day 15 vs. day 56: p<0.0001; Sham: prebleed vs. day 15:
p=0.002 day 15 vs. day 56: p=0.0028; [C] Day 56: rapamycin vs. prime only: p=0.0006.
Significant differences are indicated by * for p-values ≤ 0.05-0.01, ** p-values < 0.01-0.001, *** p-values ≤
0.001-0.0001, **** p-values < 0.0001. Lines show the comparison groups.
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+

The effect of late rapamycin treatment of CD8 T cell responses to the transgene product
of an Ad vector
Araki et al. demonstrated that limiting mTOR activity during the contraction phase
+

accelerated CD8 T cell differentiation into the central memory compartment. To assess if
inhibition of the mTOR pathway at a later stage of T cell activation following Ad immunization
affected the transgene product-specific CD8
immunized IM with 10

10

+

T cells’ fate decisions, BALB/c mice were

vp AdHu5-HIVgag and then treated daily from days 10 to 30 post

immunization with either rapamycin or sham. Mice were bled or euthanized and Gag-specific
+

+

CD8 T cells were measured at the time points indicated in Figure 3.4A. Gag-specific CD8 T
cells from both the rapamycin- and sham-treated groups expanded in the blood, spleen, and
lymph nodes, reaching a peak at 3 weeks in the spleen and lymph nodes and at 5 weeks in blood
+

following immunization. Numbers of Gag-specific CD8 T cells then remained stable in blood but
contracted in the spleen and lymph nodes. There was no significant difference in the overall
+

magnitude of the Gag-specific CD8 T cell response in the two cohorts.
We measured expression of CD62L, CD127 and KLRG1 following immunization to
determine if delaying rapamycin in relation to vaccination increased formation of Gag-specific
+

central memory CD8 T cells. As shown in Figure 3.4B, we found that differences between the
two groups were subtle and only reached significance for expression of CD127 and KLRG1 at
+

+

some time points. Specifically CD127 Gag-specific CD8 T cells were more frequent in blood on
day 21 while KLRG1 was differentially expressed in blood on day 10, in spleen on day 49 and in
lymph nodes on days 21 and 49. Taken together, these results indicate that the delayed
rapamycin treatment did not enhance memory differentiation.
+

Ad vector-induced CD8 T cells were tested following peptide stimulation in vitro for
production of IFN-γ, TNF-α, and IL-2 in blood and spleen. MIP-1α was again only included for
splenocytes. Rapamycin treatment only transiently increased numbers of cytokine-producing
+

Gag-specific CD8 T cells in the blood on day 21 (Figure 3.5A). Otherwise, the delayed drug
+

treatment did not affect the cytokine profile of Ad vector-induced CD8 T cells (Figure 3.5B),
similar to Figure 3.2B.
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At 12 weeks post-immunization both the rapamycin- and sham-treated groups were
boosted with 10

10

+

vp of AdC7-HIVgag. In all compartments, Gag-specific CD8 T cells from all

groups expanded robustly following immunization (Figure 3.6). In the blood (Figure 3.6A)
+

rapamycin treatment led to transiently higher numbers of Gag-specific CD8 T cells than sham
+

treatment. Comparison of the fold increase of Gag-specific CD8 T cells revealed that Gag+

specific CD8 T cells from rapamycin-treated mice had expanded more robustly (20.5-fold) than
those from sham-treated mice (10.7-fold). In the spleen and lymph nodes there were no
+

significant differences in numbers of Gag-specific CD8 T cells between the rapamycin- and
sham-treated groups (Figures 3.6B and 3.6C), although each group boosted robustly and
similarly. These results further support the notion that later rapamycin treatment did not enhance
+

the quality of the induced the Gag-specific CD8 T cell response.
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FIGURE 3.4. Later rapamycin treatment neither increases numbers nor alters
phenotype of Gag-specific CD8+ T cells.

10

Groups of 5 BALB/c mice were immunized intramuscularly with 10 vp AdHu5-HIVgag. 10 days after
immunization and continuing until 30 days after immunization, one group was treated intraperitoneally (IP)
with 75 µg/kg/day of rapamycin. As a control, the other group was IP injected with sham (0.1% DMSO in
PBS) treatment given at 10 µL/g. Rapamycin-treated group is indicated by black boxes while sham-treated
group is indicated by the white boxes. The grey area indicates the treatment phase. Significance between
rapamycin- and sham-treated groups was determined using multiple t-tests with Holm-Sidak correction for
multiple comparisons.
[A] All mice were bled for PBMCs or euthanized for splenocytes and lymphocytes at the indicated time
+
6
points. Graphs show the mean number of Gag-specific CD8 T cells over 10 live cells ± SD.
+

[B] Shows the longitudinal phenotyping of Gag-specific CD8 T cells from indicated time points and tissues.
+
+
Graphs show the mean frequency of Gag-specific CD8 T cells with the indicated phenotype (CD127 ,
+
lo
+
CD62L , or KLRG1 ) over the total Gag-specific CD8 T cell response ± SD. The following p-values were
+
lo
obtained: Blood: CD62L : Day 10: p=0.00372; Spleen: KLRG1 : Day 21: p=0.0056, Day 49: p<0.0001;
lo
Lymph nodes: KLRG1 : Day 21: p=0.0056, Day 49: p=0.00529.
Significant differences are indicated by * for p-values ≤ 0.05-0.01, ** p-values < 0.01-0.001, *** p-values ≤
0.001-0.0001, **** p-values < 0.0001. Lines show the comparison groups.
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FIGURE 3.5. Later rapamycin treatment transiently increases cytokine production.

Shows the kinetics of total cytokine-producing cells [A] and the cytokine profile 12 weeks following
immunization [B]. IFN-γ (G), TNF-α (T), and IL-2 (2) production was measured for PBMCs. IFN-γ, TNF-α, IL2, and MIP-1α (M) production was measured for splenocytes. For determination of the kinetics, mice were
bled or euthanized at the indicated time points and PBMCs or splenocytes were isolated, respectively. The
lymphocytes were stimulated with either the Gag peptide AMQMLKETI or the equivalent amount of an
irrelevant peptide to measure background stimulation. Line graphs show the mean number of cytokine
producing cells following the subtraction of background stimulation and summation of Boolean gates used to
determine the cytokine profile ± SD. Significance between rapamycin- and sham–treated groups was
determined for each time point using multiple t-tests with Holm-Sidak correction for multiple comparisons.
The following p-values were obtained: [A] Blood: Day 21: p=0.0078.
Significant differences are indicated by * for p-values ≤ 0.05-0.01, ** p-values < 0.01-0.001, *** p-values ≤
0.001-0.0001, **** p-values < 0.0001. Lines show the comparison groups.
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FIGURE 3.6. Later rapamycin treatment transiently improves recall response.

10

BALB/c mice treated with either rapamycin or sham were boosted with 10 vp AdC7-HIVgag 12 weeks after
first vaccination. A group of naïve mice was primed with this vaccine in order to serve as a control. Gag+
specific CD8 T cell responses in blood [A] were measured 2 days prior to the boost and again at 15 and 56
+
days after the boost. In the spleen [B] and lymph nodes [C], Gag-specific CD8 T cell responses were
measured 2 days prior to the boost and 56 days after the boost. Graphs show mean number of Gag-specific
+
6
CD8 T cells identified by staining with the tetramer over 10 live lymphocytes ± SD. In the blood [A], the
rapamycin-treated group is indicated by the black bar, the sham-treated group is indicated by the grey bar,
and the prime only group is indicated by the white bar. In spleen [B] and lymph nodes [C], the white bar
indicates the prebleed 2 days prior to boosting and the black bar indicates the day 56 post-boost time point.
Statistical significance was determined by 2-way ANOVA with Holm-Sidak correction for multiple
comparisons. The following p-values were obtained: [A] Rapamycin: Prebleed vs. Day 15: p<0.0001, Day
15 vs. Day 56: p<0.0001; Sham: Prebleed vs. Day 15: p=0.007, Day 15 vs. Day 56: p=0.0099; Day 15:
prime only vs rapamycin: p<0.0001, prime only vs. sham: p=0.0084, rapamycin vs. sham: p=0.0459 [B]
Rapamycin: Prebleed vs. Day 56: p=0.0179; Day 56: rapamycin vs. prime only: p=0.0056 [C] Rapamycin:
prebleed vs. day 56: p=0.0226; Sham: prebleed vs. day 56: p=0.0029; Day 56: p=0.0071.
Significant differences are indicated by * for p-values ≤ 0.05-0.01, ** p-values < 0.01-0.001, *** p-values ≤
0.001-0.0001, **** p-values < 0.0001. Lines show the comparison groups.
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DISCUSSION
mTOR was elegantly demonstrated to play a critical role in memory CD8

+

T cell

differentiation. Araki et al. demonstrated that limiting mTOR activity at different phases of the
+

CD8 T cell response enhanced the induction of memory cells

154

. Specifically, low doses of

rapamycin given during the T cell expansion phase to inhibit mTOR activity increased numbers of
memory cell precursors by increasing expression of Bcl-2, an anti-apoptotic protein, ultimately
leading to their increased survival during the contraction phase. Consistent with this, low dose
rapamycin

treatment

was

demonstrated

immunization with a recombinant poxvirus

to
188

dramatically

decrease

apoptosis

following

. Additionally, Araki et al. demonstrated that low

doses of rapamycin given during the contraction phase accelerated differentiation into central
memory. These results suggest that rapamycin may be a beneficial vaccine adjuvant to enhance
memory differentiation.
The current study was performed to test the potential of mTOR inhibition to increase
+

central memory development of transgene product-specific CD8 T cells induced by an Ad vectorbased vaccine. The results presented here are partially in contrast with those described above.
As expected, treatment with low doses of rapamycin during the early expansion phase following
+

Ad immunization resulted in higher transgene product-specific CD8 T cell numbers at the peak of
the response, but the effect was transient. Additionally, low dose rapamycin treatments given
+

later in the response failed to enhance transgene product-specific CD8 T cell differentiation into
central memory. These differences could possibly be due to the differences in timing of
+

rapamycin treatment with the kinetics of the induced CD8 T cells. In the Araki et al study early
rapamycin treatments coincided with the entire T cell expansion phase and ended at the peak
response and later rapamycin treatments coincided with the entire contraction phase beginning at
the peak response. However, the early rapamycin treatments given in the study presented here
only coincided with about half of the expansion phase and the later treatments covered the late
expansion and early contraction phases.

74

The differences observed in these studies could also be due to the nature of the viral
models each used. The Araki et al. study infected mice with lymphocytic choriomeningitis virus
(LCMV). As an acutely infecting virus, this pathogen is cleared completely from the host within 8
days

139

. TCR/CD28 signaling subsides as the virus is cleared and mTOR activity subsequently

subsides, allowing responding T cells to become more quiescent and differentiate. On the other
hand, adenoviruses, whether naturally acquired

65

or rendered replication-defective

123

, establish

persistent infection in activated T cells. Studies using Ad vectors carrying transgenes under the
control of strong and ubiquitous promoters have revealed that Ad vectors remain transcriptionally
active at low levels

123

. The continued presence of transgene product in turn maintains a pool of
+

activated effector and effector memory transgene product-specific CD8 T cells and delays their
differentiation into central memory cells. It is unknown how persistent antigen produced by
adenovirus transduced T cells maintains activation of other T cells. Following vaccination, Ad
+

vectors induce transgene product-specific CD8 T cells primarily through cross-presentation of
transgene product by antigen presenting cells (APC)

189

rather than directly infecting them. During

+

Ad persistence, CD8 T cells could be stimulated directly by the T cells harboring persistent
vector or by cross-presentation of transgene product when transduced cells eventually become
apoptotic. Regardless, as TCR stimulation continues mTOR would be expected to be active to
some degree.
+

Much of our knowledge of the role mTOR plays in CD8 T cell differentiation comes from
in vitro studies and mouse models with various members of the PI3K/Akt/mTOR pathway
knocked out. Only a few studies have examined this pathway in the context of acute viral
+

infections. Even less is known about the role of mTOR in CD8 T cells during persistent
infections. It appears that mTOR phosphorylation gradually declines during persistent infection
with LCMV clone 13 but, importantly, phosphorylation is not ablated

190

, which could reflect

continued TCR stimulation. Transplant recipients persistently infected with CMV who were treated
with the rapamycin analog everolimus showed a specific increase in the magnitude of CMVspecific CD8

+

polyfunctionality

effector and effector memory T cells without affecting their quality and
191

, consistent with what was presented here. A recent study in which rapamycin
75

was administered for 35 days following vaccination with Ad revealed that the effector memory
+

population of transgene product-specific CD8 T cells was enhanced in this model

192

. This

response was magnified and central memory development was enhanced only when additional
co-stimulation was provided through OX40 agonism. The results presented here are not in
complete agreement with their report, which could be due to differences in the study design, in
particular the vector dose. Using a dose 100 –fold lower than was used in the study presented in
this chapter, rapamycin treatment alone increased the formation of MPECs. It could be argued
that increase in memory differentiation was due to lower antigenic load present during the priming
that prevented the establishment of a persisting reservoir. Indeed, in a later experiment they use
the same immunization dose used here and the combined treatment did not increase central
memory development. However, both doses of Ad vector and each treatment regimen selectively
increased the proportion of effector memory cells. The results presented here (Figure 3.1)
indicate that rapamycin treatment increases, albeit transiently, the absolute number of effector
and effector memory cells without shifting the subset distribution. During the periods of rapamycin
treatment, limiting mTOR activity may have favored the formation of memory cells, as a transient
+

and subtle increase in CD127 cells was observed following early rapamycin treatment. However,
this was expected to be transient once rapamycin treatment was discontinued because continued
+

stimulation from persistent antigen could recall transgene product-specific CD8 T cells. This
would ultimately increase the overall size of the response without changing the makeup of the
pool. Consistent with the idea that persistent transgene expression prevents rapamycin treatment
from enhancing central memory development, extinguishing transgene expression from an Ad
vector during the combined rapamycin and OX40 treatment enhanced central memory
development

192

.

In conclusion, the studies presented here demonstrate that rapamycin treatment following
+

immunization with a vector that is known to persist at low levels does not enhance CD8 T cell
differentiation into central memory but increases the number of activated effector cells. Further
elucidation of the role that mTOR plays in regulating T cell metabolism during chronic infections is
necessary.
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MATERIALS AND METHODS
Mice, immunizations, and rapamycin treatments
10

Groups of BALB/c mice were immunized intramuscularly (IM) with 10

vp of the AdHu5-

HIVgag vector diluted in 100 µL of sterile PBS. In one series of experiments, groups of mice
received daily intraperitoneal (IP) injections of 75 µg/kg rapamycin (Sigma-Aldrich, St. Louis, MD)
diluted in 0.1% DMSO in sterile PBS for 10 days following immunization

154

. In a second series of

experiments, groups of mice received daily IP injections of 75 µg/kg rapamycin from day 10 after
immunization until day 30 after immunization. In both series of experiments, control mice received
daily IP injections of 10 µL/g 0.1% DMSO in PBS for the indicated length of time. In one
experiment, both groups of mice (control- and rapamycin-treated) received a second
immunization with 10

10

vp AdC7-HIVgag 12 weeks after the primary immunization with the AdHu5

vector. A group of naïve mice were immunized concurrently with 10

10

vp of AdC7-HIVgag as a

control.

Tetramer staining
Tetramer staining was preformed by staining cells in PBS with an APC-labeled tetramer
d

against the immunodominant MHC class I H-2K restricted epitope of Gag (AMQMLKETI).
Additionally, cells were stained with PerCP-Cy5.5-labeled anti-CD8, PE-labeled anti-KLRG1
(Southern Biotech, Birmingham, AL), anti-CD62L (BD Biosciences, Franklin Lakes, NJ),
Alexa700-labeled anti-CD44, anti-CD127 (eBioscience, San Diego CA), PE-Cy7-labeled antiCD44 (eBioscience), and PacBlue-labeled anti-CD62L, anti-CD127 (eBioscience). Unless
otherwise indicated, antibodies are from Biolegend (San Diego, CA). Antibodies labeled with
identical fluorophores were used in separate samples. All samples included a dye that labels
dead cells. Staining was preformed for 30 min at 4ºC. Cells were fixed with BD fixative after
staining.

Intracellular cytokine staining (ICS)
77

+

In order to detect a Gag-specific CD8 T cell response, PBMCs and splenocytes were
stimulated in the presence of Golgi Plug (BD Biosciences) for 5 hours at 37 °C with 1.25 µg/mL of
Gag peptide, AMQMLKETI, or with 1.25 µg/mL of a non-specific peptide, WIZX-2 from rabies
virus, to measure background stimulation. Peptides were prepared in DMEM containing 2%
mixed

lymphocyte

culture

media

(MLC).

Following

stimulation

and

surface

staining,

Cytofix/Cytoperm (BD Biosciences) was used to permeabilize the cells, which were subsequently
stained intracellularly with PacBlue-labeled anti-IFNγ, FITC-labeled anti-TNFα (BD Bioscience),
Alexa700-labeled anti-IL-2 (BD Bioscience); splenocytes were additionally stained with APClabeled anti-MIP-1α (R&D Systems; Minneapolis, MN). Staining at both steps was performed as
described in the previous section.

Data acquisition and analysis
All samples were collected on a BD-LSR II and analyzed using FlowJo software. For
+

tetramer staining, numbers of Gag-specific CD8 T cells were determined as follows. Acquired
+

lymphoid cells were first gated to remove doublets and dead cells, then were gated on CD8 T
cells. The remaining cells were plotted as tetramer (tet) compared to CD44. Numbers were
+

+

determined by normalizing the numbers of double positive (tet CD44 ) cells to total live cells.
+

+

6

Data are shown as tet CD8 T cells/10 PBMCs, splenocytes, or lymphocytes, depending on the
+

compartment presented. Additionally, tet CD44
lo

+

cells were phenotyped for the markers

+

described. A gate on the CD44 CD8 T cells served an internal, naïve control for phenotyping.
+

For analysis of ICS, live CD8 T cells were gated as described above, then cells positive for each
cytokine were gated. Boolean gates were generated to determine cytokine profile in each sample.
Numbers of cells acquired for each cytokine and combination of cytokines were first normalized to
6

total live cells per 10 PBMCs or splenocytes. The background obtained by stimulation with
negative peptide was then subtracted from the samples stimulated with the positive peptide. Data
+

+

are represented as cytokine CD8 /10

6

PBMC or splenocytes, depending on compartment

presented.
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Statistical analysis
Each experiment was preformed with groups of 5 mice, unless otherwise indicated, and
repeated 3 times. Statistical significance was determined using either multiple t-tests with HolmSidak correction for multiple comparisons or 2-way ANOVA with Holm-Sidak correction for
multiple comparisons.
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CHAPTER 4
	
  
ANTIGEN-EXPERIENCED CD8+ T CELLS MAINTAIN THE CD8+ T
CELL RESPONSE FOLLOWING ADENOVIRUS IMMUNIZATION

80

ABSTRACT
+

Persistent adenoviral vectors induce transgene-product CD8 T cells responses that fail
to contract and are phenotypically heterogeneous. Studies of other persistent viruses have
demonstrated that asynchronous priming of naïve CD8
mechanism by which CD8

+

+

T cells throughout infection is a

T cell pools can be maintained and remain functional during
+

persistent infection. Alternatively, functional antigen-experienced CD8 T cells may respond to
persistent antigen and thus replenish the response. Here we designed a series of adoptive
transfer experiments to distinguish between these two possibilities. Our results indicate that naïve
+

+

CD8 T cells are primarily not responsible for maintaining the transgene product-specific CD8 T
cell response. Instead it is likely that persisting transgene product recalls antigen-experienced
cells back into the response.

81

INTRODUCTION
Vectors based on adenovirus (Ad) are being extensively developed as vaccine platforms
against numerous diseases. These highly immunogenic vectors have received such attention in
+

+

part due to their ability to induce potent CD8 T cell responses. CD8 T cells are important
mediators of immune responses and are indispensible in the control of viral infections. The CD8

+

T cell response following infection with a pathogen that is cleared from the host, termed an acute
infection, is composed of three distinct stages

110

. The first phase is termed the expansion phase

and occurs following antigenic encounter and activation. During this stage, a CD8

+

T cell

undergoes vast and rapid clonal expansion. Such rapid expansion requires that the cells alter key
metabolic pathways, including the PI3K-Akt-mTOR pathway, to promote the synthesis of raw
materials needed to make new cells

105

. Armed with antiviral cytokines, such as IFN-γ, and

cytolytic effector molecules, these newly generated cells traffic to inflamed tissues in the
periphery to carry out their task of targeting and killing infected cells. After the pathogen is cleared
+

from the host, the CD8 T cell response reaches a maximal peak that delineates the next stage of
+

the response, contraction. At the peak of this response, the CD8 T cell pool is largely made up of
short-lived effector cells (SLEC) but some memory precursor effector cells (MPEC) can be
identified

114,121

. During the contraction phase, SLEC will die through apoptosis, resulting in a 90+

95% reduction of the peak population. The final phase of the primary CD8 T cell response is
memory differentiation. The MPEC that survived the contraction phase contribute to this
population, which can be composed of effector memory and central memory cells that
preferentially home to the periphery and lymph nodes, respectively. These cells further
differentiate and are maintained through self-renewal in the absence of antigen.
However, not all pathogens are acutely infecting and instead establish persistent
+

infections that are not cleared from the host. Much of our knowledge of the CD8 T cell response
during persistent infection comes from models of highly pathogenic, chronically infecting mouse
lymphocytic choriomeningitis virus (LCMV) clone 13. These studies demonstrate that responding
+

CD8 T cells are significantly impaired and undergo functional exhaustion or are deleted from the
82

T cell repertoire
functions

110

138,193

. Functional exhaustion is characterized by the hierarchical loss of T cell

. As the cells become progressively more exhausted, the ability to produce IL-2 is the

first to be lost followed by TNF-α and then IFN-γ. Additionally, they gradually lose their ability to
kill target cells and cannot be recalled robustly following secondary antigen encounter.
Adenoviruses fall into the group pathogens that establish persistent infections.
Adenoviruses establish a reservoir in the lymphatic tissues and the genome is especially enriched
in T cells

65,194

. While the viral genome can be isolated tissues following their surgical removal,

infectious virus cannot be recovered from culturing the tissues
with mitogens causes virus reactivation and replication

61

2,58

. However, in vitro stimulation

. As such, it was determined that Ad

establishes a latent infection with intermittent periods of reactivation.
Adenoviral vectors also persist in vivo. Following intramuscular vaccination, the genome
+

is enriched in activated CD8 T cells

123

detected for a year after immunization

. Importantly, low levels of transgene expression can be

123

. Many have demonstrated that following immunization

+

the transgene product-specific CD8 T cell response fails to contract

140,195

. Additionally, the CD8

+

T cell population that survives past the peak response to transition into the memory phase
+

consists effector and effector memory cells. These qualities of the CD8 T cell response are
consistent with those from other persistent viral infection models

152

. Indeed there has been a

+

report that suggests the Ad-induced CD8 T cell response becomes exhausted over time

196

.

However, exhaustion and functional impairment are directly linked to the antigen load that
persists during chronic infection

137,196,197

. The LCMV clone 13 model, from which we have

derived much information about T cell exhaustion, establishes a persistent infection characterized
by high levels of viremia

198

+

, which progressively pushes the anti-viral CD8 T cell response

toward extreme functional impairment

193,197,198

. In contrast, adenovirus establishes a latent

infection with periods of reactivation. Replication-deficient vectors follow a similar pattern.
Transgene expression can be detected long after immunization, although it is not consistently
expressed

123

+

. Therefore, the induced antigen-specific CD8 T cell responses are not constantly

exposed to high levels of antigen and likely form functional memory responses that may be
+

boosted upon antigen re-encounter. Indeed, transgene product-specific CD8 T cells gradually
83

accumulate in the lymph nodes and reacquire both IL7R-α (CD127) and CD62L many weeks
+

after immunization. Further, Ad-induced CD8 T cells are polyfunctional and undergo robust recall
responses following secondary exposure to antigen

97,123,130,195

.

While persistent transgene expression is responsible for maintaining the transgene
+

product-specific CD8 T cell response following Ad immunization, it is unknown how it does so.
There are two models that may explain how the memory population may be maintained during
+

latency. The first is that naïve virus-specific CD8 T cells are continuously recruited into the
response by viral antigens expressed during persistence, thus replenishing the population as
memory cells decay. This asynchronous priming results in a highly heterogeneous virus-specific
+

CD8 T cell population with variable CD62L expression

199

. Such variability is generated because

the individual cells composing the overall population would be primed in different contexts
depending on when priming occurred during the persistent infection. This also would cause
+

functional variability within the population. CD8 T cells primed during the acute phase of the
infection can gradually progress toward exhaustion while those primed past the acute phase are
more functional

200

+

. Asynchronously primed CD8 T cell responses are common in persistent

infection models, including polyoma virus

201

, γ-herpesviruses

202

, and to some extent CMV

203

.

+

Alternatively, the transgene product-specific CD8 response induced following Ad immunization
could be maintained by existing memory cells that are recalled when re-stimulated with
persistently expressed transgene product. This study was designed to distinguish between these
+

two models. The results presented here suggest that naïve CD8 T cells are primarily not
+

responsible for the maintenance of the CD8 T cell pool following vaccination.

RESULTS
+

Antigen-specific CD8 T cells continue to proliferate well after immunization
+

The transgene product-specific CD8 T cell response following immunization fails to
contract. In order to determine if the cells that remain continue to proliferate, a bromodeoxyuridine
(BrdU) incorporation assay was performed. Briefly, C57BL/6 mice were immunized with 10

11

vp of
84

an E1-deleted adenoviral vector based on chimpanzee serotype 68 expressing influenza
b

nucleoprotein fused to GFP by SIINFEKL, the MHC class I H2k restricted immunodominant
epitope of ovalbumin (AdC68-NPOVAGFP). Mice were euthanized ten days, one month, and five
months after immunization. 72 hours prior to euthanasia, mice were pulsed intraperitoneally (IP)
with 2 mg/mL BrdU and the drinking water was supplemented every 24 hours with 0.8 mg/mL
BrdU. Upon euthanasia, lymphocytes were isolated from blood, spleen, and pooled popliteal and
+

inguinal lymph nodes. OVA-specific CD8 T cells were measured using a MHC class I tetramer
against SIINFEKL. Figure 4.1 shows the frequency of OVA-specific CD8

+

T cells that

incorporated BrdU during the three days of treatment, as well as the frequencies of antigen+

hi

+

lo

experienced CD8 T cells (CD44 ) and naïve CD8 T cells (CD44 ) that incorporated BrdU.
During the expansion phase following immunization dramatic incorporation of BrdU in the OVA+

specific CD8 T cells was observed in all tissues. Additionally, high frequencies of other antigen
+

hi

experienced CD8 T cells (CD44 ) had incorporated BrdU. This was likely because there are
other antigens besides SIINFEKL present in the vaccine that triggered a T cell response. Taken
together, the high rates of BrdU incorporation reflect the massive amount of proliferation these
cells undergo following their induction. By normalizing the percentage of BrdU incorporation to
that of the CD44

hi

+

cells, it can be seen that the OVA-specific CD8 T cells proliferate more
hi

robustly than the general CD44 population. One month after immunization, BrdU incorporation
+

was reduced in all tissues but was still elevated. The frequency of OVA-specific CD8 T cells that
had incorporated BrdU at this time typically ranged between 10-15%, except in the lymph nodes,
where about 50% continued to incorporate BrdU (Figure 4.1C). In all tissues only 10% of the
hi

CD44 cells incorporated BrdU. Five months after immunization, BrdU incorporation was further
reduced in all tissues but continued to be detected in the lymph nodes, where about 10% of OVA+

specific CD8 T cells incorporated BrdU (Figure 4.1C). While the frequency of incorporation was
not particularly high, the OVA-specific cells still proliferated about 3.5 times more than CD44

hi

cells. Taken together these results suggest that following induction with an Ad-based vaccine,
+

transgene product-specific CD8 T cells proliferate robustly and this proliferation continues for at
least five months after immunization, particularly in the lymph nodes.
85

FIGURE 4.1. Transgene product-specific CD8+ T cells continue to proliferate
months after induction.

+

Shows Bromodeoxyuridine (BrdU) incorporation by CD8 T cells isolated from blood [A], spleen [B], and
11
lymph nodes [C]. Briefly, C57BL/6 mice were immunized with 10 vp of AdC68-NPOVAGFP and
euthanized at the indicated times. 72 hours prior to euthanasia, mice were pulsed with 2mg/mL BrdU and
+
drinking water was supplemented with 0.8 mg/mL BrdU. Frequencies of OVA-specific CD8 T cells that had
incorporated BrdU were determined from individual mice by staining with an OVA-specific tetramer. As
hi
lo
controls, BrdU incorporation was analyzed on antigen-experienced (CD44 ) cells and naïve (CD44 ) cells.
+
+
+
Data are represented as mean frequency (%) ± standard deviation (SD) of BrdU CD8 per CD8 . The
lo
second column of charts show the data represented as fold change in relation to CD44 BrdU incorporation.
lo
Frequencies were compared to CD44 population and were compared using multiple t-tests by Holm-Sidak
hi
method. The following p values were obtained: [A] Day 10: OVA: p<0.0001, CD44 : p=0.0007; 1 month:
hi
hi
hi
OVA: p=0.0135, CD44 : p=0.0262; 5 month: CD44 : p=0.0185; [B] Day 10: OVA: p<0.0001, CD44 :
hi
hi
p=0.0001; 1 month: OVA: p=0.002, CD44 : p=0.001; 5 month: OVA: p=0.0008, CD44 : p=0.0048; [C] Day
hi
hi
10: OVA:p<0.0001, CD44 : p<0.0001; 1 month: OVA: p=0.0049, CD44 : p<0.0001; 5 month: OVA:
p=0.0089.	
  Significant differences are indicated by * for p-values ≤ 0.05-0.01, ** p-values < 0.01-0.001, *** pvalues ≤ 0.001-0.0001, **** p-values < 0.0001. Lines show the comparison groups.
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Naïve cells fail to respond to low-levels of persistent antigen following adenoviral
immunization
+

Studies of other persistent infections have revealed that the CD8 T cell pool that persists
during infection is made up of asynchronously primed naïve T cells

201,204

. In order to determine if

naïve T cells proliferate in response to low-levels of transgene that persist following immunization,
6

+

+

3.14 x 10 naïve Thy1.1 CD8 T cells were isolated from the spleen and adoptively transferred
+

into congenic Thy1.2 C57BL/6 mice that had been immunized 3 weeks earlier with either 10
AdC68-NPOVAeGFP or 10

11

11

vp

vp AdC7-HIVgag, as a negative control. Mice were bled at the
+

indicated times and the number of transferred OVA-specific CD8 T cells was determined by
staining with a MHC class I tetramer specific to SIINFEKL and an antibody to Thy1.1 to
distinguish donor from host cells. As shown in Figure 4.2A, in general naïve cells did not expand
following transfer into immunized mice. In a notable exception, naïve cells transferred into one
mouse not only engrafted but also robustly expanded and persisted for many months after
transfer (Figure 4.2B).
Such disparate results between the one animal and the others may indicate that
insufficient naïve precursors specific to OVA were transferred into the four mice in which naïve
+

+

CD8 T cells did not expand. The precursor frequency of naïve CD8 T cells specific to a given
antigen is rare. Estimates vary from epitope to epitope but generally range from as low as 1
+

+

precursor per million naïve CD8 T cells to ~80 precursors per million naïve CD8 T cells
+

205,206

.

b

The frequency of CD8 T cells specific to SIINFEKL (OVA) bound to H2k was estimated to be
+

approximately 1 cell for every 150,000 CD8 T cells, which translates into approximately 130 cells
+

within the total CD8 T cell population from the lymph nodes and the spleen

207

. Therefore, it is

+

possible that the number of naïve OVA-specific CD8 T cells transferred ranged from three cells,
on the lower end of the spectrum, to twenty cells at the higher end of the spectrum per mouse. As
the size of the precursor population affects the magnitude of the primary response

207,208

and

+

because it was possible that OVA-specific CD8 T cell precursors were not transferred, it was
+

important to determine if sufficient numbers of naïve OVA-specific CD8 T cells were transferred.
87

6

+

+

To this end, 3.14 x 10 naïve Thy1.1 CD8 T cells were transferred via tail vein injection into
+

naïve Thy1.2 C57BL/6 mice. After 18 hours, mice were immunized with either 10
NPOVAGFP or 10

11

11

vp AdC68-

vp AdC68-rab.gp, as a negative control. The donor OVA-specific response
+

was measured in the blood two weeks later. The donor OVA-specific CD8 T cells expanded very
robustly following immunization (Figure 4.2C). This observation indicates that sufficient numbers
of naïve precursors were transferred in order to observe a measurable response. Therefore,
these results suggest that the antigenic load that persists three weeks after immunization with an
+

adenovirus-based vaccine in general does not suffice to prime a de novo CD8 T cell response.

88

FIGURE 4.2. Naïve transgene product-specific CD8+ T cells generally do not
respond to persistent transgene product.

+

11

11

Groups of Thy1.2 C57BL/6 mice were immunized with 10 vp AdC68-NPOVAGFP or 10 vp AdC76
+
+
HIVgag, as a negative control. Three weeks later, 3.14 x 10 naïve congenic (Thy1.1 ) CD8 T cells were
adoptively transferred via tail vein injection into each group. Mice were bled at the indicated time points for
[A] and [B]. Figure [B] shows a single mouse with exceptionally numbers of high donor cells. Frequencies
+
+
of donor-specific (Thy1.1 ) OVA-specific CD8 T cells were determined by staining with an OVA-specific
+
+
+
6
tetramer. Data for [A] and [B] are represented as mean numbers of Thy1.1 OVA CD8 T cells per 10 live
PBMCs. Lines in [A] represent SD. [C] shows that sufficient naïve precursors specific to OVA were
+
transferred in [A] and [B]. Briefly, groups of Thy1.1 C57BL/6 mice were adoptively transferred with 3.4 x
6
+
+
11
10 naïve congenic (Thy1.2 ) CD8 T cells. 18 hours later, each group was immunized with 10 vp of
11
+
AdC68-NPOVAGFP or 10 vp AdC68-rab.gp. Mice were bled 2 weeks later and OVA-specific CD8 T cells
were determined. Data shown for each plot is represented as mean ± SD. Significance was determined by
unpaired t-test resulting in a p-value of 0.0241.
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Antigen experienced cells continue to expand in response to low-level of
persistent transgene product
The antigenic load that persists three weeks following immunization with an adenoviral
+

vector is not enough to prime a de novo CD8 T cell response. Therefore, it is likely that antigenexperienced cells are recalled when they encounter persistent antigen. To further investigate if
antigen-experienced cells respond to the low levels of persistent antigen, we transferred antigen+

experienced CD8 T cells using the same protocol as described above. Briefly, C57BL/6 Thy1.1

+

7

mice were immunized IP with 10 PFU of vaccinia virus expressing the NPOVAGFP transgene
(vac-OVA). These mice were euthanized one week after immunization, which coincides with the
+

peak of the OVA-specific CD8 T cell response. At the time of euthanasia, splenocytes were
+

6

isolated, CD8 T cells were negatively selected and then 3.14 x 10 cells were transferred via tail
+

vein injection into congenic (Thy1.2 ) C57BL/6 mice that were immunized three weeks earlier with
10

11

vp AdC68-NPOVAGFP or, as a negative control, 10
+

11

vp AdC7-HIVgag. Mice were bled at
+

the indicated times and the donor (Thy1.1 ) OVA-specific CD8 transferred T cell response was
measured.
+

+

Figure 4.3 shows the OVA-specific CD8 T cell responses of donor CD8 T cells that
+

were transferred 1 week after their induction with vac-OVA. OVA-specific CD8 T cells transferred
into Ad-gag mice engrafted and persisted through the course of the experiment without any
measurable expansion. However, the opposite was observed following transfer into Ad-OVA
immunized mice. Over the course of eight weeks, the transferred cells steadily expanded,
6

reaching approximately 300 cells per 10 live PBMCs (Figure 4.3A). Several months after
transfer, the donor cell numbers showed variation. Numbers from 3 mice were largely stable but
+

remained elevated. However, donor OVA-specific CD8 T cells in two Ad-OVA immunized mice
continued to proliferate extensively until about 8 months after transfer. These results indicate that
+

antigen-experienced transgene product-specific CD8 T cells can be maintained and further
respond to low-levels of persistent transgene expression for many months.
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Low levels of persistent antigen maintains an effector-like phenotype
In order to measure the consequences of long-term stimulation with a low-level antigen
on the fate of the transferred cells, expression of CD62L and CD127 were measured on OVA+

specific CD8 T cells circulating in blood eight weeks following transfer into Ad-OVA or Ad-gag
+

immunized mice. OVA-specific CD8 T cells transferred into Ad-gag immunized mice were
hi

CD62L and had CD127 expression that was comparable to naïve cells (Figure 4.4A), indicating
that these cells had rested down and transitioned into memory. On the other hand, OVA-specific
CD8

+

T cells transferred into the Ad-OVA mice were predominantly CD62L

lo

with CD127

expression also comparable to naïve cells (Figure 4.4A). KLRG1 was included at a later time
point to measure for stimulation history. At the peak response eight months after transfer, the
+

lo

transferred OVA-specific CD8 T cells largely remained CD62L . However, they had higher levels
of CD127 than naïve cells. Taken together, these three markers indicate that these cells are
maintained in an effector memory phenotype. Supporting the notion that the expansion observed
+

(Figure 4.3A) is due to continuous antigenic stimulation, the transferred OVA-specific CD8 T
hi

cells were predominantly KLRG1 , which reflects stimulation history and may indicate that these
cells are reaching a point after which they may no longer continue to divide.
+

CD8 T cells responding to chronic infections are at risk of losing effector functions. This
is characterized by progressive loss of ability to produce multiple cytokines. IL-2 production is the
most sensitive to chronic stimulation and, as such, is the first cytokine to be lost. This is followed
by loss of TNF-α production and, upon exhaustion, IFN-γ production is also lost

209

. Persistent

transgene product expression appears to lead to the continued stimulation of antigen+

experienced transgene product-specific CD8 T cells (Figure 4.3). There has been some debate
+

over whether or not adenovirus vaccination drives responding CD8 T cells toward some degree
of exhaustion

140,196

. Therefore, in order to test the functionality of antigen-experienced cells in the

presence of low levels of persistent transgene product, intracellular cytokine staining was
+

performed. Briefly, Thy1.1 C57BL/6 mice were immunized IM with 10
or 10

11
+

11

vp AdC68-NPOVAGFP
+

vp AdC7-HIVgag, as a negative control. Three weeks later, CD8 T cells from congenic

Thy1.2 C567BL/6 mice were adoptively transferred into them. One week prior to transfer, donor
91

7

mice had been vaccinated with 10 PFU vac-OVA and the following day they had been injected
6

+

+

with 5 x 10 splenocytes from transgenic OT-1 C57BL/6 Thy1.2 mice. CD8 T cells from OT-1
mice are specific to the SIINFEKL epitope encoded in the Ad-OVA vector. Therefore, they were
+

transferred to increase the frequency of responding OVA-specific CD8 T cells in order to enable
better detection during intracellular cytokine staining. Mice were bled at the indicated time points
+

and in vitro re-stimulation was performed to detect donor OVA-specific CD8 T cell production of
IFN-γ, TNF-α, and IL-2.
+

Transfer of OVA-specific CD8 T cells into Ad-OVA immunized mice results in a number
+

of OVA-specific CD8 T that produce cytokines upon re-stimulation that remain fairly stable over
time (Figure 4.5A), although there was some fluctuation in the response at certain time points.
This fluctuation may be due to an internal boosting effect from the persistent antigen that is not
consistently expressed

123

. Additionally, the cells could be producing cytokines other than those
+

measured in this assay. The CD8 T cells transferred into Ad-gag immunized mice did not
produce cytokines following restimulation. This could be due to their egress from the blood as
+

they transitioned into memory. The profile of the OVA-specific CD8 cytokine secreting T cells
was fairly stable as well. Two weeks after transfer, the cytokine secreting cells were largely
composed of cells that produce IFN-γ alone or in combination with TNF-α following re-stimulation,
which is consistent with highly activated effector cells (Figure 4.5B). Although the total number
of cytokine secreting cells was reduced six months following transfer (Figure 4.5C), the profile
was similar to that of the cytokine producing cells at two weeks following transfer. However, the
response was clearly dominated by cells that produce IFN-γ alone following re-stimulation. While
the antigenic load clearly supports effector and effector memory cells (Figures 4.4, 4.5B, 4.5C),
these cells do not appear to be greatly losing effector functions.
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FIGURE 4.3. Antigen-experienced CD8+ T cells respond and expand in response to
persistent antigen.

+

11

11

Groups of Thy1.2 C57BL/6 mice were immunized with 10 vp AdC68-NPOVAGFP or 10 vp AdC76
+
+
HIVgag, as a negative control. Three weeks later, 3.14 x 10 congenic (Thy1.1 ) CD8 T cells were
adoptively transferred via tail vein injection into each group. Transferred cells were isolated from mice
7
immunized 1 week earlier with 10 PFU vaccinia virus expressing NPOVAGFP (vac-OVA). Mice were bled
+
+
at the indicated time points. Frequencies of donor-specific (Thy1.1 ) OVA-specific CD8 T cells were
determined by staining with an OVA-specific tetramer. Data are represented as mean numbers ± SD of
+
+
6
Thy1.1+ OVA CD8 T cells per 10 live PBMCs. The bar indicates the mean of the group. Differences
+
between numbers of OVA-specific CD8 T cells transferred into Ad-OVA and Ad-gag mice were determined
at each time point using multiple t-tests with Sidak-Bonferroni correction. The following p-values were
obtained: [A]: 6 weeks: p=0.0372, 8 weeks: p=0.0336 [B]: 8 months: p=0.0295.
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FIGURE 4.4. Antigen-specific CD8+ T cells maintain an effector memory phenotype
regardless of presence of persistent antigen.

+

+

Expression of CD62L and CD127 was measured on donor (Thy1.1 ) OVA-specific CD8 T cells 8 weeks [A]
11
and 8 months [B] after transfer into mice immunized with 10 vp AdC68-NPOVAGFP (top row of graphs) or
AdC7-gag (bottom row of graphs). KLRG1 was included at 8 months after transfer. Grey histograms
+
represent staining for naïve host CD8 T cells. Open histograms represent concatenated data from 5 mice
for each group.
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FIGURE 4.5. Antigen-experienced CD8+ T cells do not lose function over time in
response to persistent antigen.

Shows the kinetics of total cytokine-producing donor cells [A] and the cytokine profile 12 weeks following
+
11
11
immunization Groups of Thy1.1 C57BL/6 mice were immunized with 10 vp AdC68-NPOVAGFP or 10 vp
6
+
+
AdC7-HIVgag, as a negative control. Three weeks later, 3.14 x 10 congenic (Thy1.2 ) CD8 T cells were
6
adoptively transferred into each group. Congenic mice were transferred with 5 x 10 OT-1 cells and
7
+
immunized with 10 PFU vac-OVA 1 week prior to transfer into Thy1.1 mice. Mice were bled at the
indicated time points and PBMCs were stimulated with either SIINFEKL peptide or the equivalent amount of
an irrelevant peptide to measure background stimulation. [A] Shows the number of cytokine producing cells
+
following the subtraction of background stimulation. The profiles of donor CD8 cells producing cytokine
combinations are shown for 2 weeks after transfer [B] and 6 months after transfer [C] and were determined
by summation of Boolean gates for each cytokine. Data in each figure is represented as the number of
+
+
6
donor (Thy1.2 ) CD8 producing cytokines per 10 live PBMC. Standard deviation is included for [B] and
[C]. In [A], the bar represents the mean. Significance between rapamycin- and sham–treated groups was
determined for each time point using multiple t-tests with Holm-Sidak correction for multiple comparisons for
[A] and 2way ANOVA with Holm-Sidak correction for multiple comparisons for [B] and [C]. The following pvalues were obtained: [A] 4 weeks: p=0.0003, 6 weeks: p=0.0003; [B] G+T+: p=0.0048; G+: p=0.0002 [C]
G+:p<0.0001
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DISCUSSION
+

The experiments presented in this chapter were designed to address how the CD8 T cell
pool that fails to contract following immunization with an Ad-based vaccine is maintained. Two
+

possible scenarios can be envisioned. Naïve CD8 T cells could be recruited continuously into the
response as they encounter their cognate antigen during Ad persistence. These cells would
ultimately replace the terminally differentiated cells as they decay, thereby maintaining a stable
+

response. Alternatively, CD8 T cells primed early in the response that differentiated into central
memory cells could be restimulated as they encounter antigen during Ad persistence and thus
+

replenish the on-going CD8 T cell response. The data presented here largely support the latter
scenario.
Asynchronous priming of naïve CD8

+

T cells is a strategy commonly employed to

maintain stable memory T cell numbers during various persistent infections, including mouse
+

polyoma virus and CMV. Antigen-specific CD8 T cells that respond and persist during these
infections are characterized by a large degree of heterogeneity in their expression of such
markers as CD62L, CD127, and CD27

201,204

+

. As transgene product-specific CD8 T cells elicited

by Ad vector vaccination are also highly heterogeneous

123,140,195

, it stood to reason that this

+

heterogeneity could reflect that the transgene product-specific CD8 T cells are in various stages
of differentiation due to priming with their antigen at different times during the response. However,
when naïve cells were transferred into Ad immunized mice after clearance of most of the acutely
transduced cells, the overall pattern was that the cells did not expand in response to transgene
+

product. This suggests that naïve CD8 T cells are not recruited to maintain the elevated
+

transgene product-specific CD8 T cell response. Indeed, while adult mice immunized with an Adbased vaccine 8 weeks after being thymectomized mount slightly lower transgene product+

specific CD8 T cell responses, the kinetics of the response are not altered and the cells do not
have a more distinct contraction as would be expected if naïve cells were responsible for
+

maintaining the CD8 T cell pool

140

+

. Interestingly though, transferred naïve CD8 T cells in one

animal showed robust expansion and persisted for many months. Statistically, this was
96

considered an outlier. However, the results may be biologically relevant, perhaps indicating that
at the time of transfer the Ad genome was more transcriptionally active, and thus producing more
transgene product, in that mouse than in the others.
+

While these data do suggest that naïve CD8 T cells are primarily not responsible for
+

maintaining the elevated CD8 T cell response, it is important to recognize the limitations of my
+

approach. Despite demonstrating that enough transgene product-specific CD8 T cell precursors
were transferred (Figure 4.1B), the recipient mice may not have permitted their engraftment. The
recipient mice could not be T cell depleted prior to transfer as this would have removed the cells
that harbor persisting Ad vector genomes and thus may not have had available niches in which
+

the congenic naïve cells could engraft. Other groups have demonstrated a role for naïve CD8 T
cells in responding to persistent infection by creating partial hematopoietic chimeric mice
201,202,204

. To accomplish this, persistently infected mice were treated with a low dose of busulfan,

a non-immunosuppressive myeloablative agent, and then partially reconstituted with naïve,
+

congenic bone marrow. This creates a population of stem cells to give rise to naïve CD8 T cells.
+

While it has been reported that busulfan does not disturb virus-specific CD8 T cell responses

201

,

it would be critical to determine that the adenovirus reservoir is not affected and it persists in the
+

lymphatics. It has been demonstrated that bone marrow is a reservoir for central memory CD8 T
cells

210

. Whether or not these bone marrow-derived cells harbor persistent adenovirus has yet to

be confirmed.
+

To test if antigen-experienced transgene product-specific CD8 T cells maintain the CD8

+

+

T cell pool, splenic OVA-specific CD8 effector T cells were transferred into Ad immunized mice.
+

Vast and continuous accumulation of donor OVA-specific CD8 T cells was observed. This largely
+

indicates that antigen-experienced cells are responsible for the maintenance of the CD8 T cell
pool following vaccination with an Ad-based vaccine. However, these experiments do not reveal
the nature of the antigen-experienced cell responsible. We would expect that the population of
+

OVA-specific CD8 T cells present in the donor spleen seven days after immunization with vacOVA would be heterogeneous, containing both short-lived effector cells and memory precursor
cells. Therefore, we cannot rule out the possibility that a small number of memory cells were
97

transferred. In general, we would expect that those cell types would be responsible as terminally
+

differentiated antigen-specific CD8 T cells have a limited capacity for proliferation and would be
expected to decay over time. Further experiments would be warranted to determine the cell type
involved in this expansion.
The cells that continued to accumulate in this transfer model had at 8 months after
transfer an effector memory phenotype and expressed high levels of KLRG1, a marker that
reflects the history of antigen stimulation. Therefore, the high expression of KLRG1 on these cells
likely reflects that they continue to encounter their antigen. As such it would be important to
+

assess if the donor derived antigen-specific CD8 T cell response requires antigen in order to
persist. In some models of chronically infecting viruses, especially LCMV clone 13, virus-specific
+

CD8 T cells become addicted to antigen. Once antigen is removed from the system, or the
+

CD8 T cells are transferred to a naïve environment, the cells die because they minimally express
receptors for IL-7 and IL-15, which drive the homeostatic turnover over memory cells, thereby
promoting their survival

99

. However, LCMV clone 13 is not equivalent to adenovirus. There is
+

some evidence to suggest that transgene product-specific memory CD8 T cells induced following
Ad immunization do not require antigen to be maintained. Utilizing Ad vectors encoding a
SIINFEKL expression cassette that could be temporally regulated using the Tet-OFF system, the
+

Bramson group demonstrated that the primary SIINFEKL-specific CD8 T cell response only
requires SIINFEKL expression for the first two months following immunization, after which they
become antigen-independent

211

. However, whether these cells remain antigen-independent

many months following immunization remains to be elucidated. Therefore, it would be critically
+

important to assess at a longer interval after Ad immunization the antigen-specific CD8 T cells’
responsiveness to IL-7 and IL-15 as a measure of their capacity for homeostatic self-renewal and
dependency on antigen.
The continuous accumulation observed in some mice resembles a phenomenon termed
+

memory inflation, which is used to describe the accumulation of CD8 T cells responding to
+

certain epitopes following cytomegalovirus infection. CD8 T cells that respond to inflationary
epitopes have an effector memory phenotype and are highly functional, thus capable of both
98

producing cytokines following restimulation and lysing target cells

204

. This phenomenon occurs in

the absence of viral replication, CMV vectors limited to a single cycle of replication continue to
+

induce CD8 T cell inflation

212

. Indeed, memory inflation has recently been described following

immunization with a β-galactosidase expressing adenovirus

213

+

. Antigen-specific CD8 T cell

inflation occurs in response to immunodominant epitopes that due to their high affinity
outcompete lower affinity peptides for MHC class I binding

214

. The immunodominant MHC class

I-restricted epitope of ovalbumin, SIINFEKL, is a high affinity epitope that causes inflation in the
context of a CMV vector

215

. It is therefore likely, that we observed a similar effect in the study

presented here. Inflation following Ad immunization was followed for two epitopes from βgalactosidase

213

, one was inflationary and the other was not. As such different epitopes

processed from the same protein have different capacities to induce inflation. As the SIINFEKL
+

epitope included in the Ad vectors used here was part of a larger transgene, the CD8 T cell
response to additional epitopes in the transgene should be monitored for their inflationary ability.
This could have important implications in the design of transgenes used in adenoviral vaccines to
elicit protective immune responses against many pathogens, particularly those which a large pool
+

of effector memory CD8 T cells are required for protection.
+

Given that antigen-experienced transgene product specific CD8 T cells appear primarily
responsible for the maintenance of their memory pool following Ad immunization, it would be
likely that these cells periodically reencounter transgene product, which promotes their continued
expansion. Interestingly this indicates that the cells harboring persistent adenovirus vector, whose
transgene’s expression is controlled by a constitutively active promoter, are not destroyed by the
+

on-going transgene product-specific CD8 T cell response. The mechanism by which this occurs
is unclear. Gene products from the E3 domain are responsible for immunomodulation, including
blocking MHC-I antigen presentation and mediating resistance to T cell cytolysis and cytokines
that promote cell death, such as TNF-α

79,81,83

. However, later generation Ad vectors, including

those used in this study, are deleted in this domain but still retain the ability to persist in vivo

123

.

Alternatively, the persistence of an antigen depot in activated T cells could demonstrate that
+

these cells are resistant to CD8 T cell-mediated lysis.
99

MATERIALS AND METHODS
Vectors and immunizations
All experiments were performed with E1-deleted adenovirus vectors based on
chimpanzee serotype 68 (AdC68) or chimpanzee serotype 7 (AdC7). Mice were injected IM with
10

11

viral particles (vp) of either a vector encoding influenza nucleoprotein fused to green

fluorescent protein and the immunodominant MHC class I restricted epitope of ovalbumin
(SIINFEKL) (AdC68-NPOVAGFP), a vector encoding the rabies virus glycoprotein (AdC68rab.gp), or a vector encoding gag of HIV-1 (AdC7-HIVgag). Additional experiments used a
vaccinia virus vector encoding the NPOVAGFP fusion protein (vac-OVA). Vectors for
immunization were diluted to the appropriate concentration in sterile PBS (Cellgro; Manassas,
VA). Mice were immunized intramuscularly (IM) with 50 µL of diluted vector in each hind limb, for
a total of 100 µL per mouse. Where indicated, mice were immunized intraperitoneally (IP) with
200 µL of diluted vector.

Mice
+

Female 4 to 6 week old mice Thy1.2 C57BL/6 mice were purchased from the National
Cancer Institute (Frederick, MD). Thy1.1

+

C57BL/6 mice were purchased from Jackson

Laboratories (Bar Harbor, ME). Mice were housed in the vivarium at the Wistar Institute
(Philadelphia, PA). All experiments and procedures were performed in accordance with approved
+

animal protocols. C57BL/6 OT-1 breeding pairs were purchased from Jackson Laboratories and
were then bred at Wistar following approved breeding protocols.

Lymphocyte isolation
Blood was collected via submandibular bleeding into 1 mL of 4% sodium citrate. 1 mL of
L-15 (Cellgro) was added after collection. Peripheral blood mononuclear cells (PBMC) were
isolated by Histopaque-1083 (Sigma-Aldrich; St. Louis, MO) gradient purification. PBMC were
100

collected and washed in L-15 containing 1% fetal bovine serum (FBS) (Gemini Bio Products;
West Sacramento, CA). Red blood cells were lysed for 5 minutes at room temperature using RBC
lysis buffer (eBioscience; San Diego, CA).
Spleens were homogenized against a 70 µm filter screen and collected in pre-warmed L15 containing 1% FBS. Cells were pelleted at 1500 rpm for 5 minutes. Pellets were resuspended
in RBC lysis buffer for 5 minutes at room temperature to lyse red blood cells.
Popliteal and inguinal lymph nodes were collected from both hind limbs and
homogenized against a 70 µm filter screen. Lymphocytes were collected in L-15 containing 1%
FBS and washed once with the same media. Lymphocytes isolated from peritoneal lavage were
collected by flushing the peritoneal cavity with 10 mL L-15 containing 1% FBS and washing once.

BrdU Assay
C57BL/6 mice were immunized with 10

11

vp AdC68-NPOVAGFP. Mice were euthanized

10 days, 1 month, or 5 months after immunization. Three days prior to euthanasia, mice were
injected IP with 2 mg bromodeoxyuridine (BrdU) (Sigma-Aldrich) dissolved in 200 µL PBS.
Additionally, drinking water was supplemented with 0.8 mg/mL BrdU and 1% sucrose (SigmaAldrich). Water was changed and fresh solution was added each day prior to euthanasia.
Blood, spleens, and popliteal and inguinal lymph nodes were isolated and prepared as
described above. Cells were stained and permeabilized using BrdU Flow kit (BD Pharmingen;
Franklin Lakes, NJ) following the manufacturer’s protocol. Briefly, the cell surface was first
stained with PerCP-Cy5.5-labeled anti-CD8 (BD Pharminogen), PE-Cy7-labeled anti-CD44 (BD
Pharminogen), APC-labeled tetramer against the immunodominant MHC class I restricted epitope
of Ovalbumin (SIINFEKL) (courtesy of Dr. E John Wherry), and Live/Dead fixable aqua dye (Life
Technologies, Carlsbad, CA) for 30 minutes at 4°C. Following a PBS wash, samples were
permeabilized with Cytofix/cytoperm (BD Biosciences; Franklin Lakes, NJ) for 30 minutes at 4°C
then washed with 1X Perm/Wash (BD Biosciences). Cells were permeabilized further with
Cytoperm Permeabilization Buffer Plus (BD Biosciences) for 10 minutes on ice and then washed
as before. Samples were re-fixed by treating with 100 µL Cytofix/cytoperm and washed. To
101

expose BrdU for staining, samples were treated with 100 µL of 300 µg/mL DNase solution (BD
Pharmingen) for 1 hour at 37°C and washed with 1X Perm/Wash. Samples were then stained for
20 minutes at room temperature with FITC-labeled anti-BrdU (BD Pharminogen) diluted 1:50 in
1X Perm/wash and then washed.

Adoptive Transfers
+

+

CD8 T cells used in transfer experiments were harvested from C57BL/6 Thy1.1 mice.
Where indicated, naïve cells were isolated and transferred or cells were isolated from mice that
7

had been immunized intraperitoneally (IP) 7 days earlier with 10 plaque-forming units (PFU) vac+

OVA. On the day of transfer, these mice were euthanized and splenocytes were isolated. CD8 T
+

cells were isolated by negative selection using EasySep Mouse CD8 T Cell Enrichment Kit
(Stemcell Technologies; Vancouver, BC) following the manufacturer’s protocol.
+

Isolated CD8 T cells were then transferred intravenously (IV) to recipient C57BL/6
+

6

(Thy1.2 ) via tail vein at a concentration of 3.14 x 10 cells per mouse. Recipient mice had been
immunized 3 weeks earlier with 10

11

vp of either AdC68-NPOVAGFP or AdC7-HIVgag.gp, as a

negative control.

Intracellular Cytokine Staining (ICS)
Lymphocytes were plated on a 96-well plate in 200 µL of DMEM supplemented with 2%
Mixed Lymphocyte Culture medium. Lymphocytes were stimulated in the presence of Golgi Plug
(BD Biosciences) either with a positive peptide, SIINFEKL, or with a negative peptide, WIZX-2
from rabies virus. Each was used at 2.5 µg/mL. Stimulation was performed for 5 hours at 37°C in
10% CO2. Following stimulation, lymphocytes were stained at 4°C for 30 minutes with
fluorochrome-labeled antibodies against CD8, CD44, Thy1.1 or Thy1.2 to distinguish donor cells,
and with Live/Dead Fixable Aqua dye to exclude dead cells from analysis. Cells were washed
once and then permeabilized with 100 µL Cytofix/Cytoperm for 30 minutes at 4°C. Cells were
then washed with 1X Perm/Wash and additionally stained for 30 minutes at 4°C with
fluorochrome-labeled antibodies against IFN-γ, TNF-α, and IL-2 diluted 1:100 in 1X Perm/Wash.
102

Following staining, cells were washed and fixed with BD Fixative (BD Biosciences). Samples
were stored at 4°C until analysis.
Cells were analyzed with a BD LSR-II flow cytometer (BD Biosciences) and post
acquisition analysis was performed with FlowJo v.9.4 software (TreeStar, Ashland, OR). Samples
were first gated to identify lymphocytes based on forward scatter area (FSC-A) and side scatter
(SSC). Doublets were then removed using a plot of forward scatter height (FSC-H) vs. FSC-A.
+

Live lymphocytes were then gated based on exclusion of Live/Dead stain. Donor CD8 T cells
+

+

+

were identified by plotted Thy1.1/1.2 events vs. CD8 events. CD8 T cells were then gated on
each intracellular cytokine. Boolean gates were then created to identify all possible cytokine
n

combinations, equaling 2 combinations, where n is equal to the number of individual cytokines
measured.
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CHAPTER 5
	
  
THE EFFECT OF ADENOVIRUS-SPECIFIC ANTIBODIES ON
ADENOVIRAL VECTOR-INDUCED TRANSGENE PRODUCTSPECIFIC T CELL RESPONSES

104

ABSTRACT
In this study we tested the effect of neutralizing antibodies to different serotypes of E1deleted adenovirus (Ad) vectors on the immunogenicity of the homologous adenovirus vector or a
vector derived from a heterologous serotype. Our results show that, as expected, even low titers
of passively transferred neutralizing antibodies significantly reduce the homologous vectors’
+

ability to elicit transgene-specific CD8 T cell responses. In addition antibodies changed the fate
+

of transgene product-specific CD8 T cells by promoting their transition into the central memory
+

cell pool, which resulted in markedly enhanced expansion of transgene product-specific CD8 T
cells following a boost with a heterologous Ad vector. Non-neutralizing antibodies induced to one
+

adenoviral serotype had no effect on the magnitude of transgene product-specific CD8 T cells
induced by a distinct vector nor did such antibodies promote induction of more resting memory
+

CD8 T cells. These results show that antibodies to an adenovirus vaccine carrier not only affect
+

the magnitude but also the flavor of a vector-induced CD8 T cell response.

Adapted from: The effect of adenovirus-specific antibodies on adenoviral vector-induced
transgene product-specific T cell responses. JC Small*, LH. Haut*, A Bian, HCJ Ertl. Journal
of Leukocyte Biology. In press.
105

INTRODUCTION
E1-deleted adenovirus (Ad) vectors derived from human serotype 5 (AdHu5) are highly
immunogenic, inducing potent B and T cell responses against its viral components and products
of transgenes encoded from its genome. As such, these vectors are being developed as vaccine
platforms against a wide array of pathogens. However, a concern with the use of AdHu5 vectors
is that humans are commonly infected with the virus during childhood and therefore have preexisting immunity against the vector. Animal studies demonstrated that virus-neutralizing
antibodies (VNAs) against AdHu5 reduce transduction of target cells
with the coxsackie and adenovirus receptor (CAR)

91

ultimately dampening the vector’s immunogenicity
immunogenic than other vaccine platforms

217.

92

by blocking its interaction

thereby reducing transgene expression,
93,216,217.

However, AdHu5 is more

As such, an AdHu5-based vaccine encoding a

transgene made up of HIV-1 clade B gag/pol/nef was developed to induce HIV-specific T cell
responses with the goal of reducing viral load in infected individuals. Pre-clinically, the vector
protected nonhuman primates challenged with the SIV-HIV chimera SHIV-89.6P
phase trials demonstrated the vaccine’s immunogenicity in humans

219.

218

and early

The phase IIB, or STEP,

trial was designed to test the efficacy of this vaccine in individuals at high risk for HIV-1
acquisition and was tested in individuals who were both AdHu5 seronegative and seropositive.
The trial was halted early after interim analysis revealed that the vaccine was not efficacious.
More worrying though was that further analysis also demonstrated a significantly increased risk of
HIV acquisition among men who were both AdHu5 seropositive and uncircumcised at the time of
immunization

220,

although this risk appears to become less pronounced with time

221.

While most

vaccinees mounted immune responses to the HIV-1 antigens encoded in the vector, the
responses were not very strong and T cell responses were also narrowly focused on one to three
epitopes. Nevertheless, the reduced immunogenicity in seropositive participants could not explain
their increased risk of HIV infection. A subsequent trial, HVTN505, was designed to test an HIV-1
vaccine regimen using a DNA vaccine prime followed by an AdHu5 boost in AdHu5 seronegative
individuals. Again, the trial was halted because it failed to show efficacy and observed a non106

significant trend towards higher infection rates in vaccine recipients compared to placebo
recipients

222.

Although a number of theories were formulated and tested to explain the increased

acquisition rates in the STEP trial

223,224

the reasons for the apparent increased susceptibility to

HIV-1 infection in AdHu5 vaccine recipients remain elusive.
To overcome the problem of pre-existing immunity, novel recombinant Ad vectors are
being evaluated. Several groups are developing vectors based on alternative human serotypes
such as HAdV-26 (AdHu26)

225

or HAdV-35

226.

While these so-called “rare” human serotypes are

potently immunogenic, humans are still exposed to these viruses and, depending on the
geographic region, they either lack VNAs to these serotypes or they carry low titers

227.

Of note,

regions where the development of an HIV vaccine is critical to public health tend to have
seroprevalence rates to AdHu26 that are comparable to those AdHu5

228.

Therefore, these

vectors may face the same challenges as vectors derived from AdHu5. Alternatively, vectors
derived from non-human adenovirus serotypes, such as those from chimpanzees (SAdV, also
termed AdC), are also being explored

229,230.

As these viruses do not circulate in humans,

prevalence rates to such viruses are even lower than those to alternative human serotypes

231,232.

It remains an open question if these two groups of alternative Ad vectors will outperform AdHu5based vaccines in clinical trials or elicit the previously observed increased risk of HIV-1 infection
in vaccine recipients.
Here we tested if VNAs against distinct serotypes of E1-deleted Ad vectors differentially
affect the immunogenicity of the homologous vector. Although Ad-specific VNAs are serotypespecific and mainly directed to the hypervariable loops of hexon

13

, non-neutralizing antibodies to

more conserved regions of the viral surface proteins, such as fiber and the hexon stalk, crossreact between different human and simian serotypes

92

. Therefore, the effect of passive transfer

of Ad-specific antibodies on the immune response induced by vaccination with an Ad vector
derived from a heterologous serotype was also assessed. These results confirm that even low
titers of adoptively transferred antibodies can significantly reduce the vectors’ ability to elicit
+

transgene product-specific CD8 T cell responses and there was no definite difference between
107

the different serotypes. Interestingly, passive transfer of Ad VNAs changed the fate of transgene
+

product-specific CD8 T cells by promoting their transition into the central memory compartment,
resulting in their enhanced expansion following a boost with a heterologous Ad vector. Ad VNAs
+

induced to one serotype had no effect on the magnitude of transgene product-specific CD8 T
cells induced by an Ad vector of a different serotype nor did such antibodies promote induction of
+

more resting memory CD8 T cells. These results show that antibodies to an Ad vaccine carrier
+

not only affect the magnitude but also the differentiation of an Ad vector-induced CD8 T cell
response.

RESULTS
In order to determine if pre-existing vector-specific neutralizing antibodies differentially
affected immune responses to transgene products encoded in Ad-based vaccines, serotypespecific hyperimmune sera were generated against three distinct Ad species. Vectors based on
AdHu5, a common family C serotype, AdHu26, a family D serotype, and AdC6, a chimpanzeederived serotype from family E, were used to repeatedly immunize BALB/c mice to generate
hyperimmune sera. Sera were collected and tested for neutralization of the homologous virus.
After determining the vector-specific neutralizing antibody titer, each sera was transferred
intraperitoneally (IP) to groups of naïve BALB/c mice such that five days after transfer the groups
had circulating vector-specific VNA titers of 1:1000, 1:100, or 1:10. As a control, a group of mice
was treated with naïve BALB/c serum given at the equivalent volume to that used for the highest
dose of hyperimmune serum (1:1000). The day following confirmation of circulating vectorspecific VNAs mice were immunized with 10

10

viral particles (vp) of an HIV-1 Gag-expressing Ad

vector based on the identical serotype used for induction of serum the mice received. Ten days,
three weeks, and eight weeks later mice were bled and peripheral blood mononuclear cells
+

(PBMCs) were tested for Gag-specific CD8 T cell responses by staining with a tetramer specific
d

to the immunodominant, H-2 -restricted immunodominant epitope of Gag (AMQMLKETI) (Figure
+

5.1A-C). Vaccination affected overall numbers of circulating CD8 T cells; therefore, tetramer

+
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6

+

cells were normalized to 10 live PBMCs. Gag-specific CD8 T cell responses elicited by each
vector peaked three weeks after immunization and were sustained thereafter, although the
responses induced by AdHu26-gag underwent more pronounced contraction compared to those
induced by AdHu5-gag and AdC6-gag. Mice with circulating AdHu5-specific VNAs as low as 1:10
+

titer had significantly reduced Gag-specific CD8 T cell responses ten days after immunization
with AdHu5-gag. This reduction became more pronounced at later time points, particularly in
those mice with the highest titer of AdHu5-specific VNAs. Similarly, circulating AdHu26-specific
+

VNA titers of 1:100 and 1:1000 caused significant reduction of Gag-specific CD8 T cells ten days
after immunization with AdHu26-gag. By three weeks after immunization, even the lowest dose of
AdHu26-specific VNAs caused pronounced decreases in the response, which were maintained
+

eight weeks after immunization. Gag-specific CD8 T cells were reduced in those mice bearing
AdC6-specific VNAs at the time of immunization with AdC6-gag, although at the earliest time
point only mice with the highest titers had significant reduction.
To determine if immunization in the presence of vector-specific VNAs reduced Gag+

specific CD8 T cell responses in compartments other than blood, lymphocytes from spleens and
genital tract were isolated 8 weeks after immunization. Results from both tissues largely mirror
those seen in the blood. In spleens (Figure 5.1D-F), AdHu5-gag and AdC6-gag induced robust
Gag-specific CD8

+

T cell responses that were significantly reduced in mice primed in the

presence of vector-specific VNAs, regardless of dose. In contrast, AdHu26-gag induced a poor
+

Gag-specific CD8 T cell response that was only reduced in mice with the highest dose of
+

AdHu26-specific VNAs. At the genital tract (Figure 5.1G-I), Gag-specific CD8 T cell responses
induced by AdHu5-gag and AdC6-gag were comparable in control mice and, as expected, VNAs
present at the time of immunization reduced those responses. In contrast, AdHu26-gag induced a
+

poor Gag-specific CD8 T cell response at the genital tract in control mice but that was increased
in mice that had a circulating titer of AdHu26-specific VNAs of 1:10. Treatment with the higher
VNA doses resumed the pattern of reduction in responses.
+

To determine if transfer of Ad-specific VNAs altered CD4 T cell responses, PBMCs and
splenocytes were tested at eight weeks after immunization. We observed variation in the antigen109

+

+

experienced (CD44 ) CD4 T cell responses in the blood following immunization with the different
+

vectors. In comparison to CD4 T cell numbers found in blood of naïve mice, immunization with
+

AdHu5 in the absence of vector-specific VNAs significantly increased CD4 T cell responses
(Figure 5.2A). However, priming in the presence of AdHu5-specific VNAs, failed to increase
+

CD4 T cell responses, which remained comparable to those seen in naïve mice. The exception
+

to this was mice primed in the presence of the highest VNA dose, where CD4 T cell responses
became elevated above baseline. In contrast, vaccination with AdHu26 significantly reduced
+

CD4 T cell responses in all groups but for mice primed in the presence of the lowest dose of
+

AdHu26-specific VNAs. While immunization with AdC6 did not change the CD4 T cell numbers
+

in the blood, priming in the presence of AdC6-specific VNA, regardless of dose, reduced CD4 T
cell responses. CD4

+

T cell responses in the spleen were largely unchanged following
+

immunization with either AdHu5 or AdC6 (Figure 5.2B). Splenic CD4 T cells in AdC6-immunized
mice were below those seen in naïve mice regardless of transfer of AdC6-specific antibodies.
Results from the STEP trial revealed that individuals previously exposed to AdHu5 with
moderate to high levels of circulating AdHu5-specific VNAs at the time of immunization with the
AdHu5-based vaccine had slightly higher rates of HIV-1 infection than those in the placebo arm of
the trial. This seemingly enhanced susceptibility was unexpected and its underlying causes
remain elusive. However, one possible explanation is that vaccination of those individuals
+

increased numbers of activated CD4 T cells, and thus, targets of HIV-1 infection at mucosal
+

+

surfaces. To this end, numbers of activated (CD44 ) CD4 T cells were analyzed in the genital
tract in naïve mice and vaccinated mice treated with all serum doses (Figure 5.2C). Relative
+

numbers of activated CD4 T cells in the genital tract were not dramatically changed following
vaccination, although relative numbers seemed to increase following vaccination with AdHu5 but
decreased slightly upon AdHu26 vaccination. Variation in numbers was observed for immune
serum recipients, although there was no consistent trend between vectors, other than that the
+

highest dose of serum did not increase the numbers of activated CD4 T cells. Regardless, the
observed differences were modest and comparable to those observed in control mice.

110

Adenoviruses and vectors based on them are known to persist in immunologic tissues,
particularly in activated T cells

123

. During persistence, the Ad genome remains transcriptionally

active, albeit at low levels, and thus maintains high frequencies of effector T cells exhibiting
delayed kinetics in their transition into the central memory pool

123

. As circulating vector-specific

+

VNAs reduced frequencies of transgene product-specific CD8 T cells, it stands that their memory
phenotype may be altered as well. Therefore, Gag-specific CD8

+

T cells induced in this

experiment were analyzed for expression of CD62L, which can be used to distinguish effector
and memory T cells based on either low or high expression, respectively. Immunization with
either Ad vector in the presence of pre-existing vector-specific VNAs increased the frequencies of
+

hi

Gag-specific CD8 T cells with a CD62L phenotype (Figure 5.3A-C). This effect was observed
as early as ten days after vaccination with AdHu5-gag and AdHu26-gag in the blood of mice with
the highest titer of circulating vector-specific VNAs, and became more pronounced at eight weeks
after vaccination in both blood and spleens. Increased CD62L expression was only observed at
eight weeks following vaccination with AdC6-gag but was significantly increased in all groups of
mice that had received AdC6-specific immune serum. Interestingly, increased frequencies in
hi

+

CD62L Gag-specific CD8 T cells were not observed in the spleens of these mice other than
those that had received the low titer of AdC6-specific VNAs at the time of immunization.
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FIGURE 5.1. Passive transfer of Ad-immune serum reduces transgene productspecific CD8+ T cells to Ad vector immunization.

Groups of female BALB/c mice (5 per group) were injected with pooled serum from donor mice that had
been immunized twice with an Ad vector expressing the rabies virus glycoprotein. Doses of serum were
adjusted so that titers of Ad-specific VNAs measured from recipient mice 24 hours later equaled 1:10, 1:100
or 1:1000. Control mice received a volume of serum from naïve donor mice that equaled the highest volume
10
of the immune serum. Mice were injected after serum transfer with 10 vp of the Ad vector that was
homologous to the Ad used to induce the transferred serum. Ad vectors expressed HIVgag. Significant
differences are indicated by * for p-values ≤ 0.05-0.01, ** p-values < 0.01-0.001, *** p-values ≤ 0.0010.0001, **** p-values < 0.0001. Lines show the comparison groups.
[A-C] Mice were bled on day 10 (white bars), 3 (light grey bars) and 8 weeks (dark grey bars) later and
+
frequencies of gag-specific CD8 T cells were determined from individual mice by staining with a specific
+
+
6
tetramer. Data are expressed as average numbers of tetramer (tet) CD8 cells per 10 live PBMCs ±
standard deviations (SD). Differences between numbers of immune versus naïve serum were determined by
one-way ANOVA with Dunnett correction for type 1 errors. The following p-values were obtained: [A]
AdHu5: d10: 1:10 p=0.044, 1:100 p=0.0037, 1:1000 p=0.0025; wk 3: 1:1000 p=0.0006; wk 8: 1:10 p=0.0012,
1:100 p=0.0007, 1:1000 p<0.0001; [B] AdHu26: d10: 1:100 p=0.007, 1:1000 p<0.0001; wk 3: all serum
dilutions p<0.0001, wk 8: 1:10 p=0.0012, 1:100 p=0.0013, 1:1000 p<0.0001; [C] AdC6: d10 1:100 p=0.0073,
1:1000 p=0.0068, wk 3: 1:10 p<0.0001, 1:100 p<0.0001, 1:1000 p<0.0001; wk 8: 1:10 p=0.0006, 1:100
p=0.0004, 1:1000 p<0.0001.
[D-F] Splenocytes were tested 8 weeks after immunization. The following p-values were obtained: (by oneway ANOVA with Dunnett correction for type 1 errors.): [D] AdHu5: d10: 1:10 p=0.001, 1:100 p=0.0044,
1:1000 p=0.0002, [E] AdHu26: 1:1000 p=0.0061, [F] AdC6: 1:10 p=0.0057, 1:100 p=0.0086, 1:1000
p=0.0006.

FIGURE LEGEND CONTINUED ON PAGE 113
112

FIGURE 5.2. CD4+ T cell responses in blood and spleen and recruitment to the
genital tract.

+

+

-

The graphs show relative numbers of CD44 CD3 CD8 cells isolated 8 weeks after immunization from blood
+
[A], the spleen [B], and the pooled genital tracts [C] of the same mice shown in Figure 5.1. CD4 cells were
+
identified upon staining for CD8 and CD3 as cells that were CD3 CD8 . Graphs shows numbers of cells over
6
10 live cells ± standard deviations (SD). Significant differences between the number of lymphocytes from (I)
naive serum vs. immune serum and (II) number of lymphocytes from naïve mice vs. immunized mice were
determined by one-way ANOVA with Dunnet correction for type 1 errors. The following p-values were
obtained: [A] (I) AdHu5: 1:10 p = 0.025, 1:100 p = 0.0015; AdC6: 1:10 p = 0.0002, 1:100 p < 0.0001, 1:1000
p < 0.0001; (II) AdHu5: naïve serum: p = 0.0005, 1:1000 p = 0.0387; AdHu26: naïve serum: p = 0.0082,
1:100 p = 0.0038, 1:1000 p < 0.0001; AdC6: 1:10 p = 0.0378, 1:100 p = 0.0148, 1:1000 p = 0.0030 [B] (I)
AdC6: 1:100 p = 0.0143. (II) AdHu26: naïve serum: p = 0.0035, 1:10 p = 0.0064, 1:100 p = 0.0049, 1:1000 p
= 0.0041.
Significant differences are indicated by * for p-values ≤ 0.05-0.01, ** p-values < 0.01-0.001, *** p-values ≤
0.001-0.0001, **** p-values < 0.0001. Lines show the comparison groups.

CONTINUED FROM PAGE 112:
[G-E] The graphs show results of genital tract samples pooled from 5 mice as relative numbers of Gag+
6
specific CD8 T cells over 10 live lymphocytes.

113

FIGURE 5.3. Pre-existing Ad-specific VNAs increase frequencies of transgene
product-specific CD62L+CD8+ T cells.

+

Blood-derived Gag-specific CD8 T cells, identified by stains for CD3, CD8 and the Gag-specific tetramer
from groups of 5 mice serum treated and immunized as in Figure 5.1 were tested for expression of CD62L
10 days (white bars) and 8 weeks (light grey bars) after immunization. Splenocytes (dark grey bars) were
10
tested at 8 weeks after immunization with 10 vp of either AdHu5-gag [A], AdHu26-gag [B], or AdC6-gag
[C]. Differences between frequencies in serum recipients vs. controls were determined by one-way ANOVA
with Dunnett correction for type 1 errors. The following p-values were obtained for blood: [A] AdHu5: d 10:
1:100 p = 0.0005, 1:1000 p = 0.027, wk 8: 1:1000 p = 0.0014; [B] AdHu26: d 10: 1:1000 p = 0.0046, wk 8:
1:1000 p<0.0001; [C] AdC6: wk 8: 1:10 p = 0.045, 1:100 p = 0.032, 1:1000 p <0.0001 and spleens: [A]
AdHu5 1:1000 p = 0.0044, [B] AdHu26 1:1000 p = 0.0008, [C] AdC6 1:10 p = 0.0001.
Significant differences are indicated by * for p-values ≤ 0.05-0.01, ** p-values < 0.01-0.001, *** p-values ≤
0.001-0.0001, **** p-values < 0.0001. Lines show the comparison groups.
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+

Antigenic load during T cell priming is a determining factor in memory CD8 T cell
development

122

. Therefore, the increased frequencies of Gag-specific CD8

+

T cells highly

expressing CD62L could reflect that the vector-specific VNAs neutralized the vector and thus
+

reduced the antigenic load available for induction of CD8 T cell responses. If the vector-specific
VNAs reduced the amount of antigen available for priming, mice immunized with fewer viral
hi

particles would be expected to have the same increased frequencies of CD62L Gag-specific
+

8

CD8 T cells. To this end, groups of mice were immunized with AdHu5gag at doses 100- (10 vp)
9

and 10-fold (10 vp) lower than used in the previous experiments. As expected, five and eight
weeks after immunization the magnitude of Gag-specific CD8

+

T cells in the blood was

significantly reduced when lower doses of vector were used (Figure 5.4A). Nevertheless, the
frequency of CD62L

hi

+

Gag-specific CD8 T cells was not increased with any dose of vector

(Figure 5.4B), suggesting that a mechanism other than reduction of vector load at priming is at
play.
A second possible mechanism is that the vector-specific VNAs altered the Ad vectors’
ability to transduce the lymphocytes that would serve as the viral reservoir during persistence. To
address this, groups of C57BL/6 mice were treated with naïve serum or a dose AdHu5-specific
hyperimmune serum resulting in a circulating titer of 1:340. Mice were immunized 24 hours later
with 10

10

vp of an AdHu5-based vaccine that expressed a influenza nucleoprotein fused to GFP

by the immunodominant epitope of ovalbumin (NPOVAGFP). A naïve group of mice were
included as a negative control. Five weeks after immunization, mice were sacrificed and genomic
DNA was isolated from splenocytes. The DNA (20 ng) was then tested for the AdHu5 vector
genome using highly sensitive nested PCR against AdHu5 hexon (Figure 5.5). As expected, the
genome was not detected in the naïve mice but was detected in three out of five mice that were
immunized following transfer of naïve serum. The AdHu5 genome could only be faintly detected
in one of three mice that had been treated with AdHu5-specific VNAs, largely suggesting the
VNAs altered the vector’s persistence, which would allow for increased transition into central
memory.
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FIGURE 5.4. Low doses of Ad vector fail to promote increases of transgene
product-specific CD62L+CD8+ T cells.

8

9

10

Groups of 4 mice were vaccinated with 10 , 10 or 10 vp of AdHu5-gag vector. [A] PBMCs were tested 5
(white bars) and 8 (light grey bars) weeks later, splenocytes were tested 8 weeks later (dark grey bars) for
+
+
6
numbers of Gag-tet CD8 T cells over 10 live lymphoid cells. Data were analyzed by ANOVA with
uncorrected Fischer’s LSD. Lines show the comparison groups. The following differences were significant in
8
9
9
10
8
10
blood: wk 5: 10 vs. 10 vp p = 0.012, 10 vs. 10 vp p = 0.047; wk 8: 10 vs. 10 vp p = 0.033. [B]
+
+
+
Tet CD8 T cells were tested for expression of CD62L and the right graph shows % CD62L Gag-specific
+
+
+
CD8 T cells over all Gag-specific CD8 T cells. There were no differences in percentages of CD62L cells.
Significant differences are indicated by * for p-values ≤ 0.05-0.01, ** p-values < 0.01-0.001, *** p-values ≤
0.001-0.0001, **** p-values < 0.0001. Lines show the comparison groups.
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FIGURE 5.5. Pre-existing Ad-specific VNAs reduce persistence of Ad vector
genome.

Mice received naïve serum (n=5) or AdHu5 immune serum at a dose between the middle and high titers
10
from previous experiments (1:320) (n=3) and were immunized 24 hours later with 10 vp AdHu5NPOVAGFP vector. A control group (n=3) was unimmunized. Splenocytes were tested 5 weeks later for
AdHu5 hexon DNA by nested PCR and real-time nested PCR. Amplicons from non-quantitative nested PCR
(250 bp) were analyzed on 1% TAE gel.
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+

To further characterize the Gag-specific CD8 T cells induced in the presence of the high
titer of AdHu5-specific VNAs, additional differentiation markers were analyzed, including killer cell
lectin-like receptor subfamily G member 1 (KLRG1), a marker of terminal differentiation that has
+

been shown to reflect a CD8 T cell’s stimulation history in that its expression is increased on
cells that repeatedly encounter their antigen

124,148

, CCR7, a chemokine receptor that regulates T

cell migration to the lymphoid tissues and whose co-expression with CD62L on T lymphocytes is
used to differentiate between effector memory (low expression) and central memory (high
expression)

103,233

, and CD127, the IL-7 receptor which is required for formation of memory

234

. As

in the previous set of experiments, mice treated with the high dose of AdHu5-specific VNAs had
higher frequencies of circulating CD62L

+

Gag-specific CD8

+

T cells eight weeks after

immunization with AdHu5-gag. Consistent with the idea that the VNAs reduced vector
+

+

persistence, the frequencies of KLRG1 Gag-specific CD8 T cells were significantly lower in
mice that had been primed in the presence of AdHu5-specific VNAs (Figure 5.6A). Trends
+

+

+

toward higher frequencies of CCR7 and CD127 Gag-specific CD8 T cells were observed but
did not reach statistical significance.
A hallmark characteristic of memory CD8

+

T cells is that they have a very high

proliferative capacity. As such, they vastly expand during recall responses. Therefore, in order to
+

functionally confirm that the VNAs led to better induction of CD8 T cell memory, each group of
mice received a second immunization with a heterologous Ad vector. Eight weeks after priming
with AdHu5-gag, all groups of mice were boosted with 10

10

vp AdC7-gag. A group of naïve mice

+

was primed as a control. Gag-specific CD8 T cell responses were analyzed in the blood ten days
later (Figure 5.6B). As expected, the numbers of responding cells vastly expanded in all mice,
regardless of VNAs at the time priming. Although boosting resulted in higher numbers of Gag+

specific CD8 T cells in mice primed in the absence of VNAs, it is worth noting that these mice
had significantly higher frequencies at the time of the boost. As such, comparison of the relative
+

increases of Gag-specific CD8 T cells between the two groups of mice revealed that the cells
isolated from mice with circulating VNAs at the time of the prime expanded more robustly (35+

fold) than those mice treated with naïve serum (14-fold). The frequencies of CD62L Gag-specific
118

+

CD8 T cells were notably lower than before the prime and were comparable between both
+

+

groups of mice; whereas CCR7 and CD127 frequencies were unchanged (Figure 5.6C). The
+

+

frequencies of Gag-specific CD8 T cells that were KLRG1 were increased in both groups after
+

the boost, as expected, but the pattern observed before the boost remained: fewer KLRG1 Gag+

specific CD8 T cells were detected in mice who bore pre-existing AdHu5-specific VNAs at the
time priming (Figure 5.6C).
+

Expression of certain markers on Gag-specific CD8 T cells at 8 weeks after the prime
correlated very significantly with the fold increases in numbers of specific cells due to their
+

expansion following the boost. Even though the slightly higher frequencies of CD127 Gag+

specific CD8 observed in the mice primed in the presence of pre-existing VNAs was not
+

significant, the frequency of CD127 cells measured just before boosting was directly correlated
+

to Gag-specific CD8 T cell expansion after boosting (Figure 5.6D). As expected, the frequency
+

+

of KLRG1 Gag-specific CD8 T cells 8 weeks after priming was inversely correlated to their
+

expansion after the boost (Figure 5.6E). Correlations to CD62L cells, on the other hand, were
not significant (not shown). As a whole, these data indicate that priming in the presence of vectorspecific neutralizing antibodies (NAb) enhances transition into memory and, thus, leads to more
robust recall responses.
Serotype-specific neutralizing antibodies are primarily directed against the hypervariable
loops on hexon
targets

235

13

, although other capsid components, such as penton and fiber, can also be

. Other, more conserved capsid elements, such as the hexon stalk, are targets for

antibodies that cross-react between two distinct serotypes. Therefore, the induction and fate of
transgene product-specific CD8

+

T cells were analyzed in mice that were primed with a

heterologous vector in the presence of Ad vector-specific hyperimmune serum. First, each
hyperimmune serum used in the experiments described above was assessed for reactivity with
vectors derived from AdHu5, AdHu26, AdC6, and chimpanzee serotype 7 (AdC7) using ELISAs
(Figure 5.7A). Although each serum preferentially reacted with the homologous vector used for
induction, cross-reactivity between the different serotypes was observed. AdHu26 did not
significantly bind antibodies from AdHu5 and AdC6 hyperimmune serum. While AdHu5 virus
119

cross-reacted with AdHu26 and AdC6 sera, the highest levels of cross reactivity were observed
for the chimpanzee vectors, especially for AdC7 which very significantly bound antibodies from all
three hyperimmune sera.
AdHu26 has a high seroprevalence rate in developing nations

228

and transfer of
+

AdHu26-specific VNAs strongly reduced induction of transgene product-specific CD8 T cell
responses following AdHu26-gag vaccination (Figure 5.1), causing a pronounced increase in
+

+

Gag-specific CD62L CD8 T cells as early as 3 weeks after vaccination (Figure 5.3). Additionally
as AdHu26 sera showed strong cross-reactivity with AdC7 vector (Figure 5.7A), the
hyperimmune serum was chosen to continue investigation into the role, if any, cross-reactive
+

antibodies play in modulating CD8 T cell responses to heterologous Ad vectors. The AdHu26
sera’s capacity to neutralize AdC7 was next measured (Figure 5.7B). A virus neutralizing
antibody assay was performed using naïve BALB/c and the AdHu26 hyperimmune serum to test
the neutralization of AdC7 expressing GFP (AdC7-GFP). As a positive control for neutralization,
AdHu26-GFP was included. The neutralization titer was determined as the dilution at which the
serum neutralized 90% GFP expression. A titer of 10 or below was considered non-neutralizing.
As expected, naïve serum neutralized neither AdHu26-GFP nor AdC7-GFP. Additionally, AdHu26
hyperimmune serum had an extremely high titer of AdHu26-specific neutralizing NAbs that
neutralized AdHu26-GFP at the 1:40960 dilution. However, this serum did not neutralize AdC7GFP.
In order to determine if immunization in the presence of heterologous vector-specific
+

antibodies affected transgene product-specific CD8 T cell responses, AdHu26 hyperimmune
serum was transferred to BALB/c mice such that the mice had a circulating AdHu26-specific VNA
titer of 1:1000 six days later at the time of immunization. Control mice received naïve serum.
Mice were immunized with 10

10

+

AdC7-gag. Gag-specific CD8 T cell responses were measured

ten days and four weeks later in the blood and eight weeks later in the spleen. Gag-specific CD8

+

T cell responses were comparable between both the control mice and the mice that had received
AdHu26-hyperimmune serum (Figure 5.7C), indicating that AdHu26-specific antibodies failed to
neutralize AdC7 vector in vivo. CD62L, CCR7, KLRG1, and CD127 expression on Gag-specific
120

+

CD8 T cells in blood were measured four weeks after vaccination. Expression of all four markers
was comparable between both groups (Figure 5.7D), indicating that priming in the presence of
heterologous vector-specific antibodies did not alter differentiation of transgene product-specific
+

CD8 T cells. Taken together these data indicate that vector-specific neutralizing antibodies are
responsible for the observed phenomena in these studies.
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FIGURE 5.6. Ad-specific VNAs present at the time of priming promote recall
responses.

[A] A group of 5 BALB/c mice were transferred with an AdHu5 immune serum given at a dose that resulted
in a 1:1000 titers of VNAs in the recipient mice. Another group of 5 mice received the same volume of serum
10
from naïve mice. Both groups were vaccinated with 10 vp of AdHu5-gag after serum transfer. A third group
+
of 5 mice was left untreated (Controls). Eight weeks later mice were bled and Gag-specific CD8 T cells
10
were measured (light grey bars). All mice were vaccinated the following day with 10 vp of AdC7-gag
+
vector. Gag-specific CD8 T cell responses were measured from blood 10 days later (dark grey bars).
+
6
Graphs show number of Gag-specific CD8 T cells identified by staining with the tetramer over 10 live
lymphoid cells as bars (min to max) ± SD. Differences between the two groups of serum recipients were
determined by t-tests. The following p values were obtained comparing recipients of immune vs naïve
serum: after priming p = 0.0044. Differences of the same cohort comparing data after priming to those after
the boost gave the following p-values: naïve serum recipients p < 0.0001, immune serum recipients p =
+
0.0043. Fold increases of numbers of Gag-specific CD8 T cells were calculated (number after the boost
divided by numbers before the boost). Differences between the two groups were significant: p = 0.011.
Controls (no priming, AdHu5 at the time of boost) p = 0.0001.
+

[B] Graphs show percentage of Gag-specific CD8 T cells tested 8 weeks after immunization for expression
of CD62L, CCR7, KLRG1 and CD127. Differences were determined by multiple t-test with Sidak-Holm
correction. The following significant p-values were obtained: CD62L p< 0.0001, KLRG1 p = 0.00012.
+

+

[C] Graph shows percentages of Gag-specific CD8 T cells positive for the indicated markers over all CD8
T cells at 10 days after the boost for mice that receive immune or naïve serum before priming. Differences
were calculated by multiple t-test with Sidak-Holm correction. Only KLRG1 was differentially expressed (p =
0.0004). Significant differences are indicated by * for p-values ≤ 0.05-0.01, ** p-values < 0.01-0.001, *** pvalues ≤ 0.001-0.0001, **** p-values < 0.0001. Lines show the comparison groups.
+

[D] and [E] show correlations between fold increases after the boost and % of Gag-specific CD8 T cells
positive for CD127 or KRLG-1 respectively. R and p-values are shown within the graphs.
FIGURE LEGEND CONTINUED ON PAGE 123
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FIGURE 5.7. Effect of pre-existing Ad-specific antibodies on transgene productspecific CD8+ T cells to a heterologous Ad vector.

[A] Graph shows binding of the transferred sera to different Ad serotypes as shown in the legend within the
figure. Titers were calculated by determining the area under the curve of adsorbance data obtained by
serially diluted sera. ELISAs were conducted in duplicate wells and results shows mean ± SD. Differences in
titer of immune sera to naïve sera were calculated by ANOVA with Dunnett correction. The following sera
showed significant reactivity with the following vectors: AdHu5 serum: on AdHu5 vector p < 0.00001, on
AdC7 vector p = 0.0006; AdHu26 serum on AdHu5 vector p = 0.0013, on AdHu26 vector p = 0.0008, on
AdC6 vector p = 0.0132; on AdC7 vector p < 0.0001; AdC6 serum on AdHu5 vector p = 0.016, on AdC6
vector p = 0.0003; on AdC7 vector p < 0.0001.
[B] Graph shows analysis of naive BALB/c sera and AdHu26 hyperimmune sera for neutralization of
AdHu26 or AdC7. Sera were tested for virus-neutralizing antibodies (VNA) against AdC7-GFP and AdHu26GFP using VNA assay. Titers of 10 and below were considered non-neutralizing.
[C-D] Groups of 5 mice were injected with a dose of AdHu26-immune serum that resulted in a VNA titer of
1:1000 or an equal dose of serum from naïve mice. Mice were then immunized with AdC7gag. [C] shows
+
Gag-specific CD8 T cell responses tested from blood 10 days and 4 weeks later and spleens 8 weeks later.
+

[D] shows frequencies of Gag-specific CD8 T cells that were positive for the indicated markers.
Significant differences are indicated by * for p-values ≤ 0.05-0.01, ** p-values < 0.01-0.001, *** p-values ≤
0.001-0.0001, **** p-values < 0.0001. Lines show the comparison groups.

CONTINUED FROM PAGE 122:
[F] shows the gating strategy of a representative sample. After lymphocytes were identified based on FSC
and SSC, doublets were excluded (not shown). Live cells were identified based on exclusion of live/dead
+
+
+
stain. CD8 T cells were gated (CD3 CD8 ). The subsequent gates were designed to isolate Gag-specific
+
+
+
+
low
CD8 T cells (tetramer CD44 ) and naïve cells (tetramer CD44 ) as an internal control. Each population
was then gated on CD62L and CCR7 or CD127 and KLRG1 based on naïve cells’ expression of each.
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DISCUSSION
Ad vectors are very attractive vaccine platforms thanks to their robust induction of B and
T cell responses. However a major obstacle to use of these vectors is that virus-neutralizing
antibodies (VNAs) to them are common. Historically, AdHu5 has been one of the most commonly
studied vectors for this purpose. However, infection with AdHu5 often occurs during childhood,
and, as such, pre-existing immunity to this virus is extremely common. Prior studies have
demonstrated that the seroprevalence of AdHu5-specific neutralizing antibodies among adults in
developed nations, including the United States and those constituting Europe, is typically
between 30-60%
individuals

237

228,231,236

, although serum immunoglobulin against Ad may be found in all

. These seroprevalance rates are dramatically increased in developing nations.

Studies suggest that prevalence rates of neutralizing antibodies against AdHu5 are between 7080% in Brazil

228,232

, between 75-100% in the Asian nations of Thailand

between 80-100% in sub-Saharan nations

228,231,236

228,231

and India

238

, and

. In all regions, about 30% or more of adults

have moderate to high titers of AdHu5-specific VNAs

232

. As these neutralizing antibodies can

dampen the vector’s immunogenicity, this high seroprevalance of AdHu5-specific neutralizing
antibodies poses a challenge to the development of AdHu5-based vaccines to protect against
pathogens that plague the developing world.
A common strategy to circumvent the problem of pre-existing immunity to common Ad
serotypes is development of vectors based on uncommon Ad serotypes. So-called “rare” human
serotypes, such as AdHu26, circulate less frequently in humans. This “rare” designation is largely
based on seroprevalence rates found in the developed world. Indeed, AdHu26 neutralizing
antibodies are found in approximately 20% of adults in the United States and only 2% carry a titer
of 1:200 or greater

228

. However, AdHu26 is not particularly rare in developing nations.

Approximately 65-85% of adults in sub-Saharan Africa are seropositive for neutralizing antibodies
against AdHu26. Prevalence of individuals carrying titers of 1:200 or greater seems to vary in this
region but ranged from 0-22%

228

. Elsewhere, including South America and Asia, AdHu26-

specific neutralizing antibody seroprevalance rates range from about 40-70%

228,232

, with 32-37%
124

of adults carrying high titers

228

. Based on the seroprevalence rates, it would be expected that

immunogenicity of an AdHu26-based vaccine would also be compromised. Therefore, others
have focused on the development of vectors based on non-human adenovirus serotypes that do
not circulate in humans, particularly those isolated from chimpanzees, e.g. AdC6. Pre-existing
immunity to AdC6 is very rare in the United States and Thailand
nearly 20% of adults in certain regions of sub-Saharan Africa

231

229,231

. Seroprevalance climbs to

, which was speculated to be due

to the chimpanzee populations endemic to those regions. Native populations of New World
monkeys genetically unrelated to chimpanzees may be responsible for the similar seroprevalance
rate found in adults living in the Brazilian rainforest

232

.

This high incidence of pre-existing immunity to Ad has prompted extensive work looking
at how pre-existing immunity to adenovirus affects induction of T cell responses following
vaccination with an Ad-based vaccine. Models focusing on pre-exposing mice

92

and NHP

216,217

+

to adenovirus prior to vaccination have revealed that transgene product-specific CD8 T cell
responses are reduced in these animals. Pre-exposure to Ad induces both cellular and humoral
immunity directed against the vector. Neutralizing antibodies are generally directed against the
hypervariable loops of hexon

13,235

, although NAb against fiber and penton are also detected

Ad-specific T cells have also been described

237

235

.

. While pre-exposure models at least in part

mirror naturally acquired Ad infections in humans, these studies do not differentiate between the
individual roles that the cellular and humoral components play in the reduction of responses. As
such, both arms of the adaptive immune system have been implicated

93

. A recent study in which

B cell-deficient mice were pre-exposed to Ad before vaccination revealed that induction of
+

transgene product-specific CD8 T cells was unaffected by pre-exposure

239

, suggesting that

vector neutralizing antibodies are primarily responsible for this reduction. Thus, the study
presented here was performed in order to assess how pre-existing Ad-specific neutralizing
antibodies present at the time of immunization affect induction and differentiation of transgene
product-specific CD8

+

T cells generated by vectors based on distinct Ad serotypes. The

experiments presented here clearly demonstrate that pre-existing vector neutralizing antibodies
present at the time of immunization, regardless of serotype, dramatically inhibit transgene
125

+

product-specific CD8 T cell responses in the blood, spleen, and genital tract. However, the
+

results presented above demonstrate that priming of the CD8 T cell response still occurs in a
manner that is indirectly related to the titer of vector-specific NAbs present at priming. This likely
indicates that not all vector particles are neutralized and that some remain to infect target cells
and prime T cell responses.
The vectors presented in this study each represent different Adenoviridae families, as
such, they may have differences in their biology, including their ability to bind to receptors and coreceptors, their inflammatory potential that induces innate responses and their tropism, which all
+

could affect their capacity to induce transgene product-specific CD8 T cells in the face of preexisting VNAs. Although each vector was sensitive to neutralization by homologous vector+

specific VNAs, differences in the kinetics of transgene product-specific CD8 T cell induction were
observed. VNAs present at the time of immunization with either vector reduced induction of Gagspecific responses at the earliest time point measured. However, immunization with AdHu5-gag
in the presence of VNAs induced robust peak responses that were only significantly reduced in
mice treated with the highest dose of serum. These results are consistent with another report that
demonstrated using an AdHu5 pre-exposure model, which induced titers of AdHu5-specific VNAs
in mice ranging from 1:40-1:80

240

+

, that although circulating transgene product-specific CD8 T

cell responses were reduced in the presence of vector specific immunity, they still induced peak
+

responses. Gag-specific CD8 T cells induced in the presence of vector-specific VNAs by
AdHu26-gag and AdC6-gag did not show this peak response and instead remained low through
the experiment.
Ad vectors persist at low levels in a transcriptionally active state in activated T cells and
+

maintain a pool of activated effector transgene product-specific CD8 T cells that have delayed
kinetics in their transition into the central memory pool

123

. Unexpectedly, vector-specific

neutralizing antibodies present at high titers at the time of immunization promoted transgene
+

product-specific CD8 T cells’ transition into the memory pool, as evidenced by increased CD62L
+

expression and very robust recall responses. It is well known that CD8 T cell responses and fate
decisions are influenced by conditions present early in their activation. One such condition is the
126

amount and duration of antigenic stimulation. High levels of antigen and longer TCR engagement
tend to favor differentiation towards effector populations, while limiting amounts of antigen
available for priming favors development of the central memory population

122

. Therefore, it was

+

possible that increased CD62L expression observed on Gag-specific CD8 T cells primed in the
presence of vector-specific NAb was caused by the reduction of antigen available due to
neutralization of the vector. However, this result was not recapitulated by simply decreasing the
vector dosage 100-fold. While it is possible that the vector dose was not decreased enough in
order to observe increased CD62L expression, further dosage reduction would likely compromise
a measurable response.
Alternatively, pre-existing immunity could alter the innate immune response induced by
the Ad vector. Inflammation during T cell priming provides the danger signal to the T cell and
+

dramatically impacts CD8 T cell differentiation. High inflammation favors development of more
terminally differentiated effector cells
of more plastic central memory cells

114

while reduction of inflammation enhances development

241

. These developmental decisions are mediated at the

transcriptional level during T cell priming. The level of inflammatory cytokines directly affects the
level of T-bet expression in a dose-dependent manner

182

ultimately shifting the balance of

expression between T-bet and Eomesodermin. In a follow up to the STEP trial, a systems biology
approach using gene mapping revealed that AdHu5 seropositive individuals had dampened
inflammatory responses following vaccination with Merck’s Ad5-based vaccine

242

. Therefore, Ad-

specific VNAs in the study presented here may have reduced inflammation at the time of priming
+

and thus promoted differentiation towards memory. CD4 T cell help during the primary response
+

is required for induction of CD8 T cell memory responses, although this is dependent on the
+

infectious agent. CD4 T cell help promotes the activation and maturation of dendritic cells, thus
increasing their expression of CD80 and CD86, to provide costimulation to T cells through CD28,
and of proinflammatory cytokines, especially IL-12

243

+

. It is therefore possible that CD4 T cell

help played a role in changing the priming environment in the context of pre-existing vectorspecific neutralizing antibodies. The study presented here does not rule out this possibility and
+

this could be addressed by repeating these studies in CD4 T cell-deficient or MHC-II-deficient
127

mice. Although an important caveat is that studies using CD4-deficient and -depleted mice have
+

demonstrated that generation of proper CD8 T cell responses following adenovirus immunization
+

requires CD4 T cell help

244

.

These NAb-virus immune complexes could in turn affect the natural tropism of the virus.
The majority of adenoviruses enter cells by binding the coxsackie adenovirus receptor (CAR)
however coating in antibodies could retarget the virus to cells bearing Fc-receptors. In vitro
studies have revealed that these immune complexes are potentially capable of infecting and
expressing transgenes in cells that express FcγR

245

receptors either endogenously following activation
APCs

246,247

. T cells, which are capable of expressing Fc

223

or by acquiring them via trogocytosis from

, serve as the reservoir for adenovirus during its persistence

65,123

. However, instead

of enhancing transduction of T cells, the Ad-specific VNAs seem to reduce the vector reservoir
within them. In fact, we were not able to detect Ad vector genome in two out of three samples of
splenic lymphocytes from animals primed in the presence of vector specific-VNAs, but Ad
genome was detected in three out of five animals primed in the absence of vector specific-VNAs.
We performed the same nested PCR on splenocytes isolated from mice used in the boost
experiment shown in Figure 5.5. We were able to detect AdHu5 genome in 5 out of 5 mice
primed in the absence of AdHu5-specific VNAs but were unable to detect AdHu5 genome in 4 of
5 mice primed in the presence of AdHu5-specific VNAs (data not shown). Although these two
experiments are not quantitative they nevertheless suggest that pre-existing neutralizing
antibodies may interfere with the establishment of a persisting viral reservoir. This in turn may
+

have influenced the long-term development of central memory Gag-specific CD8 T cells by
reducing the persisting transgene product. KLRG1 expression reflects a T cell’s antigenic
stimulation history as it is more highly expressed with subsequent rounds of antigen exposure
124,148

hi

+

. Frequencies of KLRG1 Gag-specific CD8 T cells were reduced in mice primed in the

presence of vector-specific NAbs. Therefore, this could indicate that there was less persistent
+

antigen available to stimulate the transgene product-specific CD8 T cells.

128

These results have important implications for the use of Ad vectors as vaccine carriers as
they clearly demonstrate that although the primary response is attenuated in the presence of
vector-specific immunity, this does not preclude a robust secondary response.
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MATERIALS AND METHODS
Generation of immune sera
Groups of 20 BALB/c mice were immunized IM with 10

11

vp of AdHu5-, AdHu26-, or

11

AdC6-rab.gp and boosted IM 6 weeks later with 10 vp of the identical vector used for priming.
Mice were bled 4 weeks after the boost to confirm titers of Ad-specific VNAs. Mice immunized
with AdHu5-rab.gp and AdHu26-rab.gp were euthanized 5 weeks after the boost, serum was
collected and VNA titers were determined to be 1:13,000 and 1:40,000, respectively. Mice
immunized with AdC6-rab.gp were boosted a second time and euthanized 6 weeks later. The
serum VNA titer was determined to be 1:20,000.

Titration of Ad-specific VNAs
Sera were incubated at 56°C for 30 minutes. 100 µl of serial, two-fold dilutions, starting at
1:20, were incubated with a GFP-expressing Ad matching the serotype used for immunization for
1 hour at 37°C. The virus-serum mixtures were added to HEK 293 cells in 96-well plates and
incubated overnight at 37°C. The cells were analyzed for GFP expression 24 hours later. The
VNA titer was determined by the highest dilution with less than 50% GFP-positive cells when
compared to control wells.

Administration of immune sera and immunization of mice
Immune sera were passively transferred into mice to achieve VNA titers of 1:1000, 1:100
and 1:10. Sera were diluted in sterile PBS to a volume of 200 µl per mouse and were
administered IP. One group of mice received naïve BALB/c serum diluted to the highest dose of
immune serum. Mice were bled to confirm appropriate VNA titers 5 days after transfer and
immunized the following day IM with 10

10

vp of the indicated vector diluted in 100 µl of sterile

PBS.
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Enzyme-linked immunoadsorbent assay (ELISA)
8

ELISA plates were coated with 10 vp/well of AdHu5-HIVgag, AdHu26-HIVgag, AdC6HIVgag, or AdC7-HIVgag in 100 µl of coating buffer [2 carbonate-bicarbonate capsules (SigmaAldrich) dissolved in 100 mL H2O] and incubated overnight at 4°C. Plates were washed with
0.05% Tween (Biorad; Hercules, CA) in PBS (PBS-T) and blocked overnight at 4°C with 3% BSA
(Sigma-Aldrich) in PBS-T (blocking buffer). After PBS-T wash, two-fold serial dilutions of AdHu5,
AdHu26, and AdC6 immune sera starting at 1:200 were incubated on coated plates for 2 hours at
room temperature. Plates were washed with PBS-T and alkaline phosphatase (AP)-conjugated
anti-mouse IgG (Sigma-Aldrich) diluted to 1:30,000 was applied to plates for 1 hour at room
temperature. At the end of the incubation, plates were washed, developed (2 tabs phosphatase
substrate (Sigma-Aldrich) dissolved in 10 mL diethanolamine buffer (KPL; Gaithersburg,
Maryland) and read 30 minutes later at 405 nm. All samples were run in duplicates.

Tetramer staining
Lymphocytes were stained with an APC-labeled tetramer against the immunodominant
MHC class I restricted epitope of HIV-1 Gag (AMQMLKETI). Additionally, cells were stained with
antibodies to CD3, CD8, CD44, KLRG1 (Southern Biotech, Birmingham, AL), CD62L (BD
Pharmingen, San Jose, CA), CD127, CCR7 (eBioscience, San Diego,CA). Unless otherwise
indicated, antibodies were from Biolegend (San Diego, CA). A stain for dead cells was included in
the panel.

Data acquisition and analysis for tetramer stains
Samples were run on a BD-LSR II and analyzed by FlowJo software. After lymphoid cell
+

+

+

+

acquisition, doublets and dead cells were removed and samples were gated on CD3 CD8 T
cells. Remaining cells were plotted as tetramer against CD44. Data is shown as tet CD8 T
6

+

+

cells/10 live lymphoid cells. Additionally, tet CD44 cells were phenotyped for the markers
lo

+

described above. A gate on the CD44 CD8 T cells served an internal, naïve control for
131

+

-

phenotyping. In the genital tract, lymphocytes were additionally gated on CD3 CD8 T cells to
+

assess the CD4 T cell population.

Nested polymerase chain reaction
C57Bl/6 mice were treated with naïve serum or AdHu5 hyperimmune serum at a VNA
titer greater than 1:100. Mice were immunized IM 24 hours later with 10

10

vp of AdHu5-

NPOVAGFP. Mice were euthanized and splenocytes were harvested 4 weeks later. Genomic
DNA was isolated using DNeasy Tissue kit (Qiagen; Valencia, CA). 20 ng of genomic DNA from
each sample were used to first amplify AdHu5 hexon by polymerase chain reaction (PCR) using
5’ primer: 5’-ATCATGCAGCTGGGAGAGTC-3’ and 3’ primer: 5’-ACACCTCCCAGTGGAAAGCA3’. The PCR consisted of 30 cycles of 95°C for 30 seconds, 55°C for 30 seconds, and 72°C for 30
seconds. The resulting PCR fragment was 650 bp. The amplicon from the first PCR was diluted
1:50 and 1 µL was used as template for quantitative nested PCR. The 5’ and 3’ primers, 5’-GAC
TCC TAA AGT GGT ATT GT-3’ and 5’-GTC TTG CAA ATC TAC AAC AG-3’, respectively,
amplified a 250 bp fragment. The nested PCR consisted of 40 cycles of 95°C for 30 seconds,
56.8°C for 30 seconds, and 72°C for 30 seconds.

Statistical analysis
Significance of differences between 2 populations were calculated by t-tests with SidakHolm correction for type 1 errors in multiple tests. When normality of distribution could not be
assumed, differences were analyzed by Mann-Whitney tests. Differences between multiple
groups were tested by ANOVA with Dunnett correction for type 1 errors, Tukey’s multiple
comparison tests or with uncorrected Fischer’s LSD as indicated in the figure legends.
Correlations were conducted by Spearman with Bonferroni corrections for type 1 errors. Data
were analyzed by GraphPad Prism 6.
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CHAPTER 6
	
  
CONCLUSIONS

133

+

The contribution of central memory and effector memory CD8 T cells in controlling
infection is dependent on a number of factors, most notably the infecting pathogen. Indeed
numerous studies have demonstrated roles for each subset. Results from the LCMV clone 13
+

model have suggested that central memory CD8 T cells, with their capacity to generate large
+

amounts of effector CD8 T cells upon secondary antigen encounters, are more suited to control
infections once pathogens have spread systemically

107

. Evidence for this also comes from HIV

vaccine models, which have suggested that more anamnestic responses are necessary to lower
viral set point loads once the acute infection phase has passed

135

. On the other hand, numerous

+

other studies suggested that effector memory CD8 T cells, with their more activated, cytotoxic
nature and localization at the periphery, are necessary to halt pathogens as they invade. This
subset of cells is attributed to mediating early control of a highly pathogenic SIV in an HIV vaccine
model based on a CMV-based vaccine

134,135

. Studies of these subsets have led to the paradigm

that effector memory cells are the first line of defense at the port of viral entry while central
memory cells provide a second line of defense that provides backup in the event of a pathogen
that overwhelms the first line of defense.
As adenoviruses continue to be pursued as vaccine carriers, understanding their
interaction with the immune system and how memory responses are induced to their transgene
products is of the utmost importance. Adenoviral vectors are desirable vaccine carriers because
+

they induce potent and sustained CD8 T cell responses that are biased toward effector memory.
In these chapters we demonstrate that antigen-experienced cells maintain the transgene product+

+

specific CD8 T cell pool with little to no contribution from newly primed naïve CD8 T cells.
These data may give us insight into how memory responses following adenoviral immunization fit
current models of memory formation. One model states that memory responses are programmed
during priming and the fate of a newly activated T cell is determined by the sum of the signals it
receives at it is primed

114,115,248

. Alternatively, the linear differentiation model states that memory

differentiation occurs along a continuum following the effector phase

107,111

. In the latter model,
134

cells that survive contraction will progressively dedifferentiate from effector cells to effector
memory cells to central memory cells. An important point in this model is that this dedifferentiation occurs in the absence of antigen

107

, which largely suggests that in persistent

infections, central memory cells will never form. However, our data seem to suggest that antigen+

experienced cells maintain the CD8 TEM pool induced by adenovirus immunization. If central
memory cells are truly formed and recalled by persisting antigen, then this would suggest that
they were programmed and not dedifferentiating from effectors. Therefore, memory formation
following adenovirus immunization does not conform the linear differentiation model. In support of
this, others have found that halting transcription from the adenoviral genome two months after
priming does not cause a contraction to central memory

211

, as would be expected if memory

formation after infection with an adenovirus vector conformed to the linear differentiation model.
An optimal vaccine against a given pathogen will likely need to induce immune responses
that mimic natural, protective immune responses induced by the pathogen itself. Ample evidence
+

highlights that both CD8 TEM and TCM play a role in these protective immune responses

107,249

.A

+

primary goal of this thesis was to create a tractable vaccine carrier that could induce a CD8 T
cell response with a better balance between central memory and effector memory. A factor that
+

has been found to influence the balance of CD8 T cell memory is antigen persistence. Since
adenoviral vectors remain transcriptionally active during persistence we created vectors that
would allow us to temporally regulate transgene transcription. Their unexpected recombination
highlights the importance of considering stability when designing novel adenoviral vectors.
Novel approaches to gain transcriptional control over a transgene would have to be
explored. Transgenic mouse models expressing site-specific recombinanses are readily
available. Additionally, inducible promoters are commonly used to control gene expression
experimentally. While these are viable approaches and allow us to further address how transgene
expression influences T cell responses in in mouse models, a larger goal is to investigate how
continued transgene expression influences immune responses in larger animal models, including
non-human primates. An interesting approach may be to take advantage of a cellular pathway for
regulating gene expression. Small, non-coding RNAs, including microRNAs (miRNA), bind to and
135

prevent translation of mature mRNA sequences. Their role in regulating myriad cellular processes
is well documented and has been extended to the immune system. Indeed miRNAs have been
+

discovered that are differentially expressed during the differentiation of CD8 T cells, and are
therefore likely involved in determining the gene expression profiles of naïve, effector, and
memory CD8

+

T cell subsets

250,251

. As adenoviral vector genomes are enriched and
+

transcriptionally active in effector-like CD8 T cells, taking advantage of more highly expressed
miRNA in those subsets may allow us to regulate when and where transgenes are expressed.
The metabolic processes involved in T cell fate decisions continue to be studied. mTOR
has been identified as an important modulator of T cell responses that integrates the complex
signals involved in T cell activation to coordinate the dramatic metabolic changes required for T
cell differentiation

154,181

. Given this role, it has been suggested that drugs that target mTOR,

specifically complex 1, could be used as novel vaccine adjuvants to enhance the magnitude and
rate of central memory differentiation. However, results from this thesis suggest that rapamycin
as a vaccine adjuvant may not be applicable to vaccine modalities that persist in vivo, as we
+

failed to observe any significant enhancement in differentiation of CD8 T cells to central memory.
The reason for this may simply be that as the vector persists, and continues to produce transgene
product, low dosing of rapamycin may not be able to overcome ongoing T cell receptor-induced
mTOR activation. As we gain deeper understanding of the metabolic pathways involved in
regulating T cell fate decisions in settings in which viruses and other pathogens persist, pathways
other than those influencing mTOR complex 1 will emerge that may allow us to manipulate
memory differentiation. Indeed, a role for mTOR complex 2 in driving the rapid switch to
+

glycolysis in reactivation of memory CD8 T cells has recently been described

252

.

Preclinically, adenoviral vectors have performed well as vaccine carriers.

However,

results from clinical trials have thus far been disappointing, if not concerning. Testing of Merck’s
AdHu5-based HIV vaccine in the STEP trial was halted in 2007 due futility. Analysis revealed that
T cell responses against the vaccine’s antigens were induced, although they were not particularly
strong and were limited in breadth. However, what was more troubling was that vaccinated men
who were AdHu5 seropositive and uncircumcised at the time of vaccination were at increased risk
136

of becoming infected with HIV-1 compared to placebo recipients
has not been observed in other Ad-based HIV vaccine trials

220

253,254

. This risk was transient and

. Regardless, in response to

these alarming results, many continue to investigate the influence of pre-existing immunity to
+

adenoviral vectors on the induction of de novo CD8 T cell responses. In an effort to characterize
vectors from different subgroups of adenoviruses under consideration for vaccine development,
we discovered that while pre-existing neutralizing antibodies specific to the adenovirus capsid
+

+

dampen de novo CD8 T cell responses they also accelerate and enhance CD8 T cell central
memory differentiation in mice. These results are counterintuitive in light of the STEP trial and
+

raise an important question: how could an anamnestic, central memory-biased CD8 T cell
response increase HIV-1 acquisition? This result is also seemingly in contrast with a mouse
+

infection model that demonstrates that CD8 T cells primed in the context of both pre-existing
cellular and humoral immunity to a vector mount rapid anamnestic transgene product-specific
CD8+ T cell responses to effectively control an infection that is typically prevented by effector
memory T cells

249

. Given the complexity of HIV and the speed with which it escapes immune

control, our results may in fact reinforce the concept that a successful HIV-1 vaccine will need to
induce a layered response of both B and T cells. T cells should include both potent effector
memory cells that localize to the mucosa and a central memory cells to control virus once it
becomes systemic. In support of this, while the CMV-based HIV-1 vaccine candidate that induces
a strong effector memory T cell response but no anamnestic central memory T cells provides
early protection from SIV infection in 50% of vaccinated monkeys, those with breakthrough
infections develop high viral loads similar to unvaccinated control animals

134,135

.

Although the reasons for the increased HIV acquisition observed in the STEP trial
continue to elude us, pre-existing immunity to a vaccine carrier should be considered in the
interest of safety when designing vaccines. Indeed, adenoviral vectors based on serotypes less
common than AdHu5 are being tested in the clinic

225

. Our results here suggest that pre-existing

immunity will likely impact these vectors as well. In fact, it is safe to assume pre-existing immunity
may be detrimental regardless of the platform. Fortunately for the adenoviral platform,
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development of alternative, non-human serotypes that do not circulate in humans is under way
94,96,225

.
In testing candidate vaccines, we assess them in various animal models, including mice

and monkeys, before testing can begin in humans. Millions of years of evolution have led to vastly
different immune systems and responses to pathogens. Indeed this holds true for adenoviruses
and immune responses against them. It has been demonstrated that ongoing anti-adenovirus
immune responses to persistent adenoviruses in humans and monkeys are very different from
each other. Adenovirus seems to undergo substantial chronic replication and is consistently shed
in monkeys; in humans the virus is more latent and shedding in general is only observed for a few
weeks following an acute infection

255

. This ultimately impacts immune responses, monkeys

mount stronger systemic humoral responses and humans mount stronger cellular responses

255

.

The impact this has on immunization with adenoviral vectors and the interpretation of results in
animal models is an important future route.
It is with hope that the studies presented in this thesis continue to stimulate investigation
into the optimization of adenovirus-based vaccines. Further understanding of factors that
+

influence CD8 T cell memory development, particularly in settings involving persistent vaccine
carriers, will enable development of vaccines that can be tailored to particular pathogens.
Manipulation of factors involved in fate decisions in order to enhance vaccine development
continues to be an exciting area of research.
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